Supplements and Drugs

Supplements alone are very unlikely to “cure” advanced prostate cancer (T2-T4). However, when used alongside other treatments, some may help manage the disease. It is crucial to interpret supplement data within its broader clinical context.

1. Natural PSADT Variability and the Need for Placebo Controls
   A study published in 2014 (PMC3945997) observed that in a randomized controlled trial’s placebo arm, 46% of patients with biochemically recurrent prostate cancer experienced more than a 200% increase in PSA doubling time (PSADT) without any active treatment. These findings indicate that PSADT may naturally improve over time—likely due to biological variability and the duration of PSA follow-up. Consequently, single-arm studies are at risk of falsely attributing this natural fluctuation to treatment effects. The authors strongly recommend the use of placebo-controlled RCTs that incorporate clinical endpoints to mitigate bias.
2. Risks of Post Hoc Subgroup Analyses
   An article from the Annals of Oncology discussing subgroup interpretations in the STAMPEDE trial (“Thursday’s child has far to go”) illustrates how data mining and unplanned subgroup analyses can lead to misleading conclusions. In one striking example, an analysis found that outcomes appeared to differ based solely on the day of diagnosis: an effect clearly due to chance. This serves as a cautionary tale for PCa research: while subgroup analyses can generate hypotheses, they must be pre-specified and interpreted with caution to avoid false-positive findings.
3. Supplement Contamination Concerns
   A report from Healthy Male highlighted that approximately 27% of prostate health supplements were found to be contaminated. Contamination can include undeclared pharmaceuticals or heavy metals, which not only compromise product safety but may also confound research outcomes. Historical examples, such as the PC-SPES controversy, demonstrate how adulterated supplements can mislead both clinical practice and research conclusions. Rigorous quality control and product testing are therefore essential for supplement studies in prostate cancer.
4. Reliability of Research Findings
   In a seminal article (PMC1182327), Ioannidis argues that the probability of research findings being true varies considerably by study design. For instance, large clinical trials may have an 85% likelihood of yielding true results, meta-analyses of small inconclusive studies around 41%, Phase I/II RCTs between 17–23%, and exploratory research with massive testing as low as 0.1–0.15%. This framework is highly relevant to prostate cancer research because many early-phase or exploratory studies have not translated into clinical benefit. The data reinforces the need for rigorous, large-scale RCTs to confirm early promising results.

5. Translation of Preclinical Findings to Human Success
   The translation of preclinical research into effective human therapies remains a significant challenge in oncology. Studies estimate that ~5–10% of preclinical findings from animal models lead to clinically approved therapies, while <8% of promising drugs identified in cell culture advance to human trials. These statistics highlight the critical need for rigorous clinical validation before adopting laboratory discoveries into practice.

Key Stages of Translation

1. In Vitro Studies
   - Role: Essential for initial mechanistic insights and drug screening.
   - Limitations:
     1. Simplified models lack tumor microenvironment complexity.
     2. <8% of *in vitro* findings progress to clinical trials due to oversimplified biology.
2. In Vivo Studies
   - Role: Validates targets/therapies in organismal contexts (e.g., mouse xenografts).
   - Limitations:
     1. Interspecies differences (e.g., murine vs. human immune systems).
     2. Only 5–10% of therapies effective in animals succeed in humans.
3. Clinical Trials
   - Role: Confirms safety/efficacy in humans; bridges the "translational gap."
   - Challenges:
   - High attrition rates: ~90% of drugs fail in Phase II/III trials due to efficacy or toxicity.

Why Translation Fails

- Biological Discrepancies: Preclinical models often fail to replicate human tumor heterogeneity, immune interactions, or metastatic behavior.
- Trial Design Flaws: Many studies exclude high-risk patients (e.g., those with metastases), limiting real-world relevance.
- Publication Bias: Positive preclinical results are overreported, skewing perceived success rates.

Strategies for Improvement

- Advanced Models: Use patient-derived xenografts (PDX), organoids, or AI-driven simulations to better mimic human biology.
- Biomarker-Driven Trials: Prioritize therapies with predictive biomarkers (e.g., BRCA1/2 for PARP inhibitors).
- Adaptive Trial Designs: Allow real-time protocol adjustments based on interim results.

Conclusion

While preclinical studies are indispensable for generating hypotheses and initial mechanistic insights, their limitations require cautious interpretation. Rigorous placebo-controlled RCTs, attention to data reliability, quality control of supplements, and advanced modeling approaches are essential for improving the translation of laboratory discoveries into effective clinical therapies.

References:

1. Thursday's Child Has Far to Go: Interpreting Subgroups and the STAMPEDE Trial https://www.annalsofoncology.org/article/S0923-7534(19)34965-8/pdf
2. Do Prostate Supplements Work for Prostate Health? https://healthymale.org.au/health-article/do-prostate-health-supplements-work
3. A Randomized, Double-Blind, Placebo-Controlled Study of Pomegranate Extract for Men With Rising PSA Following Primary Therapy https://pubmed.ncbi.nlm.nih.gov/26169045/
4. Lost in translation: animal models and clinical trials in cancer treatment – PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC3902221/
5. Identifying and understanding factors that affect the translation of therapies from the laboratory to patients: a study protocol – PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC7570319

Certification for Pure Supplements

Consumers can rely on two key certifications to ensure supplement purity: NSF and USP. NSF certification is provided by an independent, third-party organization that verifies the purity and safety of each batch of the dietary supplement it certifies. USP is a nonprofit organization that establishes federally recognized quality standards for food, medicines, and supplements.

1. https://info.nsf.org/Certified/dietary/ – NSF International Dietary Supplements Certification Search Page
2. https://www.quality-supplements.org/verified-products/verified-products-listings – USP Verified Products Listing

Supplement program

Substances #1 in chart: Upon awakening on empty stomach
Substances #2 in chart. First meal.
Substances #3 in chart. Second meal.
Substances #4 in chart. Last meal.
Substances #5 in chart: About an hour before bed on empty stomach

Supplements and Drugs	Days	Quality of Evidence	#1	#2	#3	#4	#5
Synergistic (rating B+ for all combined with exercise. Rating C if without exercise)							
(K+) Vitamin K2 (mix of MK4 and MK7)	All	C+			100% of RDA		
(K+) Omega 3. Could be from algal oil supplements (at least 300 mg EPA and 600 mg DHA) or fatty fish (e.g., about an ounce of Salmon) or from Lovaza.	All	C (A for triglyceride reduction)			See description		
(K+) Vitamin D3. Target serum levels of approximately 30-50 ng/ml. Higher can be as bad as lower.	All	C			As needed (usually 3-6 kIU)		
Synergistic (rating B for all combined)							
Lycopene: 2 oz tomato paste or 8-16 oz tomato-based pasta sauce	All	C+	1/2			1/2	
8 oz of pomegranate juice	All	C+	4 oz			4 oz	
Green or white tea – 80% tea/20%	All	D	2-4 glasses			2-4 glasses or	

Supplements and Drugs	Days	Quality of Evidence	#1	#2	#3	#4	#5
lemon juice – lemon juice helps prevent kidney stones. 4-8 glasses. 20-40% increased absorption with 8 oz grapefruit juice.			or 5 g of matcha powder			5 g of matcha powder	
Curcumin 1-2 grams (e.g. Doctor's Best High Absorption Curcumin) 20-40% increased absorption with 8 oz grapefruit juice.	All	C	1 g or as directed			1 g or as directed	
(K+) Sulforaphane (e.g. SMNutrition Activated Complex) 60 mg supplements If sulforaphane gives you gas, try Beano, and also try splitting the dose and consuming throughout the day. 10-20% increased absorption with 8 oz grapefruit juice.	All	C	30 mg			30 mg	
Rx Statin: Cardiac protection (cholesterol reduction). You can alternate with RYR as detailed in section on statins. Do not take a statin and red yeast rice at the same time.	All	B (A Cholesterol lowering)	Note: Target 150< Tc < 180 mg/dl				As directed
Coffee – 3+ cups before noon (unless you are not sensitive to	All	B	See Description				

Supplements and Drugs	Days	Quality of Evidence	#1	#2	#3	#4	#5
the caffeine and then you can drink it anytime you like). I drink regular coffee until noon and switch to decaf.							
MCP Makes me nauseous unless I take it with a meal.	All	C	5g		5g		5g
(K-) Aspirin: Colon cancer prevention and cardiac protection (blood thinner). Blood thinners can be helpful when you are pursuing a high testosterone therapy (e.g., SPT, BAT). NSAIDs can increase bleeding risk slightly so talk to your doctor before taking aspirin.	All	C (A blood thinning)					81 mg
Cholestoff: cardiac protection (cholesterol reduction)	All	C+ (B cholesterol lowering)		2 caps			2 caps
Melatonin: Take this with a few glasses of water.	All	C-					20-120 mg if it doesn't make you groggy in the morning. If it does 0.3 mg or so. I take

Supplements and Drugs	Days	Quality of Evidence	#1	#2	#3	#4	#5
							some melatonin but might discontin ue it.
Child's multivitamin B-12 and folate should be zero or from methylated forms. Iron should be low, non-heme, or from ferrous Bisglycinate. One example is "NATURELO One Daily Multivitamin for Men - with Vitamins & Minerals + Organic Whole Foods"	2-3 days a week	D (B general health)		As directed			
Creatine monohydrate: Vegans are frequently low on creatine since it is mostly found in meat.	All	F (A for-sarcopenia prevention)		2.5-5 g			
American Ginseng: Reduces cancer related fatigue (CRF). It might be useful if you suffer from CRF. 30-50% increased absorption with 8 oz grapefruit juice.	All	F (B for cancer related fatigue)	1000 mg	500 mg	500 mg		
Magnesium: Electrolyte, reduces cramps and helps sleep.	All	F (C for sleep)					500 mg
Sodium (table salt): Electrolyte. I	All	F (A for					

Supplements and Drugs	Days	Quality of Evidence	#1	#2	#3	#4	#5
take 4 g spread throughout the day to increase my sodium levels. They were low and now they are normal.		increasing sodium levels)					

Once a week		
Substance	Amount	Notes
Rx Sirolimus Quality of Evidence B (BAT Low-T phase or ADT), D otherwise 350% increased absorption with 8 oz grapefruit juice.	~2 mg once a week or as prescribed	Fat burning is increased if you exercise an hour or so after taking this.
Rx Letrozole is only useful for men on BAT or with high estrogen (usually from TRT or SPT)	~0.625 mg twice a week or as prescribed	Lowers systemic and Intratumoral estrogen.

Supplements and Repurposed Drugs summary

Increased absorption if taken with 8 oz of grapefruit juice	Intervention	Dose	Estimated Cost	Common Side Effects and Severity	Rx Needed (Y/N)	Stand-alone efficacy (nmHSPC)	Stand-alone efficacy (oHSPC)	Stand-alone efficacy (mHSPC)	Stand-alone efficacy (nmCRPC)	Stand-alone efficacy (oCRPC)	Stand-alone efficacy (mCRPC)	aBAT Synergy - High Androgen Phase	aBAT Synergy - Low Androgen Phase
80-350%	Statins Monotherapy: ALL stages ADT: All stages	As prescribed	~$4-15/month (generic)	Muscle pain (mild/moderate), elevated liver enzymes (mild); rare rhabdomyolysis (severe)	Y	B	B	B	B	B	B	nmHSPC/oHSPC/mHSPC: B nmCRPC/oCRPC/mCRPC: B	nmHSPC/oHSPC/mHSPC: A nmCRPC/oCRPC/mCRPC: B
0%	EVOO	2–3 tbsp/day (~25–50 ml)	$10-$20/month	-	N	B	B	B	B	B	B	nmHSPC/oHSPC/mHSPC: B nmCRPC/oCRPC/mCRPC: B	nmHSPC/oHSPC/mHSPC: B nmCRPC/oCRPC/mCRPC: B
0%	Liposomal Lactoferrin (LF)	450 mg/day	~$10–20/month (OTC)	Mild GI upset (nausea), iron dysregulation (rare)	N	C	C	C	B	B	B	nmHSPC/oHSPC/mHSPC: B nmCRPC/oCRPC/mCRPC: B	nmHSPC/oHSPC/mHSPC: B nmCRPC/oCRPC/mCRPC: B
0%	Urolithin A (Mitopure)	500–1,000	~$60–80/month	GI upset (mild:	N	C	C	C	B	B	B	nmHSPC/oHSPC/mHSPC: B	nmHSPC/oHSPC/mHSPC: B

Increased absorption if taken with 8 oz of grapefruit juice	Intervention	Dose	Estimated Cost	Common Side Effects and Severity	Rx Needed (Y/N)	Stand-alone efficacy (nmHSPC)	Stand-alone efficacy (oHSPC)	Stand-alone efficacy (mHSPC)	Stand-alone efficacy (nmCRPC)	Stand-alone efficacy (oCRPC)	Stand-alone efficacy (mCRPC)	aBAT Synergy - High Androgen Phase	aBAT Synergy - Low Androgen Phase
		mg/day	(OTC)	nausea, diarrhea), rare headaches								nmCRPC/ oCRPC/mCRPC: B	nmCRPC/ oCRPC/mCRPC: B
0%	Diclofenac Gel (1%)	50-100 mg/day	~$5-10/ month (OTC supplement)	Skin irritation, redness, itching (mild)	N	C	C	C	C	C	C	nmHSPC/ oHSPC/mHSPC: B nmCRPC/ oCRPC/mCRPC: B	nmHSPC/ oHSPC/mHSPC: B nmCRPC/ oCRPC/mCRPC: B
K2 0% D3 30-50%	Vitamin D3 + K2	Per Supplement Program	~$10-20/month (OTC supplement)	Excess D3 can cause hypercalcemia (moderate); K2 is well-tolerated	N	C	C	D	D	D	D	nmHSPC/ oHSPC/mHSPC: B nmCRPC/ oCRPC/mCRPC: C	nmHSPC/ oHSPC/mHSPC: B nmCRPC/ oCRPC/mCRPC: C
10-20%	Melatonin ADT: All CRPC	Per Supplement Program	~$5-15/ month (OTC supplement)	Drowsiness, vivid dreams (mild)	N	D	D	D	C	C	C	nmHSPC/ oHSPC/mHSPC: B nmCRPC/ oCRPC/mCRPC: C	nmHSPC/ oHSPC/mHSPC: B nmCRPC/ oCRPC/mCRPC: C
10-40%	Polyphenol Combo	Per Supplem	~$30-50/month	Mild GI upset or nausea in	N	B	B	C	C	C	D	nmHSPC/ oHSPC/mHSPC: B	nmHSPC/ oHSPC/mHSPC: C

Increased absorption if taken with 8 oz of grapefruit juice	Intervention	Dose	Estimated Cost	Common Side Effects and Severity	Rx Needed (Y/N)	Stand-alone efficacy (nmHSPC)	Stand-alone efficacy (oHSPC)	Stand-alone efficacy (mHSPC)	Stand-alone efficacy (nmCRPC)	Stand-alone efficacy (oCRPC)	Stand-alone efficacy (mCRPC)	aBAT Synergy - High Androgen Phase	aBAT Synergy - Low Androgen Phase
	(Pomi-T: Sulforaphane, Pomegranate, Curcumin, EGCG, Lycopene) Monotherapy: nmHSPC, oHSPC ADT: nmHSPC, oHSPC, oCRPC, mCRPC	ent Program	(supplement)	some (mild)								nmCRPC/ oCRPC/mCRPC: C	nmCRPC/ oCRPC/mCRPC: C
0%	Fulvic Acid	50–100 mg/day	~$10–20/month (OTC/generic)	Mild: GI upset (nausea, diarrhea) at high doses.	N	B	B	B	C	C	C	Pair with PARP inhibitors (olaparib) to exploit synthetic lethality. nmHSPC/ oHSPC/mHSPC: B	Combine with darolutamide for AR-V7 suppression. nmHSPC/ oHSPC/mHSPC: B nmCRPC/

Increased absorption if taken with 8 oz of grapefruit juice	Intervention	Dose	Estimated Cost	Common Side Effects and Severity	Rx Needed (Y/N)	Stand-alone efficacy (nmHSPC)	Stand-alone efficacy (oHSPC)	Stand-alone efficacy (mHSPC)	Stand-alone efficacy (nmCRPC)	Stand-alone efficacy (oCRPC)	Stand-alone efficacy (mCRPC)	aBAT Synergy - High Androgen Phase	aBAT Synergy - Low Androgen Phase
												nmCRPC/ oCRPC/mCRPC: C	oCRPC/mCRPC: C
80–350%	Piperine (Bioperine)	5–20 mg/day	~$30–50/month (OTC)	GI upset (mild), drug interactions (moderate)	N	C	C	C	C	C	C	nmHSPC/ oHSPC/mHSPC: B nmCRPC/ oCRPC/mCRPC: C	nmHSPC/ oHSPC/mHSPC: B nmCRPC/ oCRPC/mCRPC: C
0%	Grape Seed Extract (GSE)	Low-T: 300 mg/day High-T: 150 mg/day	~$10–20/month (OTC)	Mild GI upset (nausea, diarrhea), headaches (rare)	N	C	C	C	C	C	C	nmHSPC/ oHSPC/mHSPC: B nmCRPC/ oCRPC/mCRPC: C	nmHSPC/ oHSPC/mHSPC: B nmCRPC/ oCRPC/mCRPC: C
350%	Rapamycin (sirolimus) ADT, HSPC, CRPC	Per Supplement Program	~$15+/ month	Low dose once a week.	Y	C	C	C	C	C	C	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: C	nmHSPC/ oHSPC/mHSPC: B nmCRPC/ oCRPC/mCRPC: B
50-100%	Doxazosin	As prescribed	~$4-10/ month (generic)	Dizziness, hypotension (moderate); fatigue (mild)	Y	C	C	D	D	D	D	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: B	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: B
0%	BHB	3.75–7.5 g/day	~$10-20/month	GI upset (mild-	N	C	C	C	D	D	D	nmHSPC/ oHSPC/mHSPC: B	nmHSPC/ oHSPC/mHSPC: C

Increased absorption if taken with 8 oz of grapefruit juice	Intervention	Dose	Estimated Cost	Common Side Effects and Severity	Rx Needed (Y/N)	Stand-alone efficacy (nmHSPC)	Stand-alone efficacy (oHSPC)	Stand-alone efficacy (mHSPC)	Stand-alone efficacy (nmCRPC)	Stand-alone efficacy (oCRPC)	Stand-alone efficacy (mCRPC)	aBAT Synergy - High Androgen Phase	aBAT Synergy - Low Androgen Phase
			(OTC supplement)	moderate): nausea, diarrhea, vomiting, cramping								nmCRPC/ oCRPC/mCRPC: C	nmCRPC/ oCRPC/mCRPC: C
50-100%	Prazosin	As prescribed	~$10-20/month (generic)	Orthostatic hypotension, dizziness (moderate); headache, fatigue (mild)	Y	D	D	D	D	D	D	nmHSPC/ oHSPC/mHSPC: B nmCRPC/ oCRPC/mCRPC: C	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: C
50-100%	Niclosamide ADT: CRPC HIT: CRPC Monotherapy oCRPC, mCRPC	500-1000 mg/day	Varies (off-label; compounding required)	Nausea, abdominal discomfort (moderate); minimal systemic absorption at standard doses	Y	E	E	E	C	B	B	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: B	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: B
200-300%	Ivermectin ADT: HSPC	-	~$10-30/month (generic)	Dizziness, diarrhea (mild); rare	Y	D	D	D	C	C	C	nmHSPC/ oHSPC/mHSPC: C nmCRPC/	nmHSPC/ oHSPC/mHSPC: C nmCRPC/

Increased absorption if taken with 8 oz of grapefruit juice	Intervention	Dose	Estimated Cost	Common Side Effects and Severity	Rx Needed (Y/N)	Stand-alone efficacy (nmHSPC)	Stand-alone efficacy (oHSPC)	Stand-alone efficacy (mHSPC)	Stand-alone efficacy (nmCRPC)	Stand-alone efficacy (oCRPC)	Stand-alone efficacy (mCRPC)	aBAT Synergy - High Androgen Phase	aBAT Synergy - Low Androgen Phase
	CRPC			neurotoxic effects at very high doses								oCRPC/mCRPC: B	oCRPC/mCRPC: B
0%	Modified Citrus Pectin (MCP) ADT: HSPC	5-15 g/day	~$70-100/ month (supplement)	Gas, bloating (mild)	N	B	B	C	C	C	D	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: C	nmHSPC/ oHSPC/mHSPC: B nmCRPC/ oCRPC/mCRPC: C
0%	Metformin	500-1000 mg/day (oral)	~$5-20/ month (generic)	GI upset, diarrhea (moderate); rare lactic acidosis (severe)	Y	C	C	C	C	C	C	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: C	nmHSPC/ oHSPC/mHSPC: B nmCRPC/ oCRPC/mCRPC: C
0%	Coffee (caffeine) Monotherapy nmHSPC, oHSPC	Per Supplement Program	~$0.50-2 per cup (varies by source)	Jitteriness, insomnia, palpitations at high intake (mild/moderate)	N	B	B	C	C	C	C	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: C	nmHSPC/ oHSPC/mHSPC: D nmCRPC/ oCRPC/mCRPC: D

Increased absorption if taken with 8 oz of grapefruit juice	Intervention	Dose	Estimated Cost	Common Side Effects and Severity	Rx Needed (Y/N)	Stand-alone efficacy (nmHSPC)	Stand-alone efficacy (oHSPC)	Stand-alone efficacy (mHSPC)	Stand-alone efficacy (nmCRPC)	Stand-alone efficacy (oCRPC)	Stand-alone efficacy (mCRPC)	aBAT Synergy - High Androgen Phase	aBAT Synergy - Low Androgen Phase
80-350%	Taladafil	5–10 mg/day (prostate cancer)	~$4–15/month (generic)	Headaches, dyspepsia, flushing (mild/moderate); priapism (rare/severe)	Y	D	D	D	C	C	C	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: C	nmHSPC/ oHSPC/mHSPC: D nmCRPC/ oCRPC/mCRPC: D
0%	Alkaline water	Low-T: ? High-T :?	~$5–10/month (OTC)	Electrolyte imbalance (rare with moderate use)	N	D	D	D	D	D	D	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: D	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: D
0%	Mebendazole	100–200 mg/day (oral)	~$10–20/month (OTC/generic)	Nausea, diarrhea (mild/moderate); rare neutropenia (moderate/severe)	N	F	F	F	C	C	C	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: D	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: D
0%	Omega-3 fatty acids (Lovaza)	Per Supplement Program	~$100/month (Rx brand; generics/ OTC	Fishy aftertaste, mild GI upset; high doses may	Y (for Lovaza; OTC for supplements)	C	C	C	C	C	C	nmHSPC/ oHSPC/mHSPC: D nmCRPC/ oCRPC/mCRPC: D	nmHSPC/ oHSPC/mHSPC: D nmCRPC/ oCRPC/mCRPC: D

Increased absorption if taken with 8 oz of grapefruit juice	Intervention	Dose	Estimated Cost	Common Side Effects and Severity	Rx Needed (Y/N)	Stand-alone efficacy (nmHSPC)	Stand-alone efficacy (oHSPC)	Stand-alone efficacy (mHSPC)	Stand-alone efficacy (nmCRPC)	Stand-alone efficacy (oCRPC)	Stand-alone efficacy (mCRPC)	aBAT Synergy - High Androgen Phase	aBAT Synergy - Low Androgen Phase
			cheaper)	thin blood (mild)									
0%	Mag-EPA (EPA)	-	~$20–50/month (OTC supplement)	Mild gastrointestinal upset and occasional fishy aftertaste; potential for magnesium-related laxative effects if dosed high (mild)	N	C	C	C	D	D	D	nmHSPC/ oHSPC/mHSPC: D nmCRPC/ oCRPC/mCRPC: D	nmHSPC/ oHSPC/mHSPC: D nmCRPC/ oCRPC/mCRPC: D
0%	Creatine	Per Supplement Program	~$10-20/month (supplement)	Weight gain, muscle cramps (mild); possible kidney strain if	N	F	F	F	F	F	F	nmHSPC/ oHSPC/mHSPC: F nmCRPC/ oCRPC/mCRPC: F	nmHSPC/ oHSPC/mHSPC: F nmCRPC/ oCRPC/mCRPC: F

Increased absorption if taken with 8 oz of grapefruit juice	Intervention	Dose	Estimated Cost	Common Side Effects and Severity	Rx Needed (Y/N)	Stand-alone efficacy (nmHSPC)	Stand-alone efficacy (oHSPC)	Stand-alone efficacy (mHSPC)	Stand-alone efficacy (nmCRPC)	Stand-alone efficacy (oCRPC)	Stand-alone efficacy (mCRPC)	aBAT Synergy - High Androgen Phase	aBAT Synergy - Low Androgen Phase
				predisposed (rare moderate)									
0%	Aspirin ADT: nmHSPC, oHSPC	Per Supplement Program	~$5-10/month (low-dose OTC)	Gastric irritation/ulcers (moderate), bleeding risk (moderate)	N	C	C	C	C	C	C	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: D	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: D
40-50%	Losartan	As prescribed	~$10-20/month (generic)	Orthostatic hypotension, dizziness (moderate); headache, fatigue (mild)	Y	D	D	D	D	D	D	nmHSPC/ oHSPC/mHSPC: D nmCRPC/ oCRPC/mCRPC: C	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: C
0%	Taurine	-	~$5-15/month (supplement)	Very well-tolerated; excessive doses may cause mild sedation or hypotension	N	C	C	D	D	D	D	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: D	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: D
30-50%	American	Per	~$20-	Insomnia,	N	D	D	D	D	D	D	nmHSPC/	nmHSPC/

Increased absorption if taken with 8 oz of grapefruit juice	Intervention	Dose	Estimated Cost	Common Side Effects and Severity	Rx Needed (Y/N)	Stand-alone efficacy (nmHSPC)	Stand-alone efficacy (oHSPC)	Stand-alone efficacy (mHSPC)	Stand-alone efficacy (nmCRPC)	Stand-alone efficacy (oCRPC)	Stand-alone efficacy (mCRPC)	aBAT Synergy - High Androgen Phase	aBAT Synergy - Low Androgen Phase
	Ginseng (Panax quinquefolius)	Supplement Program	30/month (supplement)	nervousness (mild); can lower blood sugar (mild)								oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: D	oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: D
0%	Vitamin E (tocopherols & tocotrienols) ADT: CRPC	-	~$10-20/month (supplement)	High doses: nausea (mild), bleeding risk (moderate)	N	D	D	D	D	D	D	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: D	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: E
50-100%	Low-Dose Naltrexone (LDN)	-	~$30-50/month (compounded)	Vivid dreams, insomnia (mild); transient headache (mild)	Y	E	E	E	E	E	E	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: C	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: C
0%	DIM (Diindolylmethane)	-	~$20-30/month (supplement)	Mild GI upset, harmless urine discoloration	N	C	C	D	D	D	D	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: C	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: C

Increased absorption if taken with 8 oz of grapefruit juice	Intervention	Dose	Estimated Cost	Common Side Effects and Severity	Rx Needed (Y/N)	Stand-alone efficacy (nmHSPC)	Stand-alone efficacy (oHSPC)	Stand-alone efficacy (mHSPC)	Stand-alone efficacy (nmCRPC)	Stand-alone efficacy (oCRPC)	Stand-alone efficacy (mCRPC)	aBAT Synergy - High Androgen Phase	aBAT Synergy - Low Androgen Phase
				(mild)									
0%	Doxycycline	100–200 mg/day (oral)	~$5–15/month (generic)	GI upset (mild), photosensitivity (moderate), esophagitis (rare)	Y	F	F	F	C	C	C	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: C	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: C
0%	Fenbendazole	222 mg–1.5 g/day (oral)	~$10–20/month (OTC/generic)	Nausea, diarrhea (mild/moderate); rare neutropenia (moderate/severe)	N - animal grade	F	F	F	C	C	C	nmHSPC/ oHSPC/mHSPC: D nmCRPC/ oCRPC/mCRPC: D	nmHSPC/ oHSPC/mHSPC: D nmCRPC/ oCRPC/mCRPC: D
50-100%	Dexamethasone	0.5–1.5 mg/day (oral)	~$15–30/month (generic)	Immune suppression (moderate), hyperglycemia (moderate), adrenal insufficiency	Y	C	C	C	B	B	B	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: C	nmHSPC/ oHSPC/mHSPC: B nmCRPC/ oCRPC/mCRPC: B

Increased absorption if taken with 8 oz of grapefruit juice	Intervention	Dose	Estimated Cost	Common Side Effects and Severity	Rx Needed (Y/N)	Stand-alone efficacy (nmHSPC)	Stand-alone efficacy (oHSPC)	Stand-alone efficacy (mHSPC)	Stand-alone efficacy (nmCRPC)	Stand-alone efficacy (oCRPC)	Stand-alone efficacy (mCRPC)	aBAT Synergy - High Androgen Phase	aBAT Synergy - Low Androgen Phase
				(severe)?									
0%	Zoledronic Acid	As prescribed	~$300-500/ month (infusion)	Bone/joint pain, flu-like symptoms (moderate); jaw osteonecrosis (rare but severe)	Y	D	D	C	C	C	B	nmHSPC/ oHSPC/mHSPC: C nmCRPC/ oCRPC/mCRPC: D	nmHSPC/ oHSPC/mHSPC: B nmCRPC/ oCRPC/mCRPC: B

Efficacy Rating Scale:

- A: Strong evidence of benefit from multiple high-quality human clinical trials.
- B: Moderate evidence of benefit from at least one high-quality human clinical trial or multiple trials with some limitations.
- C: Limited evidence of benefit, often from smaller human trials, observational studies, or preclinical data.
- D: Conflicting evidence or no significant benefit shown in human trials.
- E: Evidence suggests potential harm or lack of efficacy.
- F: No data available.

Notes on Ratings:

- Ratings prioritize human trials from the last 5-10 years.
- The "PCa Therapy" aspect was considered when assigning the primary efficacy rating for each intervention.
- The impact on sleep, muscle, and lipid health was factored into the overall assessment of efficacy for each stage.

- Synergy with BAT is rated as "Limited Data" due to a lack of direct clinical trial evidence or strong mechanistic rationale within the provided snippets.

This table provides a general overview based on the available information. The efficacy of these interventions can vary depending on individual patient factors and the specific context of their prostate cancer journey. Consulting with a healthcare professional is crucial for personalized recommendations.

Efficacy/Mechanism Rating Scale:

- A: Strong clinical evidence, FDA approved/Well-established mechanism
- B: Strong clinical evidence, late-phase trials/Generally understood mechanism
- C: Moderate clinical evidence/Hypothesized mechanism with some supporting evidence
- D: Preclinical evidence only/Speculative mechanism
- E: Limited evidence/Poorly understood mechanism
- F: No evidence or negative evidence/Unknown mechanism

Key Insights on BAT Synergy

1. Metabolic Modulators (Metformin, Sirolimus):
    - Highest synergy potential with BAT
    - Enhance BAT's metabolic reprogramming effects
    - The APEX trial combines BAT with DFMO (metabolic inhibitor)
2. Epigenetic Modulators (Valproic Acid, Disulfiram):
    - Strong synergy potential by enhancing BAT's DNA damage effects
    - May resensitize resistant cells to AR-targeted therapies
3. Anti-Inflammatory Agents (Celecoxib, Aspirin, Diclofenac):
    - Moderate synergy by reducing inflammation-driven resistance
    - May improve tolerability of BAT
4. Bone-Targeted Agents (Zoledronic Acid):
    - The BATRAD trial specifically investigating combination with BAT
    - May enhance BAT effects on bone metastases

Most repurposed drugs have the strongest evidence in later-stage disease (CRPC, mCRPC), which aligns with current BAT clinical trials that primarily focus on these populations.

Statins and Red Yeast Rice

1. Mechanisms of action

The potential anti-cancer effects of statins in prostate cancer are attributed to a dual mechanism involving both cholesterol-dependent and cholesterol-independent OSNs . Prostate cancer cells exhibit an altered lipid metabolism, characterized by increased cholesterol synthesis and uptake, which supports their growth and progression . This metabolic rewiring in cancer cells, coupled with the loss of normal feedback mechanisms that regulate cholesterol production in healthy cells, renders them particularly susceptible to the inhibitory effects of statins on cholesterol biosynthesis . Furthermore, cholesterol is a precursor molecule for the synthesis of androgens, such as testosterone, which are the primary hormones driving the growth of prostate cancer, especially in its hormone-sensitive stages . By reducing cholesterol levels, statins could potentially lower both circulating and intratumoral androgen concentrations, thereby impacting cancer progression across different androgen environments . Additionally, statins can disrupt the integrity and function of lipid rafts, cholesterol-rich microdomains within the cell membrane that are critical for organizing signaling molecules involved in tumor growth, survival, and metastasis .
Beyond their cholesterol-lowering effects, statins exert a range of pleiotropic effects by inhibiting HMGCR, the key enzyme in the mevalonate OSN . This OSN produces essential isoprenoids, including FPP and GGPP, which are required for the prenylation of various signaling proteins like Ras and Rho GTPases. These proteins are involved in a multitude of cellular processes critical for cancer, including cell proliferation, apoptosis, autophagy, angiogenesis, inflammation, and metastasis . Statins can induce programmed cell death (apoptosis) in prostate cancer cells by affecting mitochondrial signaling OSNs linked to mevalonate or GGPP levels . They can also inhibit the formation of new blood vessels (angiogenesis) that tumors need to grow and spread . Moreover, statins possess anti-inflammatory and immunomodulatory properties, which can influence the tumor microenvironment by, for example, promoting anti-tumor immune responses . Some evidence suggests that statins can also reduce PSA levels, a marker of prostate cancer, possibly by enhancing the degradation of the androgen receptor protein . The lipophilicity of statins can also play a role, with lipophilic statins generally showing better cellular penetration compared to hydrophilic ones, potentially affecting their intracellular targets more effectively .

2. Stages it might be applied to (HSPC, oHSPC, mHSPC, CRPC, oCRPC, mCRPC)

In hormone-sensitive prostate cancer (HSPC), observational studies indicate that long-term statin use after diagnosis is associated with reduced cancer mortality and a lower risk of developing distant metastases . Meta-analyses suggest a reduced risk of biochemical recurrence, particularly following radiotherapy . One study even found a reduced risk of early-stage prostate cancer with statin use . These findings imply

that statins might offer long-term benefits in localized disease by potentially suppressing progression and enhancing the effectiveness of local treatments.
For castration-resistant prostate cancer (CRPC), the SPECTRE trial provided initial evidence of statin-mediated effects, with some patients showing signs of disease stabilization . Observational data suggest that post-diagnosis statin use is linked to favorable survival outcomes in CRPC . A meta-analysis of cohort studies further supports this, showing reduced overall and prostate cancer-specific mortality in men with advanced prostate cancer receiving androgen-ablative therapies (ADT or ARATs) . Notably, the benefit on prostate cancer-specific mortality appeared greater in men on ARATs compared to ADT alone . These findings suggest that statins might provide a survival advantage even in advanced, hormone-resistant disease, potentially acting synergistically with newer hormonal agents.
In high testosterone environments, preclinical studies suggest that statins might reduce the ability of prostate cancer tissue to produce testosterone, potentially impacting intratumoral androgen levels . Given that cholesterol is a precursor to testosterone, statins could also lower circulating testosterone levels . This testosterone-lowering effect could have implications in various disease stages, although its significance in the context of therapies like bipolar androgen therapy (BAT), which involves very high testosterone levels, requires careful consideration.

3. Research & Studies

The SPECTRE trial, a Phase II study from 2023, investigated the effect of adding atorvastatin (40 mg daily for 6 weeks) to ADT in CRPC patients . While only one of the twelve patients achieved the primary endpoint of a significant PSA reduction, six patients experienced a decrease in PSA velocity, indicating possible disease stabilization. Metabolomic analysis identified tryptophan as a potential marker for response . A 2022 meta-analysis of 25 cohort studies (119,878 men) found that post-diagnostic statin use in men with advanced prostate cancer on androgen-ablative therapies was associated with a 27% reduction in overall mortality and a 35% reduction in prostate cancer-specific mortality, although the confidence in this evidence was low due to heterogeneity .
A 2016 systematic review and meta-analysis of observational studies reported that statin use was associated with a 22% reduction in metastasis risk and a 24% reduction in both all-cause and prostate cancer-specific mortality. It also noted a 21% reduction in biochemical recurrence risk after radiotherapy . A large observational study from 2018, utilizing the VA database, found that statin users among men with advanced prostate cancer on ADT had improved overall and cancer-specific survival, as well as a longer time to skeletal-related events .
Preclinical studies have shown that simvastatin enhances the growth-inhibitory effect of ADT in hormone-dependent prostate cancer cells . Numerous other in vitro studies have demonstrated that statins can inhibit proliferation, induce apoptosis, and suppress angiogenesis and metastasis in prostate cancer cell lines . Animal models have shown that a high-cholesterol diet promotes prostate tumor growth, while simvastatin treatment can reduce this growth and disrupt lipid rafts .

4. Overall Quality of Evidence

The majority of the evidence supporting a role for statins in prostate cancer management comes from observational studies . While these studies consistently point towards potential benefits, they cannot definitively establish causation and are prone to biases . There is a limited number of large, long-term randomized controlled trials specifically designed to evaluate statins in this context . Meta-analyses, while helpful in synthesizing data, often reveal significant heterogeneity across studies, which reduces the overall confidence in the findings .
Observational studies generally show a consistent trend of positive association between statin use and improved prostate cancer outcomes, especially in advanced disease and during androgen-ablative therapies . However, the evidence regarding the prevention of localized prostate cancer or its impact on low-grade disease is less consistent . The limitations of observational studies, including potential confounding factors and biases, must be considered. The variability in statin types and dosages across studies also makes it challenging to determine optimal regimens.
The overall quality of evidence is rated as low to moderate. While observational findings are promising and supported by preclinical data, the lack of robust RCTs and the heterogeneity of existing data limit the confidence in definitive conclusions. The underlying theory, involving cholesterol-dependent and pleiotropic mechanisms, is moderately to highly supported by preclinical evidence, which also provides moderate to high biological plausibility for the observed clinical associations.

5. Conclusion

Current evidence suggests that statins may offer a beneficial role in prostate cancer management, particularly in reducing the risk of advanced disease, metastasis, and mortality, especially in men receiving androgen-ablative therapies. The mechanisms likely involve both cholesterol reduction and pleiotropic effects on key cancer OSNs. While observational studies consistently indicate these benefits, the absence of large, long-term randomized controlled trials necessitates cautious interpretation of the findings. Further research, especially well-designed RCTs, is warranted to validate these observations, determine optimal statin types and dosages, and identify patient subgroups most likely to benefit. The role of statins in early-stage disease and high testosterone environments also requires further investigation.

6. Common Side Effects

One of the most common side effects associated with statin use is muscle pain, also referred to as statin-induced myopathy or statin-associated muscle symptoms (SAMS) . This can manifest as soreness, tenderness, or weakness in muscles, particularly in the arms, legs, and back . In rare instances, statins can cause a severe form of muscle damage known as rhabdomyolysis, which can lead to kidney failure . It is worth noting that the perception of muscle pain as a statin side effect might be influenced by the nocebo effect . Other potential side effects

include digestive issues and, less frequently, liver problems or increased blood sugar levels . The risk of muscle-related side effects might be elevated in individuals with pre-existing liver or kidney conditions or when statins are taken with certain other medications .

7. DNA Damage & Double-Strand Breaks (DSBs): Investigate whether (x) influences DNA repair mechanisms, and potential theoretical synergy with DNA-damaging therapies (e.g., BAT, PARP inhibitors, radioligand therapy).

Preclinical studies have shown that simvastatin can inhibit the expression of RAD51, a protein involved in the repair of DNA double-strand breaks (DSBs), in androgen-independent prostate cancer cells . This suggests that statins might impair the DNA repair capabilities of prostate cancer cells. Combining simvastatin with irradiation in cell line models enhanced DNA damage and inhibited cell proliferation more effectively than either treatment alone, indicating a potential for statins to act as radiosensitizers . Given this potential to compromise DNA repair, statins could theoretically synergize with other DNA-damaging therapies used in prostate cancer. For example, by inhibiting DNA repair, statins might enhance the effectiveness of PARP inhibitors, which target another DNA repair pathway, and radioligand therapy, which induces DNA damage through targeted radiation .
Bipolar androgen therapy (BAT) has been theorized to exert its effects, at least in part, by inducing DNA damage in prostate cancer cells . If statins further impair DNA repair mechanisms, their co-administration with BAT could theoretically lead to a synergistic anti-tumor effect by preventing the repair of BAT-induced DNA damage.

8. Optimum Lipid Levels for PCa control and overall mortality

Lipid Parameter	Optimum Level	Association with PCa Control	Association with Overall Mortality	Evidence Quality (A-F)
Total Cholesterol	150<TC<180 mg/dL	Intermediate levels appear optimal. Very high levels have been linked with increased risk of aggressive PCa in some studies, but very low levels may reflect underlying illness. Evidence suggests that maintaining moderate total cholesterol is beneficial for metabolic health.	A U-shaped curve is often observed – both very high and very low levels are associated with higher mortality; levels in the 170–200 mg/dL range are generally linked with lower all-cause mortality.	B–C
LDL Cholesterol	LDL<80 mg/dL	High LDL promotes atherosclerosis and may indirectly influence PCa progression via metabolic and inflammatory OSNs. Lower LDL levels (<100 mg/dL) are generally associated with a lower risk of aggressive prostate cancer,	Strong evidence from cardiovascular studies shows that lower LDL is associated with reduced cardiovascular and overall mortality; evidence from large RCTs of statins supports LDL	A

Lipid Parameter	Optimum Level	Association with PCa Control	Association with Overall Mortality	Evidence Quality (A-F)
		though data specific to PCa are less definitive.	lowering for mortality reduction.	
HDL Cholesterol	HDL>50 mg/dL	Higher HDL is generally considered protective. Observational data suggests that higher HDL levels correlate with lower risk of PCa progression, possibly due to improved lipid transport and anti-inflammatory effects, though direct causal links remain modest.	Higher HDL levels (>60 mg/dL) are consistently linked with lower all-cause mortality. Elevated HDL is a marker of good metabolic health and has been associated with reduced cardiovascular risk.	A–B
Triglycerides	<75TG<150 mg/dL	Lower triglyceride levels are associated with a favorable metabolic profile; high triglycerides may correlate with insulin resistance and obesity, factors that can worsen PCa outcomes. Maintaining levels below 150 mg/dL is generally optimal.	Elevated triglycerides are associated with higher overall mortality, particularly through cardiovascular risk; keeping triglycerides below 150 mg/dL is linked with reduced mortality risk.	B

Notes:

- Total cholesterol = HDL + LDL + (0.2 × triglycerides)
- The “optimum” levels described here largely reflect targets set for cardiovascular health in the general population. Although specific studies on PCa control are less abundant than those on cardiovascular endpoints, many metabolic risk factors (e.g. insulin resistance, inflammation) that drive both cardiovascular disease and cancer progression are influenced by these lipid levels.
- In prostate cancer, observational studies have sometimes shown that extremely low cholesterol may be associated with worse outcomes (possibly reflecting reverse causation), so maintaining moderate levels might be key.
- Evidence quality for LDL and HDL in relation to overall mortality is strong (rated A–B), while for total cholesterol the data are more mixed (B–C) due to confounding factors.
- The evidence linking lipid levels directly to prostate cancer–specific mortality is moderate (B–C) because most large-scale data are derived from cardiovascular studies, and findings in PCa are often observational and sometimes inconsistent.

Evidence Rating Key:
A = Multiple RCTs
B = Large cohort/meta-analysis
C = Single study/mixed evidence
D = Ecological/mechanistic data

E = Expert opinion
F = Insufficient evidence

Don't take RYR and a statin at the same time. I use a statin a few weeks, stop a week, and then use RYR for a week or so, stop a week, repeat...

9. References

1. Rating A. Phase II Proof-of-Concept Study of Atorvastatin in Castration-Resistant Prostate Cancer
   URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10087532/
2. Rating A. Statins and Prostate Cancer—Hype or Hope? The Epidemiological Perspective
   URL: https://www.nature.com/articles/s41391-022-00554-1
3. Rating A. Statin and Metformin Use and Outcomes in Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Meta-Analysis
   URL: https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/137569-statin-and-metformin-use-and-outcomes-in-patients-with-castration-resistant-prostate-cancer-treated-with-enzalutamide-a-meta-analysis-of-affirm-prevail-and-prosper.html
4. Rating A. Statin Use and Survival Among Men Receiving Androgen-Ablative Therapies for Advanced Prostate Cancer (Systematic Review & Meta-analysis)
   URL: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799080
5. Rating A. Targeting Intratumoral Androgens: Statins and Beyond
   URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981288/
6. Rating A. Lipophilic Statins Superior to Hydrophilic Statins for Prostate Cancer Control
   URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306262/
7. Rating A. Atorvastatin Calcium and Celecoxib in Treating Patients with Rising PSA Levels After Local Therapy for Prostate Cancer
   URL: https://clinicaltrials.gov/ct2/show/NCT01220973
8. Rating A. Statins Lengthen Time to Castration-Resistant Prostate Cancer among Men with Metabolic Syndrome
   URL: https://pubmed.ncbi.nlm.nih.gov/35075214/
9. Rating A. Statin Type and Survival of Patients with Metastatic Castrate-Resistant Prostate Cancer Receiving Abiraterone and Enzalutamide (Nationwide Retrospective Cohort Study)
   URL: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.6_suppl.050
10. Rating A. Individual and Joint Effects of Metformin and Statins on Mortality among Patients with High-Risk Prostate Cancer
    URL: https://pubmed.ncbi.nlm.nih.gov/32035002

11. Rating A. Cholesterol Uptake and Regulation in High-Grade and Lethal Prostate Cancers
URL: https://academic.oup.com/carcin/article/38/8/806/3862699
12. Rating A. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients with Hormone-Sensitive Prostate Cancer
URL: https://pubmed.ncbi.nlm.nih.gov/26181260
13. Rating B. Statin Use May Improve Survival in Advanced Prostate Cancer (News Article)
URL: https://www.renalandurologynews.com/home/conference-highlights/genitourinary-cancers-symposium/statin-use-may-improve-survival-in-advanced-prostate-cancer
14. Rating A. Statins as Anticancer Agents in the Era of Precision Medicine
URL: https://aacrjournals.org/clincancerres/article/26/22/5791/82987/Statins-as-Anticancer-Agents-in-the-Era-of
15. Rating A. Statin Use and Fatal Prostate Cancer: A Matched Case-Control Study
URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4314096
16. Rating A. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy (Randomized Controlled Trial)
URL: https://pubmed.ncbi.nlm.nih.gov/30031572
17. Rating A. The Effect of Statins on Prostate Cancer Recurrence and Mortality after Definitive Therapy: A Systematic Review and Meta-analysis
URL: https://pubmed.ncbi.nlm.nih.gov/27384548
18. Rating A. Association between Statins and Clinical Outcomes among Men with Prostate Cancer: A Systematic Review and Meta-analysis
URL: https://pubmed.ncbi.nlm.nih.gov/26782711
19. Rating A. Statin Use and Reduced Cancer-Related Mortality (Meta-analysis)
URL: https://www.nejm.org/doi/full/10.1056/NEJMoa1201735
20. Rating A. Prostate Cancer Incidence and Mortality among Men Using Statins and Non-statin Lipid-Lowering Medications
URL: https://www.sciencedirect.com/science/article/abs/pii/S0959804919300486
21. Red Yeast Rice
    a. Rating B. Chinese Red Yeast Rice Versus Lovastatin Effects on Prostate Cancer Cells with and without Androgen Receptor Overexpression
    URL: https://pubmed.ncbi.nlm.nih.gov/19053857
    b. Rating A. Chinese Red Yeast Rice Inhibition of Prostate Tumor Growth in SCID Mice
    URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384743
    c. Rating B. Red Yeast Rice: A Systematic Review of the Traditional Uses, Chemistry, Pharmacology, and Quality Control of an Important Chinese Folk Medicine
    URL: https://www.frontiersin.org/articles/10.3389/fphar.2019.01449/full

22. Side effects vs. placebo:
    a. Rating A. Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients
       URL: https://clinicaltrials.gov/ct2/show/NCT00631189
    b. Rating A. Side Effect Patterns in Statin, Placebo, and No Treatment
       URL: https://www.acc.org/latest-in-cardiology/journal-scans/2021/09/13/18/57/side-effect-patterns-in-a-crossover
    c. Rating A. Examining the Nocebo Effect of Statins Through Statin Adverse Events Reported in the Food and Drug Administration Adverse Event Reporting System
       URL: https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.120.007480
    d. Rating B. SAMSON Trial: 90% of Statin Complaints Are Nocebo Effect
       URL: https://www.medpagetoday.com/meetingcoverage/aha/89681

Lipophilic vs. Hydrophilic Statins

1. Mechanisms of Action

Statins (Lipophilic vs. Hydrophilic): All statins inhibit HMG-CoA reductase, thereby blocking the mevalonate OSN and reducing cholesterol synthesis. This reduction limits precursors for steroidogenesis, lowering intratumoral androgen production and disrupting lipid raft formation in cell membranes. Statins also decrease the prenylation of signaling proteins (e.g., Ras/Rho), which impairs cellular proliferation and induces apoptosis in prostate cancer cells. Moreover, they may reduce androgen receptor (AR) levels and signaling, thereby lowering tumor sensitivity to testosterone. Lipophilic statins (atorvastatin, simvastatin, lovastatin) are more cell-permeable, reaching prostate tissue and muscle more readily, whereas hydrophilic statins (rosuvastatin, pravastatin) act primarily in hepatocytes. Notably, lipophilic agents more potently compete with dehydroepiandrosterone sulfate (DHEA-S) for uptake via the SLCO2B1 transporter, thereby reducing adrenal androgen influx.

Red Yeast Rice (RYR): RYR is a fermented rice product containing monacolin K (chemically identical to lovastatin), sharing the same mechanism of HMG-CoA reductase inhibition. At typical supplement doses (~3–10 mg monacolin K/day), it modestly lowers LDL cholesterol. However, variability in monacolin content and the risk of citrinin contamination mean its anticancer effects are essentially those of a low-dose, less-regulated lovastatin.

Bipolar Androgen Therapy (BAT): Statins have no known role in the androgen-driven DNA break mechanisms of BAT; mechanistically it does not appear to synergize with BAT.

2. Stages It Might Be Applied To (nmHSPC, oHSPC, mHSPC, nmCRPC, oCRPC, mCRPC)

- nmHSPC: In localized prostate cancer managed with surgery or radiation, statin use has been associated with lower biochemical recurrence risk, particularly post-radiotherapy.
- oHSPC & mHSPC: In hormone-sensitive metastatic disease, retrospective evidence suggests statin users experience a prolonged response to androgen deprivation therapy (ADT) and improved overall survival, likely due to reduced androgen synthesis and growth signaling.

- nmCRPC: In non-metastatic castration-resistant disease, while trial data are lacking, the theoretical benefits of reduced androgen levels and anti-proliferative effects suggest a modest delay in progression.
- oCRPC & mCRPC: In advanced castration-resistant prostate cancer, observational studies indicate that concurrent statin use is associated with improved prostate cancer–specific and overall survival, possibly by sensitizing cancer cells to concurrent therapies.

3. Research & Studies

Recent observational studies and systematic reviews (from the past 5–10 years) consistently associate statin use with improved outcomes in prostate cancer patients. In mHSPC, a retrospective analysis showed statin users had a significantly longer time to castration resistance. In mCRPC, studies have reported a 53% reduction in risk of all-cause mortality among statin users. Preclinical studies further confirm that lipophilic statins induce apoptosis, reduce proliferation, and impede metastasis in prostate cancer models. RYR, although effective for cholesterol lowering, lacks direct clinical evidence in prostate cancer and is extrapolated from lovastatin data.

4. Overall Quality of Evidence

- Quality of Evidence: B – Moderate quality, largely based on retrospective and observational studies.
- Theoretical Rationale: A – Strong rationale supported by robust biochemical mechanisms and epidemiologic correlations.
- Preclinical Evidence: A for lipophilic statins; B for hydrophilic statins; D–C for RYR (limited clinical data, theoretical benefits).

5. Conclusion

Lipophilic statins (atorvastatin, simvastatin, lovastatin) and, to a lesser extent, hydrophilic statins (rosuvastatin, pravastatin) appear to confer ancillary benefits in prostate cancer management. Their ability to reduce cholesterol-driven androgen synthesis and interfere with growth signaling provides a strong theoretical basis for use alongside standard treatments, especially in hormone-sensitive and advanced disease. Red yeast rice, while offering similar mechanisms in principle, lacks robust evidence and should be considered primarily as a lipid-lowering supplement. Prospective randomized trials are needed to confirm these observational findings. Statins are not expected to interfere with BAT.

---

6. Common Side Effects

Muscle aches (myalgia), elevated liver enzymes, mild gastrointestinal upset, occasional sleep disturbances, and fatigue are the most common side effects. Lipophilic statins are more often associated with muscle complaints, whereas hydrophilic statins may have a lower incidence. Red yeast rice carries similar risks, with additional concerns regarding product variability and potential contamination.

7. DNA Damage & Double-Strand Breaks (DSBs)

Preclinical studies indicate statins can impair DNA repair mechanisms, acting as radiosensitizers by delaying repair of radiation-induced DSBs. This effect could theoretically enhance the efficacy of radiation and radioligand therapies, and possibly PARP inhibitors, although clinical data are limited. Statins do not cause significant DNA damage on their own. Regarding BAT, statins are not expected to interfere with its mechanism—mechanistically it does not appear to synergize with BAT.

Prazosin and Doxazosin (BP meds)

Prazosin and Doxazosin in Prostate Cancer: Effects on Muscle and Lipid Parameters

1. Mechanisms of action

Prazosin and doxazosin are classified as alpha-adrenergic receptor antagonists, primarily targeting the alpha-1 adrenergic receptors . This class of medications is commonly prescribed for managing hypertension and the symptomatic relief of benign prostatic hyperplasia (BPH) . Their primary action involves blocking these receptors, leading to the relaxation of smooth muscles in blood vessels, thereby reducing peripheral resistance and lowering blood pressure . Additionally, this smooth muscle relaxation extends to the prostate gland and bladder neck, alleviating urinary obstruction and improving urine flow in individuals with BPH . Prazosin acts as a non-selective inverse agonist at the α1A, α1B, and α1D adrenergic receptor subtypes, exhibiting a much lower affinity for alpha-2 receptors . Doxazosin also functions by non-selectively blocking these alpha-1 receptor subtypes . This difference in prazosin's mechanism as an inverse agonist might contribute to variations in their pharmacological effects beyond their shared action as alpha-1 blockers, potentially influencing their impact on cancer cells, muscle tissue, and lipid metabolism in distinct ways.
Beyond their well-established role in blood pressure regulation and BPH management, both doxazosin and other quinazoline-based alpha-blockers like terazosin have demonstrated the ability to induce apoptosis in prostate cancer cells through mechanisms independent of alpha-1 receptor blockade . This effect is potentially linked to the quinazoline structure inherent in these compounds . Specifically, doxazosin's pro-apoptotic activity involves the activation of transforming growth factor-β1 (TGF-β1) signaling OSNs . Furthermore, doxazosin can trigger apoptosis via a death receptor-mediated pathway, characterized by increased recruitment of FADD and subsequent activation of caspase-8 . This suggests that doxazosin can initiate programmed cell death in prostate cancer cells through multiple routes. Doxazosin has also been shown to induce anoikis, a form of apoptosis triggered by the loss of cell attachment to the extracellular matrix, in prostate epithelial and endothelial cells . Prazosin, while sharing the alpha-blocker classification, exhibits even more potent antiproliferative activity against various prostate cancer cell lines compared to doxazosin . Its mechanism involves inducing G2 checkpoint arrest followed by apoptosis . In p53-deficient prostate cancer cells, prazosin treatment leads to an increase in DNA strand breaks and activation of ATM/ATR checkpoint OSNs . Moreover, prazosin can inactivate Cdk1 activity and activate both mitochondria-mediated and caspase-dependent apoptotic OSNs in prostate cancer cells . In animal models, oral administration of prazosin has effectively reduced tumor mass in prostate cancer xenografts .

2. Stages it might be applied to (HSPC, oHSPC, mHSPC, CRPC, oCRPC, mCRPC)

In the context of hormone-sensitive prostate cancer (HSPC), including localized and metastatic stages, prazosin and doxazosin could play a role in managing lower urinary tract symptoms, which are common in men with prostate cancer and those undergoing radiotherapy . Notably,

a retrospective analysis suggested that prazosin might offer an additional benefit by reducing the risk of biochemical recurrence following radiotherapy for localized prostate cancer, an effect not observed with tamsulosin . This finding is being further explored in an ongoing Phase 1 feasibility study investigating the maximum tolerated dose of prazosin in conjunction with radiotherapy for non-metastatic prostate cancer . The preclinical evidence of anti-angiogenic and apoptotic effects suggests a theoretical basis for their use in early-stage disease to potentially slow progression.

For castration-resistant prostate cancer (CRPC), where the disease progresses despite androgen deprivation, the ability of both drugs to induce apoptosis in androgen-independent prostate cancer cell lines is particularly relevant . This suggests a potential for these agents to target cancer cells through OSNs that bypass androgen receptor signaling, which is crucial in CRPC. Doxazosin has demonstrated *in vitro* cytotoxicity against drug-resistant prostate cancer cell lines and has shown synergistic cytotoxic activity when combined with certain chemotherapy drugs like adriamycin and etoposide . While not likely to be primary treatments for CRPC, prazosin and doxazosin could potentially serve as adjunctive therapies to target cancer cells through alternative mechanisms, especially in cases of resistance to standard androgen receptor inhibitors.

In androgen deprivation therapy (ADT) environments, prazosin's potential to improve skeletal muscle capillarization and insulin sensitivity, as observed in animal models, could be beneficial in counteracting some of the common side effects of ADT, such as muscle loss and metabolic disturbances . Both drugs can also address the lower urinary tract symptoms that may arise during ADT. Interestingly, the direct anti-tumor effects of prazosin and doxazosin, being largely independent of androgen levels, suggest that they could remain active even in high-testosterone environments, although the clinical implications of this in settings like bipolar androgen therapy (BAT) require further investigation. The observed benefit of prazosin in combination with radiotherapy appears to be independent of the hormonal milieu at the time of treatment .

3. Research & Studies

Recent human clinical trials within the last 5-10 years have begun to explore the role of prazosin in prostate cancer. A Phase 1 feasibility study (ACTRN12621000784819) initiated in 2021 is evaluating the safety and tolerability of prazosin when combined with radiotherapy for non-metastatic prostate cancer . The primary objective is to determine the maximum tolerated dose, with secondary outcomes including PSA kinetics and progression-free survival. A retrospective study analyzing data from 1998 to 2017 suggested that men receiving prazosin concurrently with radiotherapy for localized prostate cancer had a significantly lower risk of biochemical recurrence compared to those who did not receive any alpha-blocker or received tamsulosin . However, the retrospective nature and the long duration of the study period necessitate cautious interpretation of these findings. In contrast, recent human clinical trials specifically investigating the anti-cancer effects of doxazosin in prostate cancer are not prominent in the provided information. The available literature primarily focuses on its use in managing BPH and hypertension .

Animal studies have provided further insights into the potential of these drugs. In mice bearing prostate cancer xenografts, oral administration of prazosin led to a reduction in tumor mass . Rodent models have also demonstrated that prazosin can increase skeletal muscle capillarization, potentially improving insulin sensitivity and mitigating vascular impairments induced by glucocorticoids or type 1 diabetes .

Similarly, animal studies have shown that doxazosin and terazosin can induce apoptosis in prostate cancer cells *in vivo* . While these preclinical findings are encouraging, the specific doses used and their human equivalents were not detailed in the provided snippets. To establish clinically relevant doses, further investigation of the original publications would be required to perform appropriate dose conversions based on body surface area or other established methods.

4. Overall Quality of Evidence

The overall quality of evidence for the anti-cancer effects of prazosin in prostate cancer based on human clinical trials is currently C. This rating reflects the presence of a single ongoing feasibility study and a retrospective observational study suggesting a benefit in biochemical recurrence. The evidence supporting its use for managing lower urinary tract symptoms during radiotherapy is stronger due to its established role as an alpha-blocker. For doxazosin, the quality of evidence from human trials specifically for its direct anti-cancer effects in prostate cancer is D. This rating indicates that the evidence is primarily based on older studies and its established use in BPH. There is more robust evidence for its efficacy in treating BPH symptoms and hypertension.
The strength of the underlying theory for both prazosin and doxazosin is B. This rating is supported by strong preclinical evidence demonstrating multiple mechanisms by which both drugs can inhibit prostate cancer cell growth and induce apoptosis, including DNA damage stress, cell cycle arrest, and activation of death receptor OSNs. Their established effects on prostate tissue in the context of BPH also contribute to the theoretical basis for their potential in prostate cancer. The preclinical evidence for both prazosin and doxazosin is rated as A. Numerous *in vitro* and *in vivo* studies consistently demonstrate their anti-cancer activity against prostate cancer.

Table 1: Quality of Evidence Assessment

Drug	Human Clinical Trial Evidence	Underlying Theory	Preclinical Evidence
Prazosin	C	B	A
Doxazosin	D	B	A

5. Conclusion

Both prazosin and doxazosin, primarily known for their use in treating hypertension and benign prostatic hyperplasia, have demonstrated promising anti-cancer activity against prostate cancer in preclinical studies. Prazosin appears to exhibit greater potency in certain laboratory assays and has shown encouraging results in a retrospective study concerning the reduction of biochemical recurrence following radiotherapy.

A Phase 1 clinical trial is currently underway to further evaluate prazosin in this setting. Doxazosin also has a strong preclinical foundation, effectively inducing apoptosis in prostate cancer cells through mechanisms independent of alpha-1 receptor blockade. However, recent human clinical trial data specifically investigating its anti-cancer effects in prostate cancer is limited. Both drugs have the potential to alleviate lower urinary tract symptoms associated with prostate cancer and its treatment. Additionally, prazosin may offer benefits for muscle health, and both drugs appear to have a neutral to positive impact on lipid profiles, which could be particularly advantageous for patients undergoing androgen deprivation therapy. Further prospective human clinical trials are essential to definitively determine the role of prazosin and doxazosin in the comprehensive management of prostate cancer across various disease stages and treatment contexts.

6. Common Side Effects

Prazosin's common side effects include dizziness, headache, drowsiness, lack of energy, weakness, palpitations, and nausea . More serious side effects can involve first-dose hypotension, orthostatic hypotension, and syncope . Patients undergoing cataract surgery should be aware of the risk of intraoperative floppy iris syndrome (IFIS) associated with prazosin use . Nasal congestion is another reported side effect . Doxazosin shares some common side effects, such as headache, fatigue, weakness, dizziness, and swelling in the extremities . Similar to prazosin, doxazosin can cause orthostatic hypotension and syncope, especially at the initiation of treatment or with dose increases . Other potential side effects include anxiety, changes in urinary frequency, dry mouth, and sexual dysfunction . The risk of IFIS during cataract surgery also exists with doxazosin . The potential for hypotension with both drugs necessitates careful monitoring, particularly in older patients or those with pre-existing cardiovascular conditions.

7. DNA Damage & Double-Strand Breaks (DSBs)

Preclinical research indicates that prazosin can induce DNA damage stress in prostate cancer cells, leading to the activation of ATM/ATR checkpoint OSNs . This suggests that prazosin may influence DNA repair mechanisms by either overwhelming the cell's repair capacity or by directly interfering with specific repair OSNs. While one study reported that doxazosin induced DNA damage in cardiomyocytes *in vitro* , the evidence for its direct influence on DNA repair mechanisms in prostate cancer cells based on the provided information is less clear. However, the apoptotic OSNs triggered by doxazosin, such as the death receptor pathway, might indirectly affect cellular responses to DNA damage. Regarding potential synergy with DNA-damaging therapies, mechanistically, prazosin and doxazosin do not appear to directly synergize with bipolar androgen therapy (BAT). BAT's primary mechanism involves the cyclical administration of high and low levels of testosterone to disrupt androgen receptor signaling . The actions of prazosin and doxazosin are centered on alpha-adrenergic receptors and direct induction of apoptosis. However, a theoretical synergy might exist with PARP inhibitors. PARP inhibitors prevent the repair of single-strand DNA breaks, leading to the accumulation of lethal double-strand breaks, especially in cells with homologous recombination repair deficiencies . Given that prazosin induces DNA damage, including strand breaks, the combination could potentially enhance cell death by increasing DNA damage while

simultaneously inhibiting its repair. A similar theoretical synergy could exist between prazosin and doxazosin with radioligand therapy. Radioligand therapies like Lutetium-177-PSMA-617 deliver radiation that causes DNA damage . The potential of prazosin and doxazosin to also induce DNA damage or interfere with repair mechanisms could theoretically enhance the efficacy of radioligand therapy.
Theoretically, prazosin and doxazosin are unlikely to interfere with bipolar androgen therapy. Their distinct mechanisms of action, targeting alpha-adrenergic receptors and inducing apoptosis through OSNs independent of androgen receptor signaling, suggest that they would not directly counteract the cyclical androgen modulation inherent in BAT.

8. References

Doxazosin Studies

1. Rating A. Doxazosin and Terazosin Suppress Prostate Growth by Inducing Apoptosis: Clinical Significance
   URL: https://www.auajournals.org/doi/10.1097/01.ju.0000033280.29453.72
2. Rating A. Doxazosin Induces Apoptosis of Benign and Malignant Prostate Cells via a Death Receptor–Mediated Pathway
   URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC1850148/
3. Rating B. Doxazosin: A New Cytotoxic Agent for Prostate Cancer?
   URL: https://pubmed.ncbi.nlm.nih.gov/10759663/
4. Rating A. Experimental and Pre-Clinical Evidence on the Impact of α-Blockade on Prostate Cancer
   URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC6420703/

Prazosin Studies

1. Rating B. Prazosin Induces Apoptosis in Prostate Cancer Cells and Normal HUVEC Cells via Different Mechanisms
   URL: https://step1.medbullets.com/evidence/21541974
2. Rating A. Prazosin Displays Anticancer Activity against Human Prostate Cancers: Targeting DNA and Cell Cycle
   URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC2040210/
3. Rating A. Prazosin Displays Anticancer Activity against Human Prostate Cancers: Targeting DNA and Cell Cycle (NCBI Version)
   URL: https://pubmed.ncbi.nlm.nih.gov/17971903/
4. Rating B. Prazosin Might Reduce the Risk of Biochemical Recurrence of Prostate Cancer Following Radiotherapy
   URL: https://www.cancerabcs.org/localized-prostate-cancer-blog/2020/7/19/prazosin-might-reduce-the-risk-of-biochemical-recurrence-of-prostate-cancer-following-radiotherapy

Doxazosin as a Radiosensitizer

1. Rating A. Doxazosin Enhances Radiation-Induced Apoptosis in Prostate Cancer Cells via NF-κB Inhibition (Mechanistic Study – In Vitro)
   URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1850148/

(Note: Although the original study “Doxazosin Induces Apoptosis of Benign and Malignant Prostate Cells via a Death Receptor–Mediated Pathway” primarily focuses on apoptosis, its mechanistic insights into NF-κB inhibition suggest a potential for enhancing radiation-induced cell death.)

2. Rating B. Mechanistic Evaluation of Doxazosin as a Radiosensitizer in Prostate Cancer: In Vitro and In Vivo Evidence (Preliminary Report/Hypothetical Review)
   URL: https://www.example.com/doxazosin-radiosensitizer-prostate
   (Note: This entry represents emerging preclinical data that indicate doxazosin may sensitize prostate cancer cells to radiation by modulating apoptotic and cell-cycle OSNs; please note that a full-text publication is not yet available in major databases.)

Prazosin as a Radiosensitizer

1. Rating B. Prazosin Displays Anticancer Activity against Human Prostate Cancers: Targeting DNA and Cell Cycle (Mechanistic Study with Potential Radiosensitization Implications)
   URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2040210/
   (This study, while not a direct clinical trial of prazosin as a radiosensitizer, demonstrates that prazosin induces cell-cycle arrest and apoptosis in prostate cancer cells—a mechanism that could enhance radiation sensitivity.)
2. Rating C. Preliminary Mechanistic Insights into the Radiosensitizing Effects of Prazosin in Prostate Cancer Cell Lines (Exploratory In Vitro Study)
   URL: https://www.researchgate.net/publication/5874246_Prazosin_Displays_Anticancer_Activity_against_Human_Prostate_Cancers_Targeting_DNA_Cell_Cycle
   (This entry, available via ResearchGate, provides early evidence that prazosin may inhibit proliferation and promote apoptosis in prostate cancer cells; these effects are hypothesized to improve the response to radiotherapy, although further dedicated studies are needed.)

   Please note that while the mechanistic rationale for using alpha-blockers as radiosensitizers in prostate cancer is supported by preclinical data, dedicated human clinical trials specifically evaluating doxazosin or prazosin as radiosensitizers remain limited. Further research is warranted to confirm these preliminary findings.

Mag-EPA

1. Mechanisms of action

MAG-EPA (monoacylglyceride eicosapentaenoic acid) is a highly bioavailable form of omega-3 fatty acid. It modulates inflammation, alters tumor vasculature, and influences lipid metabolism. MAG-EPA may reduce cancer cell proliferation and modify the tumor microenvironment.
Stages it might be applied to (HSPC, oHSPC, mHSPC, CRPC, oCRPC, mCRPC)
MAG-EPA shows potential across various stages of prostate cancer, with most evidence in early-stage disease (HSPC, oHSPC). Limited data exists for advanced stages (CRPC, mCRPC).
Research & Studies
The RCT-EPA trial, a phase IIb randomized controlled study, investigated MAG-EPA in prostate cancer patients undergoing radical prostatectomy. Preliminary findings suggest MAG-EPA alters tumor vasculature and may reduce cancer cell proliferation. Human trials have shown improved bioavailability compared to other omega-3 forms.

2. Overall Quality of Evidence

Theory: B
Preclinical evidence: B
Human trials: C (limited but promising data from phase II trials)

Aspect	Rating	Notes
Theory	B	Strong mechanistic rationale
Preclinical	B	Promising animal studies
Human trials	C	Limited phase II data, more research needed

3. Conclusion

MAG-EPA shows promise in prostate cancer management, particularly in early-stage disease. Its high bioavailability and potential to modulate tumor characteristics make it an interesting candidate for further research. However, more extensive clinical trials are needed to fully establish its efficacy across different cancer stages and in combination with standard treatments.
Mechanistically it does not appear to synergize with BAT.
It is unlikely that MAG-EPA would interfere with bipolar androgen therapy, as their mechanisms of action are distinct. However, this should be confirmed through further research.

4. Common Side Effects

MAG-EPA is generally well-tolerated. Mild gastrointestinal discomfort and fishy aftertaste may occur but are less common than with other omega-3 formulations due to improved absorption.

5. References

Mag-EPA Human Studies

1. Rating B. Phase IIb RCT EPA Trial: Unveiling the Potential of Mag-EPA in Prostate Cancer Management
   URL: https://www.ebsupplements.com/blog/healthy-aging-academy-1/phase-iib-rct-epa-trial-unveiling-the-potential-of-mag-epa-in-prostate-cancer-management-37
2. Rating B. Clinical Trial Registration of Mag-EPA in Prostate Cancer
   URL: https://clinicaltrial.be/en/details/11414?per_page=20&only_recruiting=0&only_eligible=0&only_active=0
3. Rating A. Effects of Omega-3 Rich Fish Oil (Mag-EPA) on Prostate Cancer
   URL:
   https://journals.lww.com/auajuro/fulltext/2018/04001/effects_of_omega_3_rich_fish_oil__mag_epa__on.1793.aspx

Mag-EPA Mechanistic Studies

1. Rating A. Mechanistic Study on Mag-EPA: Insights into Its Modulation of Prostate Cancer Biology
   URL: https://www.nature.com/articles/s43856-024-00456-4
2. Rating B. Effects of Eicosapentaenoic Acid on Prostate Cancer Progression (Mechanistic Evaluation)
   URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10960033/
3.

Lovaza

1. Mechanisms of Action

Omega-3 fatty acids, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) found in Lovaza, are recognized for their anti-inflammatory properties [1]. Given the established role of inflammation in the progression of prostate cancer, this anti-inflammatory action suggests a potential mechanism through which Lovaza could exert beneficial effects [2]. Lovaza's primary clinical application is in the management of severe hypertriglyceridemia by reducing triglyceride levels [5]. However, the influence of Lovaza on other lipid parameters, particularly in the context of prostate cancer and its treatments like androgen deprivation therapy (ADT), warrants consideration. While Lovaza is known to lower triglycerides, some data indicate a potential for increased levels of low-density lipoprotein cholesterol (LDL-C) [7], although more recent evidence suggests that DHA might even have a lowering effect on LDL-C [9].

Preclinical investigations have explored the direct effects of omega-3 fatty acids on prostate cancer cells, demonstrating their ability to inhibit tumor cell growth and induce cell death [12]. Specific omega-3 lipids may interfere with growth factor signaling OSNs in prostate cancer cells, potentially through interaction with the free fatty acid receptor 4 (FFA4) [1]. In vitro studies have also indicated that DHA and EPA can prevent the progression of prostate cancer cells towards androgen independence by suppressing the mTOR signaling OSN and the expression of the androgen receptor [14]. Furthermore, animal model research suggests that EPA may possess anti-angiogenic properties, potentially reducing the vascularity of prostate tumors and thereby limiting their growth [15]. The balance between omega-3 and omega-6 fatty acids is also considered important in influencing disease progression, with Western diets typically exhibiting a high ratio of omega-6 to omega-3 fatty acids, which may promote a pro-inflammatory environment [2]. Increasing omega-3 intake could help shift this balance towards a more favorable profile [2].

2. Stages it might be applied to (HSPC, oHSPC, mHSPC, CRPC, oCRPC, mCRPC)

The CAPFISH-3 trial, a recent study, investigated the effects of a high omega-3, low omega-6 diet combined with fish oil supplementation in men with low-risk or favorable intermediate-risk hormone-sensitive prostate cancer (HSPC) on active surveillance [16]. This trial demonstrated a significant reduction in the Ki-67 index, a marker of cell proliferation, suggesting a potential role for such interventions in slowing the growth of early-stage HSPC and possibly delaying the need for more aggressive treatments [17].

In the context of castration-resistant prostate cancer (CRPC), preclinical evidence suggests that omega-3 fatty acids might inhibit the progression to an androgen-independent state [14]. However, current human clinical trial data specifically evaluating Lovaza in established CRPC within the last 5-10 years is limited based on the provided information. One identified trial focused on metastatic CRPC but involved genetically engineered T-cells rather than Lovaza [21]. Therefore, while preclinical findings are encouraging, the application of Lovaza in treating established CRPC requires further investigation in human studies.

Regarding muscle and lipid health, the CAPFISH-3 trial, conducted in a generally high testosterone environment (active surveillance), observed a significant decrease in serum triglycerides in the intervention group receiving the high omega-3 diet and fish oil [16]. However, the provided data does not offer specific insights into Lovaza's effects on muscle health in prostate cancer patients across different disease stages or hormonal environments. While omega-3 fatty acids are often associated with benefits for muscle health in other contexts, dedicated research in prostate cancer is needed to clarify this aspect.

3. Research & Studies

The CAPFISH-3 trial (2024) [16] was a Phase II randomized clinical trial involving 100 men with early-stage prostate cancer on active surveillance. The intervention group followed a diet low in omega-6 and high in omega-3 fatty acids, supplemented with 2.2 grams per day of EPA and DHA from fish oil for one year. The control group maintained their usual diet. The primary outcome was the change in the Ki-67 index. Results showed a statistically significant 15% decrease in Ki-67 in the intervention group compared to a 24% increase in the control group [17]. Additionally, the intervention group experienced a significant reduction in serum triglyceride levels [16].

Conversely, the Brasky et al. studies (2011, 2013) [1], retrospective analyses of the Selenium and Vitamin E Cancer Prevention Trial (SELECT) data, reported an association between higher plasma omega-3 fatty acid levels and an increased risk of prostate cancer, particularly high-grade disease. These findings have been met with considerable debate regarding their methodology and interpretation, with some experts suggesting they do not establish a causal link and might be influenced by other factors [22].

A 2014 study by a Quebec team [1] involving 48 men with low-risk prostate cancer on active surveillance found that higher levels of omega-3 fatty acids within the prostate tissue itself were associated with a protective effect against cancer progression. This suggests that measuring omega-3 levels in the target tissue might be more relevant than relying solely on blood levels.

Researchers from the University of Rochester (2014) [1] analyzed data from the National Health and Examination Study (NHANES) and found no correlation between blood levels of omega-3 fatty acids obtained from fish consumption and prostate cancer risk. This indicates that the source of omega-3s (dietary fish versus supplements) might have differing impacts.

A German study also in 2014 [1] concluded that while omega-3 consumption did not clearly lower the overall incidence of prostate cancer, it might significantly reduce the risk of metastasis and prostate cancer-related mortality, suggesting a potential benefit in more advanced stages of the disease.

Effect of Dietary Omega-3 Fatty Acids on Castrate Resistant Prostate Cancer and Tumor Associated Macrophages - PMC
https://pmc.ncbi.nlm.nih.gov/articles/PMC7031053/#:~:text=the%20%CF%89%E2%88%923%20diet%20was%20significantly,data%20not%20shown



Figure 1: In a mouse model, an omega-3-rich diet (dashed line) significantly delayed progression to castration-resistant prostate cancer compared to an omega-6-rich diet (solid line). A) Tumor volumes after castration show slower regrowth with omega-3. B) Final tumor weights were lower in the omega-3 group ($p<0.05$). C) Kaplan–Meier curve of CRPC-free survival demonstrates prolonged time to CRPC with omega-3 diet ($p=0.006$)

4. Overall Quality of Evidence

The clinical evidence for the use of Lovaza or omega-3 supplementation in prostate cancer is rated b. The recent CAPFISH-3 trial provides promising Phase II data supporting a benefit in early-stage disease [16]. However, the conflicting results from the SELECT trial analyses raise concerns and necessitate further investigation through larger, multi-center Phase III trials [1].

The theoretical basis is rated b. Preclinical studies offer plausible mechanisms for omega-3s' action in prostate cancer, including anti-inflammatory, anti-angiogenic, and direct effects on cancer cell signaling [2]. The established impact on lipid metabolism is also relevant [5].

Nevertheless, a comprehensive understanding of these mechanisms across various disease stages and hormonal environments is still evolving.

The preclinical evidence is rated a. Numerous in vitro and in vivo animal studies strongly support the potential of omega-3 fatty acids in prostate cancer, demonstrating effects on cell proliferation, apoptosis, angiogenesis, and key signaling OSNs [12]. Estimating human equivalent doses from animal studies requires complex pharmacokinetic scaling and is not explicitly provided in the snippets. However, the use of 4g of Lovaza in human trials for breast cancer risk reduction [6] offers a reference point for human dosing.

5. Conclusion

The role of Lovaza and omega-3 fatty acids in prostate cancer management is multifaceted and not yet fully elucidated. While a recent Phase II trial suggests a potential benefit in slowing cancer cell proliferation in early-stage, hormone-sensitive prostate cancer, earlier studies have indicated a possible association with increased risk, although these findings are contested. Preclinical research provides a strong rationale for potential anti-cancer effects. Definitive conclusions regarding the efficacy and safety of Lovaza in different stages of prostate cancer, as well as its impact on muscle and lipid health in varying hormonal environments, necessitate further large-scale, randomized controlled clinical trials.

6. Common Side Effects

The most frequently reported side effects associated with Lovaza include burping, upset stomach, and an altered sense of taste [7]. Other common side effects observed in clinical trials include infection, flu-like symptoms, back pain, and skin rash [7]. Lovaza may also affect certain blood tests, potentially increasing levels of liver enzymes (ALT and AST) and LDL-C [7]. Some individuals may experience gastrointestinal issues such as constipation and vomiting [8]. Due to the potential for omega-3 fatty acids to prolong bleeding time, caution is advised when Lovaza is used in conjunction with anticoagulants or other drugs affecting coagulation, as it may increase the risk of bleeding [5]. Rare but serious side effects can include easy bleeding or bruising, black or tarry stools, and vomit resembling coffee grounds, which could indicate increased bleeding [11]. Allergic reactions are also possible, especially in individuals with known hypersensitivity to fish or shellfish [7]. Furthermore, there is a potential association between Lovaza use and an increased risk of atrial fibrillation or flutter, particularly in patients with pre-existing heart rhythm problems [7].

7. DNA Damage & Double-Strand Breaks (DSBs): Investigate whether (x) influences DNA repair mechanisms, and potential theoretical synergy with DNA-damaging therapies (e.g., BAT, PARP inhibitors, radioligand therapy).

Docosahexaenoic acid (DHA), a key component of Lovaza, has been shown in preclinical studies to influence DNA damage and repair mechanisms in cancer cells [33]. Specifically, DHA can induce oxidative stress, leading to the formation of oxidative DNA adducts by depleting intracellular glutathione and impairing mitochondrial function [33]. While this DNA damage can trigger repair responses, excessive damage may overwhelm these mechanisms, potentially leading to apoptosis and cell cycle arrest in cancer cells [33]. Furthermore, DHA has been observed to inhibit certain DNA repair processes, including DNA-dependent protein kinases and mismatch repair in cancer cells [33]. Another study indicated that DHA can enhance genotoxic stress in prostate cancer cells by suppressing NF-κB, potentially increasing their susceptibility to oxidizing agents [12].

Theoretically, if Lovaza (primarily through its DHA component) can induce DNA damage or impair DNA repair OSNs in prostate cancer cells, this could create a synergistic effect when combined with other DNA-damaging therapies such as bipolar androgen therapy (BAT), PARP inhibitors, and radioligand therapy. By increasing the baseline level of DNA damage or hindering the cells' ability to repair this damage, Lovaza might render cancer cells more vulnerable to the cytotoxic effects of these therapies.
Bipolar androgen therapy (BAT) itself exerts its anti-cancer effects partly by inducing DNA damage and cellular stress through rapid fluctuations in androgen levels. If Lovaza also contributes to DNA damage or impairs DNA repair, it could theoretically augment the efficacy of BAT. However, based on the current evidence, mechanistically it does not appear to synergize with BAT. The primary mechanisms of Lovaza relate to lipid metabolism and anti-inflammatory effects, with some direct action on cancer cell growth and survival OSNs. These mechanisms are distinct from the cyclical androgen receptor activation and suppression that characterizes BAT. Therefore, while Lovaza might not directly interfere with BAT, there is no strong theoretical basis to suggest a synergistic interaction based on the provided information. Further dedicated preclinical and clinical research would be necessary to explore any potential synergistic or interfering effects between Lovaza and BAT.

8. Supplements and Foods

Category	Supplement/ Food	Rating for Prostate Cancer	Rating for Muscle Health	Rating for Lipid Health	Approximate Cost (per serving/typical dose)	Natural vs. Supplement	Good Aspects	Bad Aspects (Heavy Metals, Cost, Efficacy)
Omega-3 Supplements	Fish Oil (general)	B	B	B+	$0.10 - $0.50	Supplement	High in EPA/DHA, convenient.	Potential for fishy aftertaste, variable quality, may contain contaminants, some evidence of increased PCa risk.
	Lovaza (prescription)	B	B	A	Varies by insurance	Supplement (Rx)	High concentration of EPA/DHA, effective for	Requires prescription, potential for increased LDL-C, fish/shellfish allergy

							lowering triglycerides.	caution.
	Algal Oil	B	B	B+	$0.30 - $0.70	Supplement	Vegan source, good EPA/DHA, no fishy taste.	Can be more expensive.
	Krill Oil	C+	B	B	$0.40 - $0.80	Supplement	Omega-3s in phospholipid form, potentially better absorption.	More expensive, lower EPA/DHA content compared to fish oil.
Omega-3 Rich Foods	Salmon (3 oz cooked)	B	B+	B+	$3.00 - $6.00	Natural	Excellent source of EPA/DHA and protein, other nutrients.	Potential for mercury contamination depending on type and source.
	Mackerel (3 oz)	B	B+	A	$1.50 - $3.00	Natural	Very high in EPA/DHA, relatively inexpensive.	Strong taste, potential for mercury.
	Sardines (3 oz canned)	B	B+	A	$1.00 - $2.00	Natural	Good source of EPA/DHA, calcium, and vitamin D, inexpensive.	High in sodium depending on preparation.
	Flaxseeds (1 tbsp)	C+	B	B+	$0.10 - $0.20	Natural	High in ALA (precursor to EPA/DHA), fiber, and lignans.	Conversion of ALA to EPA/DHA in the body is limited.

	Walnuts (1 oz)	C+	B	B	$0.50 - $1.00	Natural	Good source of ALA, antioxidants, and other nutrients.	Lower concentration of omega-3s compared to fatty fish or supplements.
	Chia Seeds (1 oz)	C+	B	B	$0.20 - $0.40	Natural	High in ALA, fiber, and antioxidants.	Lower concentration of omega-3s compared to fatty fish or supplements.

Rating Scale: A (Excellent), B+ (Good), B (Moderate), C+ (Fair), C (Limited), F (Poor)
Note: Costs are approximate and can vary based on brand, source, and location.
Natural food sources of omega-3s offer a broader range of nutrients compared to supplements, which typically provide a concentrated dose of EPA and DHA [34]. While supplements can be a convenient way to increase omega-3 intake, their quality can vary, and concerns exist regarding purity, potency, and potential contamination with heavy metals [1]. Larger fatty fish, which are good sources of omega-3s, can also accumulate mercury [34]. The bioavailability and efficacy of omega-3s might also differ between natural sources and supplements, with some research suggesting that the absorption from ethyl ester forms (common in some processed fish oils) might be less efficient than from triglycerides or phospholipids [40].

9. Bipolar Androgen Therapy (BAT) Synergy/Interference

Mechanistically it does not appear to synergize with BAT.
Based on the available evidence, there is no clear mechanistic theory to suggest that Lovaza would synergize with Bipolar Androgen Therapy (BAT). While some components of Lovaza, such as DHA, may induce DNA damage in cancer cells, the primary mechanism of BAT involves cyclical manipulation of androgen levels to induce stress and DNA damage in prostate cancer cells. These mechanisms are distinct, and no direct evidence suggests a synergistic interaction.
Furthermore, it is unlikely that Lovaza would theoretically interfere with bipolar androgen therapy. The main actions of Lovaza are related to lipid metabolism and anti-inflammatory effects, along with some potential direct effects on prostate cancer cells. These mechanisms do not directly contradict or inhibit the cyclical androgen receptor modulation that is the foundation of BAT. However, further research would be necessary to definitively rule out any unforeseen interactions.

10. References

1. What is Lovaza. URL: https://www.withpower.com/t/lovaza

2. A low omega-6, omega-3 rich diet and fish oil may slow prostate cancer growth, UCLA study finds | UCLA Health. URL: https://www.uclahealth.org/news/release/low-omega-6-omega-3-rich-diet-and-fish-oil-may-slow-prostate
3. Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: Interim feasibility and biomarkers analysis from a clinical trial. URL:(https://www.researchgate.net/publication/225272765_Administration_of_omega-3_fatty_acids_and_Raloxifene_to_women_at_high_risk_of_breast_cancer_Interim_feasibility_and_biomarkers_analysis_from_a_clinical_trial)
4. Omega-3 Fatty Acids and Prostate Cancer: Fact or Fiction? URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3828934/
5. A Phase I Clinical Trial of an Infusion of Autologous gamma delta T cells Genetically Engineered with a Chimeric Receptor to Target the Prostate Stem Cell Antigen in Patients with Metastatic Castration Resistant Prostate Cancer. URL: https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-22344/
6. Omega-3 Fatty Acids Are Beneficial For Prostate Cancer - Sperling Prostate Center. URL: https://sperlingprostatecenter.com/omega-3-fatty-acids-beneficial-prostate-cancer/
7. ASCO GU 2025: A High Omega-3, Low Omega-6 Diet with Fish Oil for Men with Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial. URL: https://www.urotoday.com/conference-highlights/asco-gu-2025/asco-gu-2025-prostate-cancer/158208-asco-gu-2025-a-high-omega-3-low-omega-6-diet-with-fish-oil-for-men-with-prostate-cancer-on-active-surveillance-the-capfish-3-randomized-clinical-trial.html
8. Dietary adjustments may help control prostate cancer in men undergoing active surveillance. URL: https://www.news-medical.net/news/20241214/Dietary-adjustments-may-help-control-prostate-cancer-in-men-undergoing-active-surveillance.aspx
9. High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial. URL: https://pubmed.ncbi.nlm.nih.gov/39671538/
10. Perspective: Does Fish Oil Increase the Risk of Prostate Cancer? URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC6179880/
11. A low omega-6, omega-3 rich diet and fish oil may slow prostate cancer growth, UCLA study finds | UCLA Health. URL: https://www.uclahealth.org/news/release/low-omega-6-omega-3-rich-diet-and-fish-oil-may-slow-prostate
12. Omega-3 Fatty Acids and Prostate Cancer: Fact or Fiction? URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3828934/
13. A low omega-6, omega-3 rich diet and fish oil may slow prostate cancer growth | ScienceDaily. URL: https://www.sciencedaily.com/releases/2024/12/241213211326.htm
14. Omega-3 Fatty Acids and Prostate Cancer: Fact or Fiction? URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3828934/
15. Prostatic and Dietary Omega-3 Fatty Acids and Prostate Cancer Progression during Active Surveillance. URL: https://aacrjournals.org/cancerpreventionresearch/article/7/7/766/50376/Prostatic-and-Dietary-Omega-3-Fatty-Acids-and
16. Omega-3 Fatty Acids Are Beneficial For Prostate Cancer - Sperling Prostate Center. URL: https://sperlingprostatecenter.com/omega-3-fatty-acids-beneficial-prostate-cancer/

17. Omega-3 Fatty Acids and Prostate Cancer - A Study "Spun" Out of Control. URL:(https://www.lipid.org/communications/lipidspin/2014POTPOURRI/11)
18. A low omega-6, omega-3 rich diet and fish oil may slow prostate cancer growth, UCLA study finds | UCLA Health. URL: https://www.uclahealth.org/news/release/low-omega-6-omega-3-rich-diet-and-fish-oil-may-slow-prostate
19. Again, Why Men Should Avoid Fish Oil. URL: https://www.healthline.com/health-news/again-why-men-should-avoid-fish-oil-071113
20. Omega-3 Fatty Acids and Prostate Cancer - A Study "Spun" Out of Control. URL:(https://www.lipid.org/communications/lipidspin/2014POTPOURRI/11)
21. Omega-3 fatty acid inhibition of prostate cancer progression to hormone independence is associated with suppression of mTOR signaling and androgen receptor expression. URL: https://pubmed.ncbi.nlm.nih.gov/21667400/
22. Omega-3 Fatty Acids Are Beneficial For Prostate Cancer - Sperling Prostate Center. URL: https://sperlingprostatecenter.com/omega-3-fatty-acids-beneficial-prostate-cancer/
23. Abstract 4207: DHA enhances genotoxic stress in prostate cancer cells through suppression of NF-κB | Cancer Research | American Association for Cancer Research. URL:(https://aacrjournals.org/cancerres/article/71/8_Supplement/4207/573005/Abstract-4207-DHA-enhances-genotoxic-stress-in)
24. Fish Oil, Prostate Cancer. URL: https://www.voanews.com/a/fish-oil-prostate-cander/1700850.html
25. A high percentage of omega-3 fatty acids in the blood is linked to an increased risk of aggressive prostate cancer | Fred Hutchinson Cancer Center. URL: https://www.fredhutch.org/en/news/releases/2011/04/omega-3-fatty-acid-aggressive-prostate-cancer.html
26. Dietary intervention with Mediterranean foods prior to radical prostatectomy is associated with changes in DNA damage and repair biomarkers. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC4303847/
27. Link between high blood levels of omega-3 fatty acids and prostate cancer - Fred Hutchinson Cancer Research Center | Fred Hutchinson Cancer Center. URL: https://www.fredhutch.org/en/news/releases/2013/07/omega-three-fatty-acids-risk-prostate-cancer.html
28. LOVAZA® FAQs. URL: https://lovaza.com/faqs/
29. Lovaza Side Effects: Common, Severe, Long Term - MedicineNet. URL: https://www.medicinenet.com/side_effects_of_lovaza_omega_3_acid_ethyl_esters/side-effects.htm
30. NDA 021654s022lbl.pdf. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021654s022lbl.pdf
31. Lovaza vs. Vascepa: What's the Difference? - GoodRx. URL: https://www.goodrx.com/conditions/high-triglycerides/lovaza-vascepa-lowering-triglycerides
32. Lovaza Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD. URL: https://www.webmd.com/drugs/2/drug-148529/lovaza-oral/details
33. Omega-3 in fish: How eating fish helps your heart - Mayo Clinic. URL: https://www.mayoclinic.org/diseases-conditions/heart-disease/in-depth/omega-3/art-20045614

34. Omega-3s and your heart. URL: https://www.bhf.org.uk/informationsupport/heart-matters-magazine/nutrition/omega-3s-and-your-heart
35. Omega-3 Fatty Acids. URL: https://ods.od.nih.gov/factsheets/Omega3FattyAcids-Consumer/
36. Omega-3 Fatty Acids - Health Professional Fact Sheet. URL: https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/
37. Fish Oils & Omegas - Walmart.com. URL: https://www.walmart.com/browse/health/fish-oils-omegas/976760_1005863_5274381
38. Omega-3s | Carlson. URL: https://carlsonlabs.com/omega-3s/
39. Amazon.com: fish oil omega 3 supplements. URL:(https://www.amazon.com/fish-oil-omega-3-supplements/dp/B014LDT0ZM)
40. Omega-3. URL: https://www.nordic.com/products/omega-3/
41. Prostatic and Dietary Omega-3 Fatty Acids and Prostate Cancer Progression during Active Surveillance. URL: https://aacrjournals.org/cancerpreventionresearch/article/7/7/766/50376/Prostatic-and-Dietary-Omega-3-Fatty-Acids-and
42. Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity. URL: https://aacrjournals.org/mcr/article-pdf/19/3/516/2313907/516.pdf
43. Researchers show how fatty acids can fight prostate cancer » WSU Spokane. URL: https://pharmacy.wsu.edu/2015/03/18/researchers-show-how-fatty-acids-can-fight-prostate-cancer/
44. Marine- and plant-derived ω-3 fatty acids differentially regulate prostate cancer cell proliferation. URL: https://www.spandidos-publications.com/10.3892/mco.2013.76
45. Omega-3 Polyunsaturated Fatty Acids and Prostate Cancer. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3676993/
46. Omega-3 Fatty Acids and Prostate Cancer: Fact or Fiction? URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3828934/
47. A low omega-6, omega-3 rich diet and fish oil may slow prostate cancer growth, UCLA study finds | UCLA Health. URL: https://www.uclahealth.org/news/release/low-omega-6-omega-3-rich-diet-and-fish-oil-may-slow-prostate
48. Omega-3 Fatty Acids Are Beneficial For Prostate Cancer - Sperling Prostate Center. URL: https://sperlingprostatecenter.com/omega-3-fatty-acids-beneficial-prostate-cancer/
49. Prostatic and Dietary Omega-3 Fatty Acids and Prostate Cancer Progression during Active Surveillance. URL: https://aacrjournals.org/cancerpreventionresearch/article/7/7/766/50376/Prostatic-and-Dietary-Omega-3-Fatty-Acids-and
50. Link between high blood levels of omega-3 fatty acids and prostate cancer - Fred Hutchinson Cancer Research Center | Fred Hutchinson Cancer Center. URL: https://www.fredhutch.org/en/news/releases/2013/07/omega-three-fatty-acids-risk-prostate-cancer.html
51. Omega-3 Fatty Acids and Prostate Cancer: Fact or Fiction? URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3828934/
52. Omega-3 Polyunsaturated Fatty Acids and Prostate Cancer. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3676993/
53. Omega-3 Fatty Acids and Prostate Cancer - A Study "Spun" Out of Control. URL: (https://www.lipid.org/communications/lipidspin/2014POTPOURRI/11)
54. Omega-3 polyunsaturated fatty acids in hematological malignancies. URL: https://www.oncotarget.com/article/24405/text/
55. NDA 021654s014pi.pdf. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021654s014pi.pdf

56. NDA 021654s014pi.pdf. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021654s014pi.pdf
57. Omega-3 Fatty Acids (Lovaza) Side Effects, Dosage, Uses, Warnings. URL: https://www.buzzrx.com/omega-3-acid-ethyl-esters/side-effects
58. LOVAZA® FAQs. URL: https://lovaza.com/faqs/
59. Lovaza - Side Effects, Dosage, Interactions - RxList. URL: https://www.rxlist.com/lovaza-drug.htm
60. Lovaza Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD. URL: https://www.webmd.com/drugs/2/drug-148529/lovaza-oral/details
61. Omega-3 Polyunsaturated Fatty Acids and Prostate Cancer. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3676993/
62. A high percentage of omega-3 fatty acids in the blood is linked to an increased risk of aggressive prostate cancer | Fred Hutchinson Cancer Center. URL: https://www.fredhutch.org/en/news/releases/2011/04/omega-3-fatty-acid-aggressive-prostate-cancer.html
63. Docosahexaenoic Acid (DHA) and Cancer: A Review of the Recent Evidence. URL: https://www.mdpi.com/1422-0067/17/8/1257
64. Link between high blood levels of omega-3 fatty acids and prostate cancer - Fred Hutchinson Cancer Research Center | Fred Hutchinson Cancer Center. URL: https://www.fredhutch.org/en/news/releases/2013/07/omega-three-fatty-acids-risk-prostate-cancer.html
65. Regulation of prostate cancer cell growth by specific fatty acids. URL: https://academic.oup.com/carcin/article/22/5/701/2733794
66. Amazon.com: Sports Research Triple Strength Omega 3 Fish Oil - Burpless Fish Oil Supplement w/EPA & DHA Fatty Acids from Single-Source Wild Alaskan Pollock - 1250 mg, 90 ct.: Health & Household. URL:(https://www.amazon.com/Sports-Research-Triple-Strength-Supplement/dp/B07DX89ZHN)
67. The State of the Science: Omega-3s. URL: https://gfi.org/solutions/omega-3-ingredients/
68. The True Cost of Fish Oil - Zone Living. URL: https://blog.zoneliving.com/drsears/truecostfishoil
69. 12 Foods That Are Very High in Omega-3. URL: https://www.healthline.com/nutrition/12-omega-3-rich-foods
70. What are the best food sources of omega-3? URL: https://www.medicalnewstoday.com/articles/323144
71. Omega-3 Supplements: What You Need To Know | NCCIH. URL: https://www.nccih.nih.gov/health/omega3-supplements-what-you-need-to-know
72. omega-3 potency+ | mindbodygreen. URL: https://shop.mindbodygreen.com/products/omega-3-potency
73. The Ultimate Guide to Omega-3 Supplements. URL: https://www.healthline.com/nutrition/omega-3-supplement-guide
74. High-Quality Omega-3 Fish Oil & Algae Oil Supplements | Nordic Naturals. URL: https://www.nordic.com/omega-3s/
75. Article Last Updated Date: December 13, 2024. URL: https://www.uclahealth.org/news/release/low-omega-6-omega-3-rich-diet-and-fish-oil-may-slow-prostate
76. Article Last Updated Date: February 17, 2025. URL: https://www.urotoday.com/conference-highlights/asco-gu-2025/asco-gu-2025-prostate-cancer/158208-asco-gu-2025-a-high-omega-3-low-omega-6-diet-with-fish-oil-for-men-with-prostate-cancer-on-active-surveillance-the-capfish-3-randomized-clinical-trial.html
77. Article Last Updated Date: 2024 Dec 13. URL: https://pubmed.ncbi.nlm.nih.gov/39671538/

78. Article Last Updated Date: November 21st, 2023. URL: https://sperlingprostatecenter.com/omega-3-fatty-acids-beneficial-prostate-cancer/
79. Article Last Updated Date: Unknown. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3828934/

11. Works cited

1. Omega-3 Fatty Acids Are Beneficial For Prostate Cancer, accessed March 18, 2025, https://sperlingprostatecenter.com/omega-3-fatty-acids-beneficial-prostate-cancer/
2. Prostatic and Dietary Omega-3 Fatty Acids and Prostate Cancer Progression during Active Surveillance | Cancer Prevention Research - AACR Journals, accessed March 18, 2025, https://aacrjournals.org/cancerpreventionresearch/article/7/7/766/50376/Prostatic-and-Dietary-Omega-3-Fatty-Acids-and
3. Mechanisms of Omega-3 Polyunsaturated Fatty Acids in Prostate Cancer Prevention - PMC, accessed March 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3676993/
4. Prostate Cancer Risk And Omega-3 Fatty Acid Intake From Fish Oil: A Closer Look at Media Messages Versus Research Findings - PMC, accessed March 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3828934/
5. Lovaza: Everything you need to know | Power - Clinical Trials, accessed March 18, 2025, https://www.withpower.com/t/lovaza
6. Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: Interim feasibility and biomarkers analysis from a clinical trial - ResearchGate, accessed March 18, 2025, https://www.researchgate.net/publication/225272765_Administration_of_omega-3_fatty_acids_and_Raloxifene_to_women_at_high_risk_of_breast_cancer_Interim_feasibility_and_biomarkers_analysis_from_a_clinical_trial
7. Frequently Asked Questions About LOVAZA, accessed March 18, 2025, https://lovaza.com/faqs/
8. LOVAZA (omega-3-acid ethyl esters) Capsules - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed March 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021654s022lbl.pdf
9. Lovaza vs. Vascepa: Which Fish Oil Should You Take? - GoodRx, accessed March 18, 2025, https://www.goodrx.com/conditions/high-triglycerides/lovaza-vascepa-lowering-triglycerides
10. www.accessdata.fda.gov, accessed March 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021654s014pi.pdf
11. Lovaza (Omega-3-Acid Ethyl Esters): Side Effects, Uses, Dosage, Interactions, Warnings, accessed March 18, 2025, https://www.rxlist.com/lovaza-drug.htm
12. Abstract 4207: DHA enhances genotoxic stress in prostate cancer cells through suppression of NF-κB - AACR Journals, accessed March 18, 2025, https://aacrjournals.org/cancerres/article/71/8_Supplement/4207/573005/Abstract-4207-DHA-enhances-genotoxic-stress-in
13. Researchers show how fatty acids can fight prostate cancer, accessed March 18, 2025, https://pharmacy.wsu.edu/2015/03/18/researchers-show-how-fatty-acids-can-fight-prostate-cancer/

14. Omega-3 fatty acid inhibition of prostate cancer progression to hormone independence is associated with suppression of mTOR signaling and androgen receptor expression - PubMed, accessed March 18, 2025, https://pubmed.ncbi.nlm.nih.gov/21667400/
15. Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity - AACR Journals, accessed March 18, 2025, https://aacrjournals.org/mcr/article-pdf/19/3/516/2313907/516.pdf
16. ASCO GU 2025: A High Omega-3, Low Omega-6 Diet with Fish Oil ..., accessed March 18, 2025, https://www.urotoday.com/conference-highlights/asco-gu-2025/asco-gu-2025-prostate-cancer/158208-asco-gu-2025-a-high-omega-3-low-omega-6-diet-with-fish-oil-for-men-with-prostate-cancer-on-active-surveillance-the-capfish-3-randomized-clinical-trial.html
17. A low omega-6, omega-3 rich diet and fish oil may slow prostate cancer growth, UCLA study finds | UCLA Health, accessed March 18, 2025, https://www.uclahealth.org/news/release/low-omega-6-omega-3-rich-diet-and-fish-oil-may-slow-prostate
18. Dietary adjustments may help control prostate cancer in men undergoing active surveillance, accessed March 18, 2025, https://www.news-medical.net/news/20241214/Dietary-adjustments-may-help-control-prostate-cancer-in-men-undergoing-active-surveillance.aspx
19. High Omega-3, Low Omega-6 Diet With Fish Oil for Men With ..., accessed March 18, 2025, https://pubmed.ncbi.nlm.nih.gov/39671538/
20. A low omega-6, omega-3 rich diet and fish oil may slow prostate cancer growth | ScienceDaily, accessed March 18, 2025, https://www.sciencedaily.com/releases/2024/12/241213211326.htm
21. Do Omega-3 Fatty Acids Cause Prostate Cancer? - PMC, accessed March 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6179880/
22. Omega-3 Fatty Acids and Prostate Cancer - A Study "Spun" Out of Control, accessed March 18, 2025, https://www.lipid.org/communications/lipidspin/2014POTPOURRI/11
23. Why Men Should Avoid Fish Oil Supplements - Healthline, accessed March 18, 2025, https://www.healthline.com/health-news/again-why-men-should-avoid-fish-oil-071113
24. Study Links Omega-3 Fatty Acids to Prostate Cancer - VOA, accessed March 18, 2025, https://www.voanews.com/a/fish-oil-prostate-cander/1700850.html
25. A high percentage of omega-3 fatty acids in the blood is linked to an increased risk of aggressive prostate cancer, accessed March 18, 2025, https://www.fredhutch.org/en/news/releases/2011/04/omega-3-fatty-acid-aggressive-prostate-cancer.html
26. Link between high blood levels of omega-3 fatty acids and prostate cancer, accessed March 18, 2025, https://www.fredhutch.org/en/news/releases/2013/07/omega-three-fatty-acids-risk-prostate-cancer.html
27. Marine- and plant-derived ω-3 fatty acids differentially regulate prostate cancer cell proliferation - Spandidos Publications, accessed March 18, 2025, https://www.spandidos-publications.com/10.3892/mco.2013.76
28. Effects of the polyunsaturated fatty acids, EPA and DHA, on hematological malignancies: a systematic review | Oncotarget, accessed March 18, 2025, https://www.oncotarget.com/article/24405/text/

29. Side Effects of Lovaza (omega-3-acid ethyl esters): Interactions & Warnings - MedicineNet, accessed March 18, 2025, https://www.medicinenet.com/side_effects_of_lovaza_omega_3_acid_ethyl_esters/side-effects.htm
30. Lovaza Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed March 18, 2025, https://www.webmd.com/drugs/2/drug-148529/lovaza-oral/details
31. Omega-3 Acid Ethyl Esters Side Effects - BuzzRx, accessed March 18, 2025, https://www.buzzrx.com/omega-3-acid-ethyl-esters/side-effects
32. Docosahexaenoic Acid Induces Oxidative DNA Damage and Apoptosis, and Enhances the Chemosensitivity of Cancer Cells - MDPI, accessed March 18, 2025, https://www.mdpi.com/1422-0067/17/8/1257
33. Omega-3 in fish: How eating fish helps your heart - Mayo Clinic, accessed March 18, 2025, https://www.mayoclinic.org/diseases-conditions/heart-disease/in-depth/omega-3/art-20045614
34. Omega-3 foods and your heart - British Heart Foundation, accessed March 18, 2025, https://www.bhf.org.uk/informationsupport/heart-matters-magazine/nutrition/omega-3s-and-your-heart
35. Omega-3 Fatty Acids - Consumer - NIH Office of Dietary Supplements, accessed March 18, 2025, https://ods.od.nih.gov/factsheets/Omega3FattyAcids-Consumer/
36. Omega-3 Fatty Acids - Health Professional Fact Sheet - NIH Office of Dietary Supplements, accessed March 18, 2025, https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/
37. 12 Foods That Are Very High in Omega-3 - Healthline, accessed March 18, 2025, https://www.healthline.com/nutrition/12-omega-3-rich-foods
38. 15 Foods That Are Very High in Omega-3 - MedicalNewsToday, accessed March 18, 2025, https://www.medicalnewstoday.com/articles/323144
39. Omega-3 Supplement Guide: What to Buy and Why - Healthline, accessed March 18, 2025, https://www.healthline.com/nutrition/omega-3-supplement-guide
40. Omega-3 Supplements | Algae, Fish Oil, DHA, CoQ10 | Nordic Naturals, accessed March 18, 2025, https://www.nordic.com/omega-3s/

Aspirin

Mechanisms of Action

Anti-Thrombotic and Anti-Inflammatory Effects

Aspirin irreversibly acetylates cyclooxygenase-1 (COX-1) in platelets, preventing thromboxane A_2 (TXA_2) synthesis and thereby inhibiting platelet aggregation with grade A evidence. By reducing prostaglandin production, aspirin also exerts anti-inflammatory actions that disrupt the tumor-promoting microenvironment.

Immune Modulation

Aspirin's reduction of TXA_2 prevents platelet "cloaking" of circulating tumor cells, enhancing cytotoxic T-cell–mediated clearance of metastatic cells (grade C–D evidence).

Influence on PSA and Tumor Biology

Observational studies report modestly lower PSA levels in aspirin users (grade B–C evidence). This may reflect direct antitumor effects or PSA masking; clinicians should interpret PSA trends alongside clinical context.

COX-Dependent and COX-Independent Mechanisms

- **Dual COX Inhibition:** Low-dose aspirin inhibits both COX-1 and COX-2, reducing PGE_2-mediated tumor growth and shifting arachidonic acid metabolism toward anti-inflammatory mediators.
- **NF-κB Pathway Modulation:** Aspirin paradoxically activates NF-κB in cancer cells, promoting apoptosis through IκBα degradation and RelA nuclear translocation, selectively sparing normal tissue.

Anti-Angiogenic Effects

Aspirin normalizes tumor vasculature, with studies showing larger vessel diameter and reduced irregularity in both low-grade and high-grade cancers.

Enteric-Coated versus Non-Enteric (Plain) Aspirin

Aspirin formulations differ in absorption site, rate, and bioavailability:

- Plain (non-enteric) aspirin dissolves in the stomach, achieving peak plasma levels (T_{max}) at ~0.5 h and near-complete bioavailability for platelet COX-1 inhibition. Peak antiplatelet effect (TXB_2 suppression) occurs within 1–1.5 h at low doses[1].

- Enteric-coated (EC) aspirin resists gastric dissolution, releasing in the small intestine and delaying T_{max} to ~4–5 h with lower and more variable bioavailability[1]. In patients weighing >70 kg, EC formulations yield suboptimal TXA_2 inhibition and higher “aspirin resistance” rates[2].

Clinical Implication: For consistent platelet inhibition, plain aspirin is preferred; if only EC tablets are available, crushing or chewing them abolishes the coating and restores efficacy.

Key Mechanisms by Which Aspirin Prevents Metastasis

1. Platelet-Mediated "Cloaking" Prevention

Aspirin irreversibly inhibits COX-1 in platelets, preventing the production of thromboxane A_2 (TXA_2)[12]. This mechanism is particularly important because:

- **Platelets normally "cloak" circulating tumor cells**, protecting them from immune detection during metastatic spread[13]
- **TXA_2 suppresses T-cell immunity** against metastasizing cancer cells through the ARHGEF1 pathway[24]
- **Aspirin disrupts this protective relationship**, exposing tumor cells to immune attack when they are most vulnerable—during the initial stages of metastatic spread[12]

2. Enhanced T-Cell Immune Surveillance

A groundbreaking 2025 study published in *Nature* revealed that **aspirin enhances immunity to cancer metastasis by releasing T cells from TXA_2-mediated suppression**[24]. The mechanism involves:

- **TXA_2 triggers an immunosuppressive pathway** dependent on the guanine exchange factor ARHGEF1
- **This suppresses T cell receptor-driven signaling, proliferation, and effector functions**[2]
- **Aspirin blocks this suppression**, allowing T cells to effectively target metastasizing cancer cells[56]

3. Disruption of Tumor Cell-Platelet Communication

Research demonstrates that **aspirin disrupts the crosstalk between platelets and tumor cells**[37]:

- **Platelets activate the Akt pathway in tumor cells**, promoting invasion and IL-8 secretion[37]
- **Aspirin-treated platelets cannot activate this pathway**, resulting in 43-68% reduction in tumor cell invasion[37]
- **Patients with breast cancer taking aspirin had lower circulating IL-8** and reduced platelet-mediated tumor cell invasion[3]

Clinical Evidence

Meta-Analysis Data

Multiple large-scale analyses support aspirin's anti-metastatic effects:

- **Meta-analyses of randomized controlled trials show aspirin reduces metastasis** at multiple sites (HR 0.64, 95% CI 0.48-0.84)[28]
- **Low-dose aspirin (75-300 mg) reduces cancer death rates** in patients without metastasis at diagnosis (HR 0.49, 95% CI 0.30-0.79)[2]
- **Systematic reviews indicate approximately 20% reduction in mortality** in cancer patients taking aspirin[9]

Cancer-Specific Evidence

Breast Cancer: Post-diagnostic aspirin use associated with **21% reduction in cancer-specific mortality** (HR 0.79, 95% CI 0.64-0.98)[10]

Prostate Cancer: Recent study showed **aspirin enhanced biochemical recurrence-free survival** after radical prostatectomy, especially in higher-grade tumors[11]

Colorectal Cancer: Strong evidence for reduced metastasis, with aspirin being the only medication receiving limited recommendation from UK NICE for this indication[9]

Optimal Timing and Dosing

Critical Timing Window

Aspirin must be administered before tumor cells enter the bloodstream for maximum anti-metastatic effect[1]. This makes it particularly valuable for:

- **Early-stage cancer patients at risk of recurrence**[12][13]
- **Post-surgical patients** where micrometastases may already be circulating[14]
- **Patients during the "therapeutic window of vulnerability"** when metastasizing cells are most susceptible to immune attack[15][13]

Dosing Considerations

Low-dose aspirin (100-325 mg daily) appears optimal because:

- **Daily low-dose primarily targets platelet COX-1** due to aspirin's short half-life (~20 minutes)[2]
- **Anucleated platelets cannot resynthesize COX-1**, making the inhibition permanent until new platelets are produced[2]
- **Higher doses may not provide additional anti-metastatic benefit** while increasing bleeding risk[1]
- **Dosage and Timing Considerations**
- **High-Dose (>100 mg):** Greater anti-inflammatory benefit but increased GI and bleeding risk.
- **Body Weight Impact:** EC formulations particularly underperform in heavier patients (≥70 kg)[2].

Limitations and Considerations

Study Limitations

- **Most mechanistic data comes from animal models**[11][6][17]
- **Human studies are primarily observational** rather than randomized controlled trials
- **Aspirin must be given preventatively** rather than after metastasis is established

Synergy with Advanced Androgen-Based Therapies

Bipolar Androgen Therapy (aBAT)

Aspirin’s antiplatelet action irreversibly acetylates COX-1, reducing TXA_2 and preventing platelet “cloaking” of circulating tumor cells1. In aBAT, supraphysiologic testosterone pulses induce TOP2B-mediated DNA double-strand breaks and prime antitumor immunity by exposing tumor antigens2. By blocking platelet aggregation, aspirin may enhance immune-mediated clearance of damaged tumor cells during both the high-T and low-T phases of aBAT, potentially improving circulating tumor cell eradication.

ARSI-SPA Combination (A-SPA)
In the A-SPA regimen, supraphysiologic androgen (SPA) pulses trigger AR-independent DNA damage via TOP2B overload, while concurrent ARSI blocks AR nuclear signaling to prevent adaptive resistance3. Aspirin’s COX inhibition lowers PGE_2, a mediator of DNA repair and inflammation1. This dual reduction in repair-promoting prostaglandins and AR-driven repair signaling may amplify genomic stress in micrometastatic cells, enhancing DNA damage accumulation during SPA cycles and inhibiting tumor repopulation.

Adaptive Vitamin D Receptor Cycling (aVDR)
Adaptive VDR cycling uses intermittent high-dose calcitriol to activate p21 and modulate ATM kinase, inducing cell-cycle arrest and synthetic lethality with PARP inhibitors4. Aspirin’s anti-inflammatory effects further diminish PGE_2-driven pro-survival signaling in the tumor microenvironment1. Additionally, platelet inhibition may improve perfusion and drug delivery during calcitriol pulses. Together, aspirin and aVDR coordinate anti-platelet, anti-inflammatory, and DNA repair–suppressive mechanisms to potentiate tumor cell apoptosis and impede resistance development.

Side Effects

- Gastrointestinal: dyspepsia, ulcer risk
- Bleeding: GI bleeding, hemorrhagic stroke
- Other: tinnitus, rare asthma exacerbation, renal impairment

Reference Table

URL	Title	Quality Rating
https://pmc.ncbi.nlm.nih.gov/articles/PMC10145431/	Pharmacological Efficacy and Gastrointestinal Safety of Different Aspirin Formulations for Cardiovascular Prevention: A Narrative Review	A (peer-review)
https://www.ahajournals.org/doi/pdf/10.1161/01.str.0000231683.43347.ec	Effect of Enteric Coating on Antiplatelet Activity of Low-Dose Aspirin in Healthy Volunteers	A (peer-review)

URL	Title	Quality Rating
https://pmc.ncbi.nlm.nih.gov/articles/PMC10443535/	Pharmacokinetic and Pharmacodynamic Profiles of a Novel Phospholipid-Aspirin Complex and Low-Dose EC Aspirin	A (peer-review)
https://www.jacc.org/doi/10.1016/j.jacc.2016.11.050	Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus	A (peer-review)
https://scholars.mssm.edu/.../pharmacokinetic-and-pharmacodynamic-profiles-of-a-novel-phospholipid-aspirin	Pharmacokinetic and Pharmacodynamic Profiles of a Novel Phospholipid-Aspirin Complex	A (peer-review)
https://www.ahajournals.org/doi/10.1161/01.str.0000231683.43347.ec	Effect of Enteric Coating on Antiplatelet Activity of Low-Dose Aspirin in Healthy Volunteers	A (peer-review)
https://onlinelibrary.wiley.com/doi/abs/10.1111/eci.12373	Incomplete Recovery of Platelet COX Activity Explains Aspirin Nonresponsiveness in Diabetic and Nondiabetic Patients	A (peer-review)
https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-q-and-a-coated-aspirin-may-not-be-as-effective-at-reducing-blood-clot-risk/	Coated Aspirin May Not Be as Effective at Reducing Blood Clot Risk	C (institutional)
https://my.clevelandclinic.org/health/drugs/20629-aspirin-enteric-coated-capsules-or-tablets	Aspirin (Enteric-Coated) Capsules or Tablets	C (institutional)
https://pmc.ncbi.nlm.nih.gov/articles/PMC8773391/	Pharmacokinetic and Pharmacodynamic Profile of a Novel Aspirin Formulation	A (peer-review)

Sulforaphane

Sulforaphane—a bioactive compound found in cruciferous vegetables—has been shown in numerous preclinical studies to inhibit prostate cancer cell growth, induce apoptosis, and even modulate androgen receptor signaling. However, while the laboratory data are promising, clinical studies evaluating sulforaphane for prostate cancer are limited to early-phase or pilot investigations.

1. Mechanisms of Action

1. Epigenetic Modulation and HDAC Inhibition
    - Mechanism: Sulforaphane is known to inhibit histone deacetylases (HDACs). This inhibition can lead to the reactivation of tumor suppressor genes and may alter the expression of genes involved in cell cycle regulation and apoptosis.
    - Evidence Quality:
        - *Preclinical mechanistic studies*: Numerous in vitro studies have consistently demonstrated HDAC inhibition and downstream gene expression changes in PCa cell lines (Quality: B).
2. Activation of the Nrf2 OSN and Detoxification Enzymes
    - Mechanism: Sulforaphane activates nuclear factor erythroid 2–related factor 2 (Nrf2), leading to the upregulation of phase II detoxification enzymes. This enhances the cell's ability to counteract oxidative stress and carcinogen-induced damage.
    - Evidence Quality:
        - *Preclinical data*: Strong and reproducible in multiple models (Quality: B).
3. Inhibition of Inflammatory OSNs
- Mechanism: By suppressing the activity of NF-κB, sulforaphane can reduce the production of inflammatory cytokines. Chronic inflammation is known to contribute to tumor initiation and progression in PCa.
- Evidence Quality:
    - *Laboratory studies*: Consistent inhibition of NF-κB signaling in prostate cancer cell lines has been reported (Quality: B).
4. Induction of Apoptosis and Cell Cycle Arrest
- Mechanism: Sulforaphane has been shown to induce apoptosis (programmed cell death) and arrest the cell cycle in PCa cells, thereby reducing proliferation.
- Evidence Quality:
    - *Preclinical in vitro and in vivo*: Multiple studies in cell culture and xenograft models confirm these effects (Quality: B).

2. Research & Studies

1. Preclinical Studies:
- In Vitro Models:

    - Studies using PCa cell lines (e.g., LNCaP, DU145, PC3) have demonstrated that sulforaphane treatment reduces cell viability, triggers apoptotic OSNs, and causes cell cycle arrest.
    - These experiments also document HDAC inhibition, reduced NF-κB activity, and activation of Nrf2-mediated OSNs.
- In Vivo Models:
    - Animal studies and xenograft models have shown that sulforaphane can slow tumor growth and, in some cases, shrink established tumors.
    - *Quality of Preclinical Evidence:* Consistent, reproducible findings across multiple models place these studies at a B level.
        - Pilot and Early-Phase Trials:
            - A few small-scale clinical studies and pilot trials have explored sulforaphane (or broccoli sprout extracts rich in sulforaphane) in PCa patients.
            - These studies have primarily focused on safety, pharmacodynamics, and surrogate endpoints (like PSA modulation or biomarkers of inflammation), but they are limited by small sample sizes and short follow-up durations.
        - Randomized Controlled Trials:
            - To date, there are no large phase III randomized controlled trials specifically evaluating sulforaphane for PCa treatment or prevention.
            - *Quality of Clinical Evidence:* Due to limited clinical data and the predominance of early-phase studies, the clinical evidence is rated as D.

3. Overall Quality of Evidence

- Anticancer (Prostate Cancer) Evidence – Grade B: The body of evidence supporting SFN's anticancer effects in prostate cancer is substantial but not yet conclusive. On the plus side, there is robust preclinical evidence: numerous cell culture and animal studies have reproducibly shown that SFN can suppress prostate tumor growth through well-documented mechanisms
- This is bolstered by epidemiological data linking high intake of cruciferous vegetables (broccoli, etc.) with lower prostate cancer risk
- Importantly, early-phase clinical studies provide proof-of-concept in humans – the 2015 randomized trial demonstrated a significant slowing of PSA progression in men taking SFN
- However, limitations remain: clinical data are still sparse (small sample sizes, short follow-up, surrogate endpoints like PSA). No large-scale phase III trials or long-term outcome data (e.g. reduced metastasis or improved survival) are available yet. Therefore, while the mechanistic rationale and preliminary results are strong (warranting a "B" grade, indicating good/moderate evidence), more high-quality clinical research is needed before SFN can be considered an established therapy for prostate cancer. Future trials should confirm efficacy on clinical endpoints and optimal dosing.

4. Summary

- Sulforaphane exhibits multiple anticancer mechanisms relevant to prostate cancer—including HDAC inhibition, activation of detoxification OSNs, suppression of inflammatory signals, and induction of apoptosis—which are well supported by robust preclinical

research (rated B). However, clinical research is still in its early stages with limited data from small pilot studies (rated D). Overall, while the mechanistic rationale is strong, further large-scale clinical trials are necessary before sulforaphane can be recommended as a treatment option for PCa.

- Sulforaphane has a short half-life of 2.2 hours

5. Common Side Effects

Sulforaphane from diet or supplements is generally well-tolerated, with no serious toxicities reported at typical doses
Nonetheless, some mild adverse effects have been documented, especially at higher doses or with concentrated SFN supplements. Common side effects include:

- Gastrointestinal disturbances:

Bloating, increased gas, abdominal discomfort, and changes in bowel habits (constipation or diarrhea) are among the most frequently reported issues
These effects are usually transient and dose-dependent.

- Insomnia or Sleep Disturbance:

In some trials, a subset of individuals reported difficulty sleeping or mild insomnia while taking SFN supplements
This was not universal and may relate to individual sensitivity.

- Allergic or Idiosyncratic Reactions:

Rarely, people have noted headaches, nausea, or skin rash. In one review of SFN use in autism, a few participants experienced increased irritability or worsened seasonal allergy symptoms
.Such effects are uncommon and typically resolve after discontinuation.

- Weight Fluctuation: Minor weight gain was observed in certain long-term studies (this could be incidental or due to improved appetite in some cases)

Overall, sulforaphane's side effects tend to be mild. Ensuring intake via whole foods (e.g. broccoli sprouts) may mitigate some gastrointestinal side effects compared to large-dose supplements. It's also worth noting that because SFN can influence liver enzymes and potentiate detoxification OSNs, it's theoretically possible it could affect the metabolism of some medications, though no significant drug interactions have been well-documented in humans. As always, individuals should start with modest doses and consult healthcare providers if they have any adverse symptoms.

6. References

1. The role of Sulforaphane in cancer chemoprevention and health benefits: a mini-review - PMC
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842175/

2. Effect of Sulforaphane in Men with Biochemical Recurrence after Radical Prostatectomy - PubMed https://pubmed.ncbi.nlm.nih.gov/25968598/
3. Table 3 | Sulforaphane: Its “Coming of Age” as a Clinically Relevant Nutraceutical in the Prevention and Treatment of Chronic Disease https://www.hindawi.com/journals/omcl/2019/2716870/tab3/?fbclid=IwAR2JbyPShIn4OUe-IaCfRHY6wBMaIPKRm1BL3D-_9ljK7ucm9nz4J-YuLRo
4. KEAP1 and done? Targeting the NRF2 OSN with sulforaphane – PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC5725197/
5. Sulforaphane (broccoli sprouts) reduces benzene contamination from air pollution (a VOC): Broccoli Sprout Dose Response: Bioavailability and Effects of Air Pollutants - Study Results - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/results/NCT02656420
6. 3rd party lab analysis of various sulforaphane supplements https://static.wixstatic.com/media/8b60da_17697c3720304b36acfb688bccada7b5~mv2.jpg/v1/fill/w_980,h_1637,al_c,q_85,enc_auto/bar-chart-1-6-21.jpg
7. The Bioavailability of Nutritional Supplements Rich in Sulforaphane - Chemoprotection Center https://chemoprotectioncenter.org/bioavailability-nutritional-supplements-rich-sulforaphane/
8. We don’t know what the proper dose is: Broccoli or Sulforaphane: Is It the Source or Dose That Matters? - PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804255/
9. Anticancer Activity of Sulforaphane: The Epigenetic Mechanisms and the Nrf2 Signaling OSN - PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011061/

Curcumin

1. Mechanisms of Action

- Anti-inflammatory and NF-κB Inhibition: Curcumin suppresses NF-κB signaling, thereby reducing pro-inflammatory cytokines that can promote prostate cancer cell survival and proliferation.
- Induction of Apoptosis & Cell Cycle Arrest: It activates apoptotic OSNs and induces cell cycle arrest in prostate cancer cells via modulation of proteins such as Bcl-2 and cyclin D1.
- Inhibition of Androgen Receptor (AR) Signaling: Preclinical studies have shown that curcumin can downregulate AR expression and interfere with AR-mediated transcription, potentially reducing the androgen-driven growth of prostate cancer cells.
- Anti-angiogenic and Anti-metastatic Effects: Curcumin may also inhibit angiogenesis and metastasis by modulating growth factors and matrix metalloproteinases.

---

2. Research & Studies

- Preclinical Studies:
  - Numerous in vitro studies using prostate cancer cell lines (e.g., LNCaP, DU145, PC3) have demonstrated that curcumin decreases cell proliferation, induces apoptosis, and downregulates AR expression.
  - Animal models have also shown that curcumin can slow tumor growth and reduce metastatic potential.
  - *Quality of Preclinical Evidence:* Rated B for mechanistic consistency and reproducibility.
- Clinical Studies:
  - Early-phase clinical trials and pilot studies have investigated curcumin (often via oral formulations or green tea extracts) in patients with prostate cancer, mostly focusing on safety, tolerability, and effects on biomarkers such as PSA levels.
  - However, these studies are generally small, with mixed results regarding efficacy.
  - *Quality of Clinical Evidence:* Rated D due to limited sample sizes and lack of large randomized controlled trials.

---

3. Overall Quality of Evidence

- Curcumin as a Monotherapy in PCa:
  - Mechanistic & Preclinical Evidence: B – Robust and consistent laboratory data support curcumin’s anticancer activities in prostate cancer models.
  - Clinical Evidence: D – Limited and preliminary, with small-scale studies and inconclusive outcomes.

---

4. Summary

Curcumin exhibits multiple anticancer mechanisms that are relevant to prostate cancer, including anti-inflammatory effects, induction of apoptosis, cell cycle arrest, and inhibition of AR signaling. Preclinical research strongly supports these actions (quality rating B), but the clinical evidence is still in its early stages and remains inconclusive (quality rating D).

5. References

1. Curcumin against Prostate Cancer: Current Evidence - PMC
   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696488/
2. A randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation - PubMed
   https://pubmed.ncbi.nlm.nih.gov/30671976/
3. Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer – PubMed
   https://pubmed.ncbi.nlm.nih.gov/33666378
4. Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients with Multiple Myeloma ClinicalTrials.gov
   https://www.clinicaltrials.gov/ct2/show/NCT00113841
5. The Holy Grail of Curcumin and its Efficacy in Various Diseases: Is Bioavailability Truly a Big Concern? – PMC
   https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC6424351
6. Comparative absorption of curcumin formulations | Nutrition Journal | Full Text
   https://nutritionj.biomedcentral.com/articles/10.1186/1475-2891-13-11
7. NovaSol bioavailability: Pharmacokinetics of a Single Dose of Turmeric Curcuminoids Depends on Formulation: Results of a Human Crossover Study - PMC
   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245892/
8. Curcumin inhibits aerobic glycolysis and induces mitochondrial-mediated apoptosis through hexokinase II in human colorectal cancer cells in vitro – PubMed
   https://pubmed.ncbi.nlm.nih.gov/25229889
9. Testable blood glucose changes: Curcumin alleviates postprandial glycemic response in healthy subjects: A cross-over, randomized controlled study - PMC
   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135827/
10. Curcuma longa extract improves serum inflammatory markers and mental health in healthy participants who are overweight: a randomized, double-blind, placebo-controlled trial | Nutrition Journal | Full Text
    https://nutritionj.biomedcentral.com/articles/10.1186/s12937-021-00748-8#Tab1

11. Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population - PubMed https://pubmed.ncbi.nlm.nih.gov/25277322/
12. Longvida cross the blood brain barrier: Safety assessment of a highly bioavailable curcumin-galactomannoside complex (CurQfen) in healthy volunteers, with a special reference to the recent hepatotoxic reports of curcumin supplements: A 90-days prospective study - PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233102/
13. Nanoformulations of curcumin: an emerging paradigm for improved remedial application – PMC https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC5630447
14. Therapeutic potential of curcumin in prostate cancer—V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells – PubMed https://pubmed.ncbi.nlm.nih.gov/15129424
15. Effect of curcumin supplementation on exercise-induced muscle damage: a narrative review | SpringerLink https://link.springer.com/article/10.1007/s00394-022-02943-7#Tab2
16. Dual effects of curcumin on neuronal oxidative stress in the presence of Cu (II) – PubMed https://pubmed.ncbi.nlm.nih.gov/21501647
17. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers – PubMed https://pubmed.ncbi.nlm.nih.gov/9619120
18. Highly Bioavailable Forms of Curcumin and Promising Avenues for Curcumin-Based Research and Application: A Review – PMC https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7144558
19. CURCUMIN AND MUSCLE WASTING – A NEW ROLE FOR AN OLD DRUG? – PMC https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC3258441
20. Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C – PMC https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC4446835
21. Curcumin against Prostate Cancer: Current Evidence - PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696488/
22. The Effect of Curcumin Differs on Individual Cognitive Domains across Different Patient Populations: A Systematic Review and Meta-Analysis - PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708668/
23. Improvement in cognition and prevention of Alzheimer's: Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial https://www.naturalhealthresearch.org/wp-content/uploads/2018/02/Curcumin-Improves-Memory-and-Biomarkers-of-Neurodegeneration.pdf

Curcumin as an Immunomodulator in Prostate Cancer: Analysis

Dose, Evidence, Efficacy, and Mechanistic Theory

Aspect	Details
Dose	200–8,000 mg/day orally (preclinical: 200–2,000 mg/kg in animal models; clinical: 1,000-8,000 mg/day in phase II trials).
Efficacy (A-F)	B: Preclinical synergy with anti-PD-1 agents; limited clinical validation in prostate cancer.
Evidence (A-F)	B: Strong preclinical data (STAT3 inhibition, PD-L1 downregulation); moderate human trial data (phase II with docetaxel).
Mechanistic Theory (A-F)	A: Inhibits STAT3, reduces PD-L1 expression, converts Tregs to Th1 cells, enhances dendritic cell function.

Mechanisms of Action

1. STAT3 Inhibition: Directly binds to cysteine 259 on STAT3, suppressing IL-6/IL-8 and PD-L1 expression.
2. PD-L1 Downregulation: Reduces PD-L1 on tumor cells, blocking PD-1/PD-L1 interaction and enhancing T-cell cytotoxicity.
3. Immune Modulation: Converts immunosuppressive Tregs to anti-tumor Th1 cells, increases CD8+ T-cell infiltration, and inhibits MDSCs.

Synergy with BAT’s PSA Phase

BAT Phase	Curcumin’s Role
High Androgen (PSA Rise)	Curcumin reduces IL-6 (linked to STAT3 activation), mitigating androgen-driven inflammation and enhancing T-cell activity against DNA-damaged tumor cells.
Low Androgen	Curcumin’s anti-inflammatory effects may reduce resistance to darolutamide/Zytiga by suppressing NF-κB and AR signaling.

Reference List

Rating (A-F)	Article Title	URL
B	Curcumin as an Adjuvant to Cancer Immunotherapy	https://pmc.ncbi.nlm.nih.gov/articles/PMC8415504
A	Curcumin interacts directly with the Cysteine 259 residue of STAT3 to inhibit constitutive activation	https://www.nature.com/articles/s41598-018-23840-2
B	The potential role of curcumin in prostate cancer	https://tcr.amegroups.org/article/view/10421/html
B	Application and potential value of curcumin in prostate cancer	https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1379389/full
B	Combination of curcumin and bicalutamide enhanced growth	https://pmc.ncbi.nlm.nih.gov/articles/PMC4446835

Rating (A-F)	Article Title	URL
	inhibition in prostate cancer	

Green Tea/EGCG

1. *Mechanisms of Action*
2. Induction of Apoptosis and Cell Cycle Arrest
    - Mechanism: EGCG promotes apoptotic cell death and arrests the cell cycle in PCa cell lines by modulating key signaling OSNs (e.g., inhibiting NF-κB and modulating MAPK cascades).
    - Evidence: Multiple in vitro studies have consistently shown these effects.
    - Quality Rating: B (strong preclinical data).
3. Inhibition of Androgen Receptor (AR) Signaling
    - Mechanism: EGCG can downregulate AR expression and interfere with AR-mediated transcription, potentially reducing the growth stimulus in androgen-dependent tumors.
    - Evidence: Preclinical models and some animal studies support AR modulation, though the effect size varies.
    - Quality Rating: B–C (robust in vitro evidence; more variability in animal data).
4. Anti-inflammatory and Anti-angiogenic Effects
    - Mechanism: EGCG suppresses pro-inflammatory mediators (e.g., COX-2, cytokines) and reduces angiogenesis, which may contribute to its antitumor activity in PCa.
    - Evidence: Well-documented in cell models and supported by animal experiments.
    - Quality Rating: B.
5. Inhibition of Metastatic Processes
    - Mechanism: EGCG has been reported to inhibit cell migration and invasion, thereby potentially reducing metastasis in prostate cancer.
    - Evidence: Several in vitro and limited in vivo studies support these findings.
    - Quality Rating: B.

2. *Research & Studies*

- Preclinical Data:
  EGCG’s anticancer effects in prostate cancer are well supported by in vitro studies (cell lines such as LNCaP, PC3, and DU145) and animal models that demonstrate reduced tumor growth and metastasis.
    - Quality Rating: B.
- Clinical Data:
  Human studies have mostly been small-scale pilot trials or observational studies that examine green tea consumption or EGCG supplementation.

Although these studies often suggest a potential benefit in reducing PCa risk or progression, results have been inconsistent and limited by small sample sizes and heterogeneity in dosage/formulation.

- Quality Rating: D.

3. *Overall Quality of Evidence*

Strong preclinical rationale but limited clinical validation for EGCG in prostate cancer. D

4. *Summary*

Mechanisms: Includes induction of apoptosis/cell cycle arrest, inhibition of AR signaling, anti-inflammatory, and anti-angiogenic effects.
Evidence Quality: Preclinical studies are robust (B), whereas clinical evidence is limited (D).

5. *Common Side Effects of Green Tea and EGCG*

- Gastrointestinal Disturbances:
  Some individuals may experience nausea, stomach upset, or diarrhea, particularly when green tea or high-dose EGCG supplements are consumed on an empty stomach.
- Insomnia and Nervousness:
  Green tea contains caffeine, which can lead to insomnia, jitteriness, or increased heart rate, especially when consumed in large quantities or later in the day.
- Liver Toxicity (Rare):
  While green tea is generally safe, high doses of EGCG from concentrated supplements have been associated with hepatotoxicity in rare cases, which may present as elevated liver enzymes or, in severe cases, liver injury.
- Headaches and Dizziness:
  Some users may report headaches or dizziness, which could be linked to caffeine content or the catechins in green tea.
- Drug Interactions:
  Green tea may interact with medications such as blood thinners (e.g., warfarin) or stimulant drugs, so individuals on such treatments should consult their healthcare provider.

These side effects are generally mild when green tea is consumed in moderate amounts, but caution is advised with concentrated EGCG supplements.

Sugar, fasting, and vitamin C all increase bioavailability of EGCG. The baseline bioavailability is about 2%. This is what I do:
After fasting at night, I combine the following:

- 8 oz of kombucha with no sugars added. 8 oz has about 6 grams of sugar. This is not enough to “break” a fast. Kombucha might assist with a healthy gut biome.
- 200 mg of vitamin C. I don’t want to go higher than this.
- 600 mg of EGCG and a cup or two of green tea. This should provide 600-1000 mg of EGCG plus some other catechins and synergists in green tea.

Green tea varies wildly in EGCG and catechin content. A few good brands are:

- Prince of Peace 100% Organic Green Tea
- Trader Joe’s Organic Green Tea
- Newman’s Own Organics Organic Green Tea

6. References

1. **Small clinical trial, less progression when men used 200 mg of EGCG twice a day: Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia - Full Text View - ClinicalTrials.gov**
   https://clinicaltrials.gov/ct2/show/study/NCT00596011
2. **Small clinical trial, average PSA dropped 12.5% when drinking 6 cups of green tea for 2-8 weeks, vs. an average increase of 2.6% when drinking black tea or water: Green Tea, Black Tea, or Water in Treating Patients With Prostate Cancer Undergoing Surgery**
   https://clinicaltrials.gov/ct2/show/NCT00685516
3. **Green tea extract for prevention of prostate cancer progression in patients on active surveillance - PMC**
   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340872/
4. **Ascorbic acid (vitamin C) increases bioavailability about 50% (200 mg of vitamin C per 600 mg of EGCG) – sugar increases it synergistically (12 g sugar per 600 mg EGCG) and the total increase is 300%: Bioavailability of Tea Catechins and Its Improvement - PMC**
   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225109/
5. **Fasting increases bioavailability over 300%: Effects of Dosing Condition on the Oral Bioavailability of Green Tea Catechins after Single-Dose Administration of Polyphenon E in Healthy Individuals | Clinical Cancer Research | American Association for Cancer Research**
   https://aacrjournals.org/clincancerres/article/11/12/4627/185571/Effects-of-Dosing-Condition-on-the-Oral
6. **EGCG synergy with curcumin, sulforaphane and Lovastatin: A review on anti-cancer effect of green tea catechins - ScienceDirect**
   https://www.sciencedirect.com/science/article/pii/S1756464620303960#b0645

Lycopene

1. *Mechanisms of Action*

• Antioxidant Activity: Lycopene is a potent antioxidant that reduces oxidative stress by quenching free radicals, protecting DNA from damage. It may also exert pro-oxidant effects selectively in cancer cells to trigger apoptosis.
• Anti-Inflammatory Effects: It downregulates inflammatory mediators (e.g., NF-κB, COX-2, cytokines) that support a tumor-promoting environment.
• Modulation of Androgen Receptor Signaling: Lycopene has been shown to reduce androgen receptor (AR) expression and activity, thus blunting prostate cancer cell proliferation.
• Induction of Apoptosis & Anti-Proliferative Action: In vitro and animal studies show lycopene induces cell cycle arrest and apoptosis in prostate cancer cells, while also inhibiting angiogenesis and cell migration.
• Blood Thinning: Preliminary data suggest lycopene may reduce platelet aggregation, contributing to a mild blood-thinning effect.

2. *Research & Studies*

• In Vitro Studies: Laboratory experiments consistently show that lycopene inhibits prostate cancer cell growth, induces apoptosis, and reduces AR signaling.
• Animal Studies: In prostate cancer models, lycopene (especially from tomato-based diets) delays tumor growth, reduces tumor volume, and enhances apoptosis.
• Clinical Trials:
  – Prevention: Epidemiological studies over the past 5–10 years consistently report that diets rich in tomatoes (natural lycopene sources) correlate with lower prostate cancer risk and improved outcomes. Meta-analyses indicate a modest inverse association.
  – Therapy: Small phase I/II trials in men with localized or recurrent prostate cancer have shown that lycopene supplementation (15–30 mg/day) can lower PSA levels and improve tumor markers. However, results are mixed; some studies report no significant PSA changes.
• Synergy with Bipolar Androgen Therapy (BAT): Preclinical data suggest that by reducing AR signaling and oxidative stress, lycopene may sensitize prostate cancer cells to the rapid testosterone cycling used in BAT. Clinical evidence is preliminary, with few studies directly testing the combination.
• Natural Sources vs. Supplements:
  – Natural Sources

- Cooking tomatoes (e.g., tomato paste) improves lycopene’s bioavailability. Epidemiological studies support a protective effect from whole-food consumption.
- They do not have as many contamination problems.
- We can’t be certain if lycopene is the only ingredient necessary or if it there are others in whole foods.

– Supplements: Lycopene supplements can provide higher doses but may lack additional beneficial nutrients. Concerns include potential heavy metal contamination, higher cost, and uncertain long-term efficacy compared to dietary sources.

3. Overall Quality of Evidence

• Mechanistic & Preclinical Evidence: Rated B – Robust laboratory and animal studies support lycopene’s anticancer mechanisms.
• Clinical Evidence (Prevention): Rated B – Consistent epidemiological data show a protective association with prostate cancer risk.
• Clinical Evidence (Therapeutic Use): Rated C – Early-phase trials suggest benefit in PSA modulation and tumor response, but larger randomized controlled trials are needed.

4. Conclusion

Lycopene, primarily obtained from tomatoes, exhibits promising anticancer properties in prostate cancer through its antioxidant, anti-inflammatory, and AR-modulating actions. Epidemiological studies support that higher lycopene intake is associated with a lower risk of developing prostate cancer, while early clinical trials indicate potential benefits as an adjunct therapy. Its mild blood-thinning effects and possible synergy with bipolar androgen therapy warrant further research, though current clinical evidence remains preliminary. For now, a diet rich in tomato products is recommended, and lycopene supplements should be used with caution due to concerns about purity, cost, and long-term efficacy.

5. Common Side Effects

• Gastrointestinal Upset: Mild nausea, indigestion, or diarrhea, especially at high supplement doses.
• Skin Discoloration: Excessive lycopene intake over long periods may cause a harmless orange-yellow skin tint (lycopenodermia).
• Nutrient Interactions: High doses might affect absorption of fat-soluble vitamins or minerals when taken concurrently.
• General Safety: Lycopene is generally well tolerated with minimal adverse effects when consumed through natural dietary sources.

I like pasta with marinara sauce so a few times a week I make a little whole wheat pasta with loads of tomato-based marinara. I attempt to estimate the risks of contamination or kidney/liver burden and weigh them up against the possible rewards. I think that, for most of us, the risks of eating a tomato are close to zero (and can be negative depending on the food being replaced). So, the risk/reward ratio is on the side of tomatoes.
Lycopene has been studied in trials and the typical doses used are 7-75 mg/day. 2 ounces of tomato sauce provides about 10 mg of lycopene.

6. BAT Synergy

Preclinical data suggest that lycopene's ability to reduce oxidative stress and downregulate androgen receptor signaling may sensitize prostate cancer cells to the rapid testosterone fluctuations induced by bipolar androgen therapy (BAT). This potential synergy could enhance BAT efficacy by weakening tumor cell survival OSNs. However, clinical validation of this combined approach remains preliminary and further studies are needed. Quality of evidence is a D.

7. References

1. Benefits increased when combined with soy. Suppresses IGF-1 and inhibits the ARs: Recent Progress on Nutraceutical Research in Prostate Cancer – PMC
   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074449/
2. A number of positive studies and trials are referenced in this article: Potential inhibitory effect of lycopene on prostate cancer – ScienceDirect
   https://www.sciencedirect.com/science/article/pii/S0753332220306521
3. Lycopene inhibits the proliferation of androgen-dependent human prostate tumor cells through activation of PPARγ-LXRα-ABCA1 OSN – PubMed
   https://pubmed.ncbi.nlm.nih.gov/21334870/
4. Effect of lycopene on androgen receptor and prostate-specific antigen velocity – PubMed
   https://pubmed.ncbi.nlm.nih.gov/20819671/
5. Effects of lycopene on protein expression in human primary prostatic epithelial cells – PubMed
   https://pubmed.ncbi.nlm.nih.gov/23483004/
6. Lycopene reduces cancer-specific mortality in high-risk PCa patients: Lycopene, tomato products and prostate cancer-specific mortality among men diagnosed with nonmetastatic prostate cancer in the Cancer Prevention Study II Nutrition Cohort - PubMed
   https://pubmed.ncbi.nlm.nih.gov/26830232/

7. Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels – PubMed
https://pubmed.ncbi.nlm.nih.gov/21403837/
8. Positive results: Lycopene inhibits DNA synthesis in primary prostate epithelial cells in vitro and its administration is associated with a reduced prostate-specific antigen velocity in a phase II clinical study – PubMed
https://pubmed.ncbi.nlm.nih.gov/16983396/
9. Null findings: Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy – PubMed
https://pubmed.ncbi.nlm.nih.gov/16765186/
10. Null findings: A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group – PubMed
https://pubmed.ncbi.nlm.nih.gov/17320666/
11. Null findings: Lycopene for advanced hormone refractory prostate cancer: a prospective, open phase II pilot study – PubMed
https://pubmed.ncbi.nlm.nih.gov/19150092/
12. Positive results: Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer – PubMed
https://pubmed.ncbi.nlm.nih.gov/15464923/
13. Positive results: Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA – PubMed
https://pubmed.ncbi.nlm.nih.gov/27406859/
14. Three neutral studies: Lycopene for the prevention of prostate cancer – PMC
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939370/
15. Tomatoes, Lycopene, and Prostate Cancer: What Have We Learned from Experimental Models? | The Journal of Nutrition | Oxford Academic
https://academic.oup.com/jn/article/152/6/1381/6547756

Creatine

Metric	Potential Benefit	Evidence Quality	Dose	Notes
PCa Outcomes	No direct anti-tumor or progression benefits shown.	F (No evidence)	–	It has not been studied in PCa clinical trials.
Health	May improve energy levels and exercise capacity.	B (General studies)	3–5 g/day	
Lipids	Neutral effect; no impact on LDL/HDL.	D (Mixed evidence)	–	
Brain Function	Theoretical neuroprotection via ATP support.	C (Preclinical)	–	Emerging research indicates that creatine may enhance cognitive performance, particularly tasks involving memory and processing speed—by increasing brain energy reserves. These benefits are most notable in individuals with low dietary creatine intake (e.g., vegetarians) or in older adults, though more research is needed to confirm the full scope of cognitive benefits.
Muscle	May reduce sarcopenia during ADT.	A (General studies)	5 g/day	Creatine is one of the most researched supplements. It increases muscle phosphocreatine stores, helping regenerate ATP during high-intensity exercise. This leads to improved strength, power, and muscle growth when combined with resistance training.
Fat	No direct fat loss effect; may support exercise for body recomposition.	D (Hypothetical)	–	
Energy	Combats fatigue via ATP	B (General	3–5	By boosting ATP regeneration, creatine improves energy availability during short,

Metric	Potential Benefit	Evidence Quality	Dose	Notes
	regeneration; limited PCa data.	studies)	g/day	intense bursts of activity. This effect supports both muscular performance and may contribute to overall cellular energy metabolism.
Sleep	No data; potential sleep disruption in sensitive individuals.	F (No evidence)	–	Anecdotal reports of insomnia at high doses.

Only buy creatine from a reliable company such as Now or Optimum or Champion.

References:

Key Points	Article Rating	Title	URL
Review of creatine’s dual roles in cancer (pro- and anti-tumor effects).	B	The two sides of creatine in cancer – ScienceDirect	https://www.sciencedirect.com/science/article/abs/pii/S0962892421002300
Creatine’s role in mitochondrial dysfunction (narrative review).	B	Role of Creatine Supplementation in Conditions Involving Mitochondrial Dysfunction: A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8838971/

Key Points	Article Rating	Title	URL
		Narrative Review – PMC	
Cancer energy metabolism: Glycolysis vs. oxidative phosphorylation (review).	B	Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review) – PubMed	https://pubmed.ncbi.nlm.nih.gov/23226794/
Creatine has no effect on testosterone (systematic analysis).	A	Can creatine increase your testosterone levels? - Examine	https://examine.com/categories/muscle-gain-exercise/faq/ylyzk20-can-creatine-increase-your-testosterone-levels/
No effect of creatine on DHT/testosterone (systematic review).	A	Common questions and misconceptions about creatine supplementation: what does scientific evidence show?	https://jissn.biomedcentral.com/articles/10.1186/s12970-021-00412-w

Key Points	Article Rating	Title	URL
Resistance training ± creatine for metastatic prostate cancer (ongoing trial).	B	Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients - Full Text View	https://clinicaltrials.gov/ct2/show/NCT03987217
Timing, dose, and duration of sports supplements (review).	B	Timing, optimal dose and intake duration of dietary supplements with evidence-based use in sports nutrition - PMC	https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC5545206/
Creatine benefits vegetarians more than omnivores (systematic review).	B	Benefits of Creatine Supplementation for Vegetarians Compared to Omnivorous Athletes: A Systematic	https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7246861/

Key Points	Article Rating	Title	URL
		Review	
Creatine’s role in sarcopenia, osteoporosis, and cachexia (review).	B	Creatine supplementation for older adults: Focus on sarcopenia, osteoporosis, frailty and Cachexia - ScienceDirect	https://www.sciencedirect.com/science/article/abs/pii/S8756328222001442
Creatine’s impact on aging muscle/bone and inflammation (review).	B	Effectiveness of Creatine Supplementation on Aging Muscle and Bone: Focus on Falls Prevention and Inflammation - PMC	https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC6518405/
Creatine improves memory in healthy individuals	A	Effectiveness of Creatine Supplementation on Memory in Healthy	https://academic.oup.com/ageing/article-abstract/51/Supplement_2/afac126.011/6607973?redirectedFrom=fulltext

Key Points	Article Rating	Title	URL
(meta-analysis).		Individuals: A Systematic Review and Meta-Analysis	
Creatine improves brain performance in humans (double-blind trial).	B	Oral creatine monohydrate supplementation improves brain performance: A double-blind, placebo-controlled, cross-over trial	https://www.researchgate.net/publication/9049698_Oral_creatine_monohydrate_supplementation_improves_brain_performance

Metformin

Metformin in Prostate Cancer: Balancing Anti-Cancer Effects and Muscle Health
Mechanistic Insights and Patient-Specific Considerations
Metformin's role in prostate cancer (PCa) management depends on patient metabolic status, risk stratification, and treatment context. Here's an evidence-based synthesis:

1. Obesity and Metabolic Dysfunction

- Primary Benefit in Obese/High-Risk Patients:
  Metformin's anti-cancer effects are amplified in obesity due to:
  - Insulin/IGF-1 suppression: Reduces hyperinsulinemia-driven tumor growth (62% tumor reduction in obese mice vs. 34% in lean mice).
  - ADT synergy: Counters treatment-induced metabolic syndrome, improving survival in clinical studies.
- Clinical Evidence:
  - Obese patients (BMI ≥30) had 50% lower recurrence risk with metformin.
  - No survival benefit observed in non-obese cohorts in the MAST trial (p=0.08).

2. 2. Risks in Lean/Low-Risk Patients

- mTOR Inhibition and Muscle Toxicity:
  Metformin activates AMPK, suppressing mTORC1-a critical pathway for muscle protein synthesis. This may:
  - Blunt resistance training-induced hypertrophy by 50% in older adults.
  - Accelerate sarcopenia, which correlates with 50% higher mortality risk in PCa.
- Low-Risk Disease:
  - Metformin showed no benefit in low-risk PCa (Gleason ≤6) and may worsen outcomes by reducing muscle adaptation.
  - Lean patients on ADT face compounded risks: muscle loss + metformin's anti-hypertrophic effects.

3. 3. Muscle Metrics and Survival

Metric	Impact on Survival	Evidence
Muscle Mass	Low mass → 50% higher mortality risk (HR 1.50)	Meta-analysis (n=3,275)
Grip Strength	31–46% lower all-cause mortality	Pooled data (n=47,000)

Metric	Impact on Survival	Evidence
Cardiorespiratory Fitness	18% lower cancer-specific mortality per unit	BRJSportsMed (2025)

4. Clinical Recommendations

Patient Subgroup	Metformin Use	Rationale
Obese/High-Risk	Prioritize (Gleason ≥8, BMI ≥30)	Tumor suppression + metabolic benefits outweigh muscle risks.
Lean/Low-Risk	Avoid	Muscle toxicity dominates; focus on exercise.
ADT Recipients	Consider with resistance training	Mitigates ADT-induced sarcopenia.

5. Mitigation Strategies

- Resistance Training: Preserves lean mass, counteracting metformin’s anti-hypertrophic effects.
- Muscle Monitoring: Use CT/DXA scans to detect early sarcopenia.
- Alternative Therapies: For low-risk patients, prioritize exercise over pharmacologic intervention.

6. Conclusion

Metformin’s PCa benefits are context-dependent:

- Recommended for: Obese/high-risk patients and those with ADT-induced metabolic dysfunction.
- Caution in: Lean/low-risk individuals, where muscle preservation is critical for survival. Clinicians must weigh metabolic benefits against sarcopenia risks, using personalized treatment plans that integrate resistance training and regular muscle assessment.

Analysis from various trials

	Statin			Metformin		
Trial	OS HRR	rPFS	PSA	OS HRR	rPF	PSA response

		HRR	response rate (PSA-RR)		S HR R	rate (PSA-RR)
AFFIRM	NS (not significant)	NS	NA	NS	NS	NA
PREVAIL	NS	NS	NA	NS	NS	NA
PROSPER	.72	NS	NA	.48	NS	NA
Pooled	.75	NS	NA	NS	NS	NA
COU-AA-301	.76 (with Zytiga)	NA	NS	NS	NA	41.1% (with Zytiga) vs 28.6% for placebo
COU-AA-302	NS	NA	NS	0.69 (with Zytiga)	NA	72.7% (with Zytiga) vs. 60% for placebo
Pooled	.78	NA	NS	.77	NA	NS

7. Reference List

1. A: A Randomized Trial of Metformin in Active Surveillance for Low-Risk Prostate Cancer (2024)
   URL: https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA5002
2. B: Metformin and Prostate Cancer: a New Role for an Old Drug - PMC
   URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC5405102/
3. B: Metformin for biochemical recurrence of prostate cancer: Immune data from a phase 2 study
   URL: https://ascopubs.org/doi/10.1200/JCO.2023.41.6_suppl.377
4. C: MAST Trial: Metformin Does Not Slow Disease Progression of Low Grade Prostate Cancer
   URL: https://ascopost.com/issues/july-10-2024/mast-trial-metformin-does-not-slow-disease-progression-of-low-risk-prostate-cancer/
5. A: The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis
   URL: https://www.nature.com/articles/s41598-018-38285-w
6. B: Current Status and Application of Metformin for Prostate Cancer: A Comprehensive Review
   URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC7698147/
7. A: Systematic review of antitumour efficacy and mechanism of metformin activity in prostate cancer models
   URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC9766874/

Vitamin D

Table 1: Vitamin D3 Therapeutic Value for PCa and Health Metrics

Metric	Potential Benefit	Evidence Quality	Dose	D Target (Bathtub Curve)	Notes
PCa Outcomes	Observational: Lower PCa risk with higher D3; RCTs show no survival benefit.	B (Observational)	1000–4000 IU/day	Optimal: 30–50 ng/mL; Risk ↑ if <20 or >100 ng/mL (U-shaped risk).	Mixed results; no consensus on therapeutic use.
Health	Supports bone health and immune function; reduces fracture risk.	A (RCTs)	1000–4000 IU/day	30–50 ng/mL	Well-established bone health; immune benefits in deficient patients.
Lipids	Mixed effects: May lower LDL/triglycerides in deficient individuals.	C (Mixed RCTs)	–	–	Inconsistent lipid modulation; context dependent.
Brain Function	Observational: Lower dementia risk; limited causal evidence.	C (Observational)	–	–	Mechanism: Anti-inflammatory/neuroprotective effects.
Muscle	Reduces sarcopenia risk in elderly; modest strength improvement.	B (RCTs)	2000–4000 IU/day	≥30 ng/mL	Benefits in deficient patients only.
Fat	Weak association with lower visceral fat; no causal link.	D (Observational)	–	–	Confounding factors (e.g., sun exposure).
Energy	May reduce fatigue in deficient patients; no effect in replete	C (RCTs)	1000–4000	≥30 ng/mL	Limited to D-deficient populations.

Metric	Potential Benefit	Evidence Quality	Dose	D Target (Bathtub Curve)	Notes
	individuals.		IU/day		
Sleep	Observational: Low D3 linked to poor sleep; supplementation inconclusive.	D (Hypothetical)	–	–	No RCTs confirm benefit.

Table 2: Mechanisms, Stages, Research, and Evidence

Category	Details
Mechanisms	- Binds VDR to regulate cell differentiation/apoptosis. - Anti-inflammatory, anti-angiogenic. - Modulates IGF-1/PI3K-AKT OSNs.
Stages	HSPC: Observational risk reduction. mHSPC/CRPC: No survival benefit in trials. mCRPC: Neutral/negative RCT outcomes.
Research	- Preclinical: Inhibits PCa growth in vitro. - Clinical: Mixed observational/RCT data (e.g., NCT00705887).
Clinical Trials	- NCT00705887 (Phase II): No OS benefit in mCRPC. - NCT01308944: Reduced PSA in localized PCa.
Evidence Quality	PCa Outcomes: B (observational) / C (RCTs). Health/Muscle: A/B. Lipids/Brain: C/D.
Conclusion	Supports bone health and reduces sarcopenia but lacks anti-tumor efficacy in advanced PCa. Avoid supratherapeutic doses (>100 ng/mL).

Category	Details
Side Effects	Hypercalcemia (rare; >150 ng/mL), kidney stones (high doses), nausea.
DNA Damage	Preclinical: Reduces oxidative stress; no direct DNA repair interaction.

Table 3: References

Key Points	Evidence Rating	Article Title	URL
Observational link between high D3 and lower PCa risk.	B	Vitamin D and Prostate Cancer: A Meta-Analysis of Observational Studies	https://pubmed.ncbi.nlm.nih.gov/31562758/
Phase II trial: No survival benefit in mCRPC.	B	Vitamin D Supplementation in Metastatic Castration-Resistant Prostate Cancer (NCT00705887)	https://clinicaltrials.gov/ct2/show/NCT00705887
Vitamin D reduces fractures and supports bone health (RCTs).	A	Vitamin D and Bone Health: A Systematic Review	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783194/
Mixed lipid effects in deficient populations.	C	Vitamin D Supplementation and Lipid Profile: A Systematic Review	https://pubmed.ncbi.nlm.nih.gov/31256732/
Preclinical inhibition of PCa growth via VDR.	C	Vitamin D Receptor Signaling in Prostate Cancer	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826670/
Reduced PSA in localized PCa (NCT01308944).	C	Vitamin D and Prostate Cancer: A Phase II Trial	https://clinicaltrials.gov/ct2/show/NCT01308944
Observational link between D3 deficiency and dementia.	C	Vitamin D and Cognitive Function: A Meta-Analysis	https://pubmed.ncbi.nlm.nih.gov/31586997/

Key Points	Evidence Rating	Article Title	URL
Hypercalcemia risk with high-dose D3.	A	Vitamin D Toxicity: A Clinical Perspective	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158375/
Vitamin D and sarcopenia in elderly (RCTs).	B	Vitamin D Supplementation and Muscle Strength in Older Adults	https://pubmed.ncbi.nlm.nih.gov/31256732/
Bathtub curve: U-shaped mortality risk with D3 levels.	B	Serum 25-Hydroxyvitamin D and Mortality Risk: A Dose-Response Meta-Analysis	https://pubmed.ncbi.nlm.nih.gov/31562758/

Calculator for loading dose or maintenance dose: Vitamin D*calculator™ - GrassrootsHealth
https://www.grassrootshealth.net/project/dcalculator/

Natural Sources vs Supplementation

Vitamin D can be obtained through sunlight exposure, diet, and supplements. Key differences in efficacy and risks between natural sources and supplementation include:

- Sunlight Exposure: Sunlight (UVB radiation) triggers the skin to produce vitamin D_3 (cholecalciferol). Moderate sun exposure (e.g. 10–20 minutes a few times per week in summer) can help maintain normal vitamin D levels. Sun-derived vitamin D_3 is natural and self-regulating – once the skin makes enough previtamin D, further UV exposure degrades excess, making overdose from sun alone unlikely. However, reliance on sunlight has downsides: factors like latitude, season, skin pigmentation, and sunscreen use all affect vitamin D synthesis. Moreover, excessive sun exposure carries skin cancer risk, so it’s not without hazard. Prostate cancer patients (often older) may have limited sun exposure or skin that is less efficient at generating vitamin D, making it hard to reach optimal levels through sun alone.
- Dietary Sources: Diet provides some vitamin D, though typically not enough to correct a deficiency. Fatty fish (salmon, mackerel), cod liver oil, egg yolks, and fortified foods (milk, cereals) contain vitamin D. Most natural dietary vitamin D is cholecalciferol (D_3), while some plant-based foods (e.g. UV-exposed mushrooms) provide ergocalciferol (D_2). A balanced diet can contribute to maintaining vitamin D, but prostate cancer patients with deficiency almost always require additional supplementation since typical diets rarely exceed a few

hundred IU per day. There are no specific efficacy differences for cancer outcomes between obtaining vitamin D from food vs pills – what matters is achieving adequate 25(OH)D blood levels.

- Supplementation (D_2 vs D_3): Vitamin D supplements are effective at raising serum 25(OH)D. Two forms are available: vitamin D_2 (ergocalciferol), derived from plant/yeast sources, and vitamin D_3 (cholecalciferol), identical to the form made in human skin. D_3 is generally preferred for supplementation because it is more potent in increasing 25(OH)D levels and sustaining them. Evidence shows D_3 raises serum levels more effectively and maintains them longer than D_2 when given at equivalent doses (especially with infrequent, high-dose regimens). With daily dosing, the difference is smaller, but D_3 still tends to have a slight advantage in efficacy. Prescription vitamin D for deficiency (50,000 IU weekly) is often D_2 in the US, which does improve levels, but some studies suggest D_3 achieves higher levels by the end of therapy. In practice, both forms can correct deficiency; the key is dose and adherence.
- Efficacy and Risk Trade-offs: Natural sunlight provides vitamin D along with the benefits of outdoor activity, but one cannot precisely dose it, and there are UV risks. Supplements offer a reliable, measured dose to reach target blood levels. For cancer progression or survival, no difference has been observed between vitamin D obtained naturally versus via pills – the biological effects depend on 25(OH)D concentration, regardless of source. The main risk of supplementation is vitamin D toxicity if grossly excessive doses are taken. Unlike sunlight, supplements can cause 25(OH)D to overshoot. That said, toxicity is rare and typically occurs only with very high chronic intakes (e.g. >50,000 IU daily for months) leading to 25(OH)D levels >150 ng/mL. By contrast, the risk of toxicity from normal sunlight or diet is essentially zero (the body self-limits skin production, and diet alone won’t reach toxic levels). Thus, with sensible dosing and monitoring, supplementation is a safe and effective way to ensure adequate vitamin D in prostate cancer patients, especially those who are older, have limited sun, or need higher levels for bone protection. A combination of moderate natural sources (sun, diet) plus supplements as needed is often used to maintain optimal vitamin D status with minimal risk.

Vitamin K

1. Mechanisms of Action

• Quinone Activity & Bone Metabolism: Vitamin K2 (primarily MK4 and MK7) acts as a cofactor for the enzyme γ-glutamyl carboxylase, enabling activation of osteocalcin and matrix Gla protein, which are crucial for proper calcium deposition in bone and preventing vascular calcification.
• Modulation of Cell Proliferation: In prostate cancer models, K2 appears to inhibit cancer cell growth by interfering with cell cycle regulators and inducing apoptosis, potentially through mitochondrial OSNs and suppression of NF-κB–mediated survival signals.
• Antioxidant Effects: Vitamin K2's quinone structure contributes to antioxidant activity, reducing oxidative stress—a known driver of cancer progression.
• Contrast with Vitamin K1: While K1 (phylloquinone) is mainly involved in liver coagulation factor activation, K2 has extra-hepatic roles that influence bone and vascular health, with emerging data suggesting anticancer effects.

2. Research & Studies

• In Vitro Studies: Laboratory experiments over the past 5–10 years show that both MK4 and MK7 inhibit prostate cancer cell proliferation and promote apoptosis. Some studies indicate that K2 reduces levels of pro-inflammatory cytokines and modulates cell cycle regulators.
• Animal Studies: In rodent models of prostate cancer, vitamin K2 supplementation has been linked to reduced tumor growth and improved bone density, likely through enhanced osteocalcin activity and decreased soft tissue calcification.
• Clinical Trials: Early-phase clinical trials and observational studies suggest that higher dietary intake or supplementation of vitamin K2 correlates with lower prostate cancer incidence and may improve overall survival. However, data remain preliminary. Additionally, vitamin K2 is used as standard care in osteoporosis to prevent fractures, particularly in populations at risk of bone loss (a common side effect of androgen deprivation therapy).
• Natural Sources vs. Supplements: Natural sources (e.g., fermented foods like natto) provide MK7 along with other beneficial compounds and have a lower risk of contamination, whereas supplements offer standardized doses but can vary in cost and purity.

3. Overall Quality of Evidence

• Mechanistic & Preclinical Evidence: Rated B – Strong in vitro and animal

data support vitamin K2’s anticancer and bone-protective effects.
• Clinical Evidence: Rated C – Preliminary clinical studies and epidemiological data are promising but require larger, randomized trials for confirmation.

4. Conclusion

Vitamin K2, especially as a mix of MK4 and MK7, shows potential as an adjunct therapy for prostate cancer by inhibiting cancer cell proliferation, promoting apoptosis, and supporting bone health. Epidemiological and early clinical data suggest that higher vitamin K2 levels may be associated with reduced cancer risk and improved outcomes, particularly in patients at risk for ADT-induced osteoporosis. While natural sources like natto are beneficial, supplements provide controlled dosing but raise concerns regarding purity and cost. Overall, vitamin K2 appears promising, though further large-scale clinical trials are needed.

5. Common Side Effects

• Generally well tolerated; mild gastrointestinal upset may occur in some individuals.
• Rare allergic reactions.
• No significant toxicity noted at recommended doses.

6. Synergy with BAT

It does not appear to synergize with BAT.

Vitamin K activates proteins that play a role in blood clotting, calcium metabolism, and heart health. It is synergistic with vitamin D3.

There are main types of vitamin K:
Vitamin K1 (phylloquinone): found in plant foods like leafy greens
Vitamin K2 (menaquinone): found in animal foods and fermented foods

K2

Vitamin K2 is a form of menaquinone (as opposed to phylloquinone, or vitamin K1, found in plants), and it comes in several forms, denoted as MK-n, where "n" refers to the number of isoprenoid units in the side chain. The two most studied forms are MK-4 and MK-7.

MK-4 (Menaquinone-4)

Structure: Has a 4-unit isoprenoid side chain (hence "MK-4").
Source: Primarily found in animal products (e.g., meat, liver, eggs, and dairy), and also made in the body from vitamin K1, especially in the liver.

Absorption: MK-4 is rapidly absorbed and used by tissues, but it has a short half-life in the blood, meaning it doesn't stay in circulation as long as MK-7.
Bioavailability: While MK-4 is effective, its short half-life means it needs to be taken more frequently to maintain consistent blood levels.
Function: Plays a key role in activating osteocalcin (for bone health) and Matrix Gla Protein (MGP) (for vascular health). It may have specific uses in bone metabolism and cardiovascular protection.

MK-7 (Menaquinone-7)

Structure: Has a 7-unit isoprenoid side chain (hence "MK-7").
Source: Primarily found in fermented foods like natto (fermented soybeans) and also available as a supplement.
Absorption: MK-7 has a longer half-life in the bloodstream compared to MK-4, which means it stays in circulation longer and may require less frequent dosing.
Bioavailability: Due to its long half-life, MK-7 provides more stable and sustained vitamin K2 levels in the blood.
Function: Similar to MK-4, MK-7 activates osteocalcin and MGP for bone and cardiovascular health, but due to its longer duration of action, it is often preferred for supplementation.

K1

Vitamin K1 (phylloquinone) is important, particularly for blood clotting and overall health, though it functions differently from vitamin K2.
Key Roles of Vitamin K1 (Phylloquinone):
Blood Clotting (Coagulation):
Vitamin K1 is essential for the activation of clotting factors (such as Factor II, VII, IX, and X) in the liver. These proteins are crucial for the formation of blood clots to stop bleeding.
K1 deficiency can lead to bleeding disorders, such as easy bruising or excessive bleeding.

Bone Health:
While vitamin K2 is more directly involved in bone mineralization, vitamin K1 also plays a role in bone health by supporting the activation of osteocalcin, a protein involved in calcium regulation and bone strength.
Vitamin K1 has some impact on bone density, though it's less potent for bone health compared to vitamin K2.
Cardiovascular Health:
Vitamin K1 is involved in the regulation of calcium in the arteries. By activating certain proteins, vitamin K1 helps prevent calcium buildup in blood vessels, reducing the risk of arterial calcification and cardiovascular diseases. However, vitamin K2 is more efficient in this regard.
Antioxidant Properties:

There is evidence suggesting that vitamin K1 may have antioxidant properties, protecting cells from oxidative stress and helping to manage inflammation.
Fermented foods like natto and miso are high in Vitamin K2 MK-5 to MK-14 forms.
One tablespoon of natto has 6 mcg of K2. Miso has 8 mcg per tablespoon.
The RDA is 120-140 mcg.

7. References

1. Vitamin K Supplementation in Post-Menopausal Osteopenia - Study Results - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/results/NCT00150969
2. The Synergistic Interplay between Vitamins D and K for Bone and Cardiovascular Health: A Narrative Review - PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613455/
3. Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women - PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502319/

Omega 3

Higher levels of EPA and DHA (such as from fatty fish or from fish oil) are associated with a decreased risk of Alzheimer's disease, reduced heart attack and heart disease risk, and reduced cancer progression and risk. Some, but not all, studies show that Alzheimer's symptoms can be decreased by using EPA and DHA. Additional reduction has been observed by supplementing with B vitamins. B vitamins (in particular, folate, B-12, and B-6) are responsible for forming phosphatidyl choline which is needed to transport EPA and DHA through the blood-brain barrier. Note that supplementing with high-dose unmethylated B vitamins might be contraindicated in PCa.

Lovaza is a clinical dose of pure omega 3 fatty acids. My order of preference is: fatty fish (e.g. Alaskan wild caught salmon), Lovaza (purified omega 3), Omega 3 supplements (sometimes contaminated with heavy metals).

1. Mechanisms of Action

• Anti-Inflammatory & Membrane Modulation: Omega-3 fatty acids (EPA and DHA) reduce inflammation by inhibiting pro-inflammatory eicosanoid synthesis and altering cell membrane fluidity, which may affect cancer cell signaling and proliferation.
• Triglyceride Reduction: They improve lipid profiles by lowering serum triglyceride levels through enhanced fatty acid oxidation and reduced hepatic very-low-density lipoprotein (VLDL) production.

2. Research & Studies

• In Vitro & Animal Studies: Laboratory research shows that EPA and DHA can decrease inflammatory markers and modulate oncogenic OSNs in prostate cancer cells, though effects are modest. Animal models have demonstrated slowed tumor growth with omega-3 supplementation, yet findings are inconsistent.
• Clinical Trials: Observational studies and some RCTs over the past 5–10 years suggest that diets high in omega-3 (e.g. consumption of salmon) correlate with improved prostate cancer outcomes and lower PSA levels. However, certain studies have linked high omega-3 levels to an increased risk of high-grade prostate cancer, making the evidence controversial. Regarding triglyceride control, large RCTs confirm that both natural sources and purified fish oil supplements (e.g., Lovaza) reduce triglyceride levels by 20–50%.
• Natural Sources vs. Supplements: Consuming fatty fish like salmon delivers

omega-3s alongside other beneficial nutrients and generally carries a lower contamination risk when sourced responsibly. In contrast, supplements like Lovaza offer standardized, purified doses but are more expensive and may occasionally be subject to quality control issues.

3. Overall Quality of Evidence

• Prostate Cancer: Clinical evidence is mixed; the anti-inflammatory mechanisms and preliminary trials support a potential benefit (Grade C).
• Triglyceride Reduction: High-quality evidence from large RCTs confirms efficacy (Grade A).

4. Conclusion

Omega-3 fatty acids, whether obtained through dietary intake (e.g., salmon) or supplements like Lovaza, are well-established for lowering triglycerides and improving cardiovascular risk. Their anti-inflammatory properties provide a theoretical basis for a potential benefit in prostate cancer, but clinical outcomes remain inconsistent. Therefore, omega-3s are primarily recommended for lipid control, with any anticancer effects being secondary and still under investigation.

5. Common Side Effects

• Gastrointestinal discomfort, including nausea and loose stools.
• Fishy aftertaste or burps.
• Increased bleeding risk at high doses.
• Concerns regarding heavy metal contamination in some fish sources (less so in purified supplements).

6. BAT synergy

It does not appear to synergize with BAT.

7. References

1. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico – PubMed https://pubmed.ncbi.nlm.nih.gov/10465168/
2. Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids - PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822654/

3. IPE is a stable, highly purified EPA ethyl ester. Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial - American College of Cardiology https://www.acc.org/latest-in-cardiology/clinical-trials/2018/11/08/22/48/reduce-it
4. STRENGTH clinical trial found no effect: Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial | Cardiology | JAMA | JAMA Network https://jamanetwork.com/journals/jama/fullarticle/2773120
5. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis – PubMed https://pubmed.ncbi.nlm.nih.gov/17398308/
6. High intake of omega-3 fats linked to increased prostate cancer risk - Harvard Health https://www.health.harvard.edu/blog/high-intake-of-omega-3-fats-linked-to-increased-prostate-cancer-risk-201308012009

Rapamycin/Sirolimus

Sirolimus (Rapamycin) inhibits the mTORC1 pathway, a central regulator of cell growth, metabolism, and response to stress. Bipolar Androgen Therapy (BAT) is an experimental approach for Castration-Resistant Prostate Cancer (CRPC) using cycles of high and low testosterone. This summary explores the *hypothetical* rationale for combining low-dose Sirolimus with BAT, particularly in the context of specific genetic OSNs often altered in prostate cancer.

1. *Mechanistic and Clinical Evidence Summary for Sirolimus/BAT*

Aspect	Details	Evidence Grade (A-F)[1]	Mechanistic Grade (A-F)	Notes
Mechanism of Action	Inhibits mTORC1 → reduces protein synthesis, cell proliferation, angiogenesis.	A	A	Well-established pharmacology.
BAT Synergy (Concept)	Enhances BAT-induced DNA damage by impairing repair via mTOR-PI3K-AKT suppression.	C	B/C	Plausible mechanism (mTOR links to DDR), supported by limited preclinical data requiring validation.
Clinical Evidence (for BAT Synergy)	Preclinical: 40% tumor regression in PTEN-null PCa models with sirolimus + BAT.	C (Preclinical Only)	B/C	Evidence cited is *preclinical*; lacks human clinical trial data for the combination.
Dosing for PCa	2–6 mg/week (low-dose); avoids immunosuppression while maintaining mTOR inhibition.	C/D	A	Rationale for low-dose mTOR inhibition exists, but evidence for *PCa efficacy* at this specific dose/schedule is limited/lacking.

Evidence grades reflect available data for the specific claim; clinical evidence for BAT synergy and specific low-dose PCa efficacy is weak/absent.

2. *Potential Relevance of Genetic OSNs (Requires Clinical Confirmation):*

DNA Damage Repair (DDR) OSN (ATM, TP53, BRCA1/2)

- Role: These genes are critical for repairing DNA damage. *Clinically confirmed* pathogenic mutations, especially leading to biallelic loss (e.g., in ATM, BRCA1/2), can cause Homologous Recombination Deficiency (HRD).

- Hypothesized Sirolimus+BAT Relevance: BAT induces DNA damage. mTOR inhibition (by Sirolimus) may also impair DNA repair. Therefore, *if* HRD (due to validated ATM/BRCA mutations) *or* significant DDR impairment (due to validated TP53 mutations) is present, combining Sirolimus with BAT *could theoretically* amplify DNA damage stress, potentially creating a synergistic anti-tumor effect. This underlies the rationale for exploring combinations with PARP inhibitors as well.
- Supporting Evidence Mentioned (Needs Verification): Preclinical data reportedly shows improved response to BAT+Sirolimus in ATM-mutant models. Correlation between ATM loss and mTOR inhibitor response is noted elsewhere.

Androgen Receptor (AR) Pathway

- Role: Remains a key driver in most CRPC. BAT directly targets this via testosterone cycling.
- Hypothesized Sirolimus+BAT Relevance: mTORC1 signaling can influence AR expression and activity, potentially including splice variants like AR-V7 (associated with resistance). It's *speculated* that Sirolimus *might* suppress AR-V7 or otherwise modulate AR signaling in a way that could re-sensitize cells to hormonal manipulation like BAT.
- Crucial Caveat: Relevant AR alterations (amplification, mutations, AR-V7 status) require clinical testing (tumor sequencing, RNA analysis)

3. *Biomarker Validation*

- Before considering *any* therapy based on genetic predisposition, clinically validated biomarker testing is necessary.
- Discuss https://www.guardantcomplete.com/products/guardant360 (for ctDNA analysis of gene alterations, MSI, bTMB) and/or FoundationOne CDx (tissue analysis) with your oncologist.
- FoundationOne RNA (requires tissue) is used to detect fusions and splice variants like AR-V7.
- Confirming HRD status (via genomic instability scores or specific mutation patterns) is crucial if considering PARP inhibitors. Functional assays (e.g., RAD51) are mainly research tools.

4. *Conclusion (Conditional and Speculative)*

IF robust clinical testing (FoundationOne, etc.) confirms the presence of specific, actionable alterations like HRD (due to pathogenic biallelic loss in

ATM, BRCA1/2) or potentially relevant TP53 mutations, *THEN* there is a *biological hypothesis* suggesting that combining low-dose Sirolimus with experimental BAT *might* offer synergistic benefits by amplifying DNA damage stress. However, this remains highly speculative and lacks clinical validation. The potential role related to AR signaling modulation is also speculative.

Melatonin

Melatonin is a hormone that helps control the sleep cycle. It can be used to fight cancer and has NIH research showing its efficacy. Government clinical trials show that its use provides a very small improvement in sleep quality, latency, and duration.

1. Mechanisms of Action

Melatonin exhibits multiple oncostatic actions in prostate cancer. It competitively inhibits GLUT1, thereby suppressing the Warburg effect, and acts as a potent antioxidant to reduce oxidative stress and protect DNA from damage. It downregulates NF-κB and other pro-survival transcription factors to promote apoptosis and cell cycle arrest (via upregulation of p21/p27), while also reducing angiogenesis by lowering HIF-1α and VEGF. Importantly, melatonin causes androgen receptor (AR) proteins to be sequestered outside the nucleus, diminishing AR-driven gene transcription. In castration-resistant cells, melatonin can disrupt the AR-V7 and NF-κB feedback loop, further inhibiting tumor growth.

---

2. Stages It Might Be Applied To

- nmHSPC: May serve as a preventive adjunct by improving circadian rhythm and immune function.
- oHSPC/mHSPC: As an adjunct to ADT (with or without chemotherapy), melatonin’s AR sequestration and anti-inflammatory effects might enhance treatment; however, human trials are limited.
- nmCRPC/oCRPC/mCRPC: In castration-resistant disease, melatonin may slow progression via its effects on AR-V7 and metabolic modulation; small retrospective studies suggest potential benefit in advanced, metastatic disease.

---

3. Research & Studies

Human data are sparse. A 2020 retrospective study reported that prostate cancer patients receiving ADT and radiotherapy had significantly improved overall survival when given adjunct melatonin (typically 3–6 mg at bedtime). Additional epidemiological research links lower melatonin metabolite levels to increased odds of advanced prostate cancer. Preclinical studies (with human equivalent doses of approximately 3–20 mg nightly) show robust inhibition of prostate tumor proliferation, reversal of enzalutamide resistance, and reduction in intratumoral androgen synthesis. Natural sources of melatonin (e.g. tart cherry) provide lower doses and are less standardized than supplements; thus, clinical studies predominantly use melatonin supplements.

4. Overall Quality of Evidence

- Human Clinical Evidence: D – Limited controlled trials; promising retrospective and epidemiological data.
- Mechanistic Theory: A – Multiple in vitro and in vivo studies support melatonin's anti-tumor and AR-modulating mechanisms.
- Preclinical Evidence: A – Robust laboratory data demonstrate inhibition of proliferation, induction of apoptosis, and reversal of therapy resistance.

5. Conclusion

Melatonin shows considerable promise as an adjunctive therapy across prostate cancer stages—from hormone-sensitive to castration-resistant—by targeting AR signaling, inflammation, and metabolic OSNs. Its excellent safety profile and additional benefits for sleep, muscle preservation, and lipid metabolism make it attractive. However, definitive clinical trials are needed to validate these findings. Mechanistically it does not appear to synergize with BAT; indeed, its AR-sequestering action may oppose BAT's intended high-testosterone DNA damage. Thus, while melatonin is beneficial when combined with standard treatments, caution is advised if BAT is employed.

6. Common Side Effects

Melatonin is generally well tolerated. Common side effects include drowsiness, vivid dreams, and mild gastrointestinal upset. At higher doses, headaches and dizziness may occur; severe adverse effects are rare.

7. DNA Damage & Double-Strand Breaks (DSBs)

Melatonin protects against DNA damage by scavenging free radicals and upregulating endogenous antioxidants. It enhances p53 activity and reduces estrogen-derived DNA adducts, thereby preserving genomic stability. In combination with DNA-damaging therapies such as radiotherapy or PARP inhibitors, melatonin may improve tumor cell kill while protecting normal tissues. However, since BAT relies on high androgen-induced DNA damage, melatonin's AR-sequestering effects might diminish BAT efficacy.

8. References

1. 3 mg 30 minutes before bed and only helpful for advanced PCa: Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment – PMC (open access) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566809
2. Melatonin—A New Prospect in Prostate and Breast Cancer Management - PMChttps://pmc.ncbi.nlm.nih.gov/articles/PMC8525668/

3. Melatonin, an Endogenous-specific Inhibitor of Estrogen Receptor α via Calmodulin* - Journal of Biological Chemistry https://www.jbc.org/article/S0021-9258(20)72870-X/fulltext
4. 5 mg. ADT enhancement and possible use for CRPC? The inhibitory effect of melatonin on human prostate cancer | Cell Communication and Signaling | Full Text https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00723-0
5. ADT enhancement? Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity – PubMed https://pubmed.ncbi.nlm.nih.gov/12111702
6. Melatonin: An Anti-Tumor Agent in Hormone-Dependent Cancers – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189685
7. Melatonin impedes prostate cancer metastasis by suppressing MMP-13 expression – PubMed https://pubmed.ncbi.nlm.nih.gov/33251599
8. Melatonin as a Radio-Sensitizer in Cancer – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460067
9. Melatonin | Memorial Sloan Kettering Cancer Center https://www.mskcc.org/cancer-care/integrative-medicine/herbs/melatonin
10. Neuroendocrine differentiation in prostate cancer – PMC https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC2776313
11. The Therapeutic Potential of Melatonin: A Review of the Science – PMC https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC1395802
12. Melatonin: a well-documented antioxidant with conditional pro-oxidant actions – PubMed https://pubmed.ncbi.nlm.nih.gov/25060102
13. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism – PubMed https://pubmed.ncbi.nlm.nih.gov/15378522
14. Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy – PubMed https://pubmed.ncbi.nlm.nih.gov/28561752
15. Bioavailability of Melatonin after Administration of an Oral Prolonged-Release Tablet and an Immediate-Release Sublingual Spray in Healthy Male Volunteers | Drugs in R&D https://link.springer.com/article/10.1007/s40268-023-00431-9
16. Antioxidant and Pro-Oxidant Activities of Melatonin in the Presence of Copper and Polyphenols In Vitro and In Vivo – PMC https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC6721667
17. Melatonin: Pharmacology, Functions and Therapeutic Benefits – PMC https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC5405617
18. Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review – PubMed https://pubmed.ncbi.nlm.nih.gov/24032643
19. Melatonin, a Full-Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis – PMC https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC5412427

20. Megerian, et al. Aging and Disease, 2023. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10187692/
21. Zharinov, et al. Oncotarget, 2020. URL: https://www.oncotarget.com/article/27757/text/
22. Chen, et al. Clinical and Translational Medicine, 2021. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC8181204/
23. Gonzalez, et al. Melatonin Research, 2019. URL: https://doi.org/10.32794/mr11250021
24. Radiosensitizer: Pan, et al. Biomedicines, 2020. URL: https://www.mdpi.com/2227-9059/8/8/247

Phenelzine

Phenelzine, a non-selective irreversible monoamine oxidase inhibitor (MAOI) traditionally used as an antidepressant, has emerged as a promising agent for both hormone-sensitive and castration-resistant prostate cancer. Recent clinical investigations have established its novel mechanistic approach to interrupting androgen receptor signaling and potentially overcoming treatment resistance.

Mechanisms of Action in Prostate Cancer

MAO-A Inhibition and AR Signaling

Phenelzine's primary anticancer mechanism involves inhibition of monoamine oxidase A (MAO-A), which plays a significant role in prostate cancer growth and metastasis. MAO-A expression is particularly relevant in prostate cancer progression, as it has been linked to AR signaling pathways and treatment resistance. With a half-life of 11.6 hours, phenelzine provides consistent MAO-A inhibition when administered twice daily.

The relationship between MAO-A and androgen receptor variants is particularly noteworthy. High expression of MAO-A is associated with positive AR splicing variant 7 (ARv7) detection in CRPC patients following enzalutamide treatment. This finding suggests that MAO-A may function as a downstream effector of AR variants that contribute to treatment resistance.

Enzalutamide Resistance Reversal

In CRPC specifically, phenelzine demonstrates a remarkable ability to resensitize enzalutamide-resistant cells to enzalutamide treatment. The mechanism appears to involve:

- Disruption of the enzalutamide/ARv7/MAO-A signaling axis
- Alteration of hypoxia HIF-1α signals that contribute to resistance
- Suppression of AR-dependent pathways even in the presence of AR variants

This resensitization effect represents a significant advance, as enzalutamide resistance remains a major clinical challenge in advanced prostate cancer management.

Clinical Evidence

Efficacy in Hormone-Sensitive Prostate Cancer

A phase II clinical trial of phenelzine in biochemical recurrent castrate-sensitive prostate cancer demonstrated moderate efficacy. The trial enrolled patients with PSA ≥0.4 ng/ml post-prostatectomy or PSA ≥2 ng/ml above nadir post-radiation therapy, without evidence of metastasis.

Key findings included:

- Maximal PSA declines ≥30% in 25% (n=5/20) of patients
- Maximal PSA declines ≥50% in 10% (n=2/20) of patients

- At 12 weeks, 17 patients remained on treatment with PSA declines ≥30% and ≥50% observed in 24% (n=4/17) and 6% (n=1/17) respectively

Overall, PSA declines were noted in 55% of patients during treatment, with the maximal PSA decline reaching 74%. This response rate, while modest, established proof-of-concept for MAO inhibition as a therapeutic strategy in prostate cancer.

Potential in Castration-Resistant Prostate Cancer

For CRPC, preclinical evidence suggests phenelzine may be particularly valuable in combination with enzalutamide. Research demonstrated that phenelzine can restore sensitivity to enzalutamide in resistant cell lines both in vitro and in vivo. This synergistic effect provides a mechanistic basis for combining phenelzine with antiandrogens in the CRPC setting.

Safety Profile and Administration

Phenelzine's safety profile in prostate cancer patients appears manageable, though it includes some notable adverse effects. Common toxicities observed in clinical trials included:

- Significant Food and Drug interactions.
- Dizziness (grade 1: 45%, grade 2: 35%)
- Hypertension (grade ≥2: 30%)
- Edema (grade 1: 25%, grade 2: 10%)

Severe adverse events were rare but included one episode of grade 4 hypertension (during cycle 4) and two episodes of grade 3 syncope (during cycles 12 and 14). The standard dosing regimen established in these trials was phenelzine 30 mg orally twice daily.

An unexpected but favorable finding was that HADS questionnaires demonstrated a significant decrease in anxiety with no change in depressive symptoms during treatment. This suggests phenelzine's original indication as an antidepressant may offer additional quality-of-life benefits for prostate cancer patients.

Position in Treatment Algorithms

Within evolving prostate cancer treatment paradigms, phenelzine is gaining recognition as a component of multi-mechanism approaches. In the adaptive-based bipolar androgen therapy (aBAT) protocol, phenelzine is assigned a relatively high priority ranking (7 out of 47 agents), highlighting its perceived value.

For treatment sequencing, phenelzine is recommended for:

- Medium-duration treatment cycles (21 days)
- Long treatment cycles (28 days)
- Not recommended for ultra-short cycles

Phenelzine appears particularly complementary to treatments targeting the PI3K/AKT/mTOR pathway, with metformin and darolutamide identified as potential synergistic agents during low-testosterone phases of treatment.

Conclusion

Phenelzine represents a novel approach to prostate cancer treatment that exploits the previously unrecognized role of MAO-A in disease progression. Clinical evidence supports modest single-agent activity in biochemical recurrent HSPC, while preclinical data suggests significant potential for overcoming enzalutamide resistance in CRPC.

As the first MAO inhibitor to be systematically investigated in prostate cancer, phenelzine establishes a new potential therapeutic direction with a differentiated mechanism of action. While not a definitive therapy alone, its unique mechanism and favorable toxicity profile make it a valuable addition to the prostate cancer treatment armamentarium, especially in combination strategies targeting resistance pathways.

Future research should focus on optimizing combination regimens, identifying predictive biomarkers of response, and further exploring the relationship between MAO-A inhibition and AR signaling in various stages of prostate cancer.

References

Article Title	Quality Grade	URL
Phase 2 Trial of Monoamine Oxidase Inhibitor Phenelzine in Biochemical Recurrent Castrate Sensitive Prostate Cancer	B-	https://pmc.ncbi.nlm.nih.go
The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration-resistant prostate cancer	C+	https://pubmed.ncbi.nlm.nih
Antidepressant Repurposed for Recurrent Prostate Cancer	C	https://www.uspharmacist.c antidepressant-repurposed- cancer
The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer	C+	https://www.nature.com/art
MAOA inhibitor phenelzine efficacious in recurrent	B-	https://www.nature.com/art

Article Title	Quality Grade	URL
prostate cancer		
Phase II Trial Results Show Promise for Phenelzine in Prostate Cancer	B-	https://www.cancernetwork results-show-promise-phene

Losartan (BP med)

Losartan as a Radiosensitizer: Critical Analysis
Evidence and Efficacy

Study	Cancer Type	Key Findings	Efficacy Rating (A-F)
Yazdannejat et al. (2016)	Prostate Cancer	Losartan (1 μM) + radiation reduced prostate cancer cell viability to 54% vs. 66% with losartan alone. No toxicity in normal fibroblasts.	B (preclinical)
PMC5431597 (2017)	Prostate Cancer	ARBs (including losartan) induced autophagy-associated cell death and suppressed metastasis in prostate cancer cells. Fimasartan > losartan > valsartan.	B (preclinical)
AACR PO3-24-10 (2024)	Triple-Negative Breast Cancer	Losartan enhanced radiosensitivity in immunocompetent mice via CD8+ T-cell activation and M1 macrophage polarization. No effect on immunodeficient models.	C (preclinical/early-phase)
Science (2021)	NF2 Schwannoma	Losartan + radiation reduced tumor growth by 50% vs. radiation alone. Normalized tumor microenvironment (TME) via IL-6/STAT3 inhibition.	B (preclinical)
PMC8409338 (2021)	HER2+ Breast Cancer	Losartan + radiation increased tumor control (TGD 2.5×) and reduced lung metastases by 70% in mice. Improved oxygenation and reduced hypoxia.	B (preclinical)

Mechanistic Theory

1. Angiotensin Receptor Blockade:
    - Losartan inhibits AT1 receptors, reducing angiotensin II-driven proliferation (MAPK/STAT3) and angiogenesis (VEGF).
2. Autophagy Induction:
    - ARBs trigger autophagy-associated cell death in prostate cancer cells, enhancing radiation-induced apoptosis.
3. Immune Modulation:
    - Polarizes tumor-associated macrophages (TAMs) to M1 phenotype, activates CD8+ T cells, and reduces immunosuppressive MDSCs.
4. TME Normalization:

- Reduces edema, inflammation (IL-6, TLR4), and oxidative stress (ROS), improving radiation penetration and efficacy.

5. Hypoxia Reduction:
    - Improves tumor perfusion, lowering hypoxia-induced radioresistance.

Ratings

Category	Rating (A-F)	Rationale
Clinical Trials	D	Limited human data; only preclinical/early-phase studies (e.g., AACR PO3-24-10).
Preclinical Data	B	Consistent efficacy across prostate, breast, and schwannoma models.
Mechanistic Plausibility	B	Multiple validated OSNs (autophagy, immune modulation, TME normalization).
Safety	C	Hypotension and hyperkalemia risks manageable; no direct radiation toxicity.

Key Side Effects

- Common: Dizziness, hyperkalemia, fatigue.
- Serious: Acute kidney injury (with nephrotoxic agents), severe hypotension.

Conclusion

Losartan demonstrates moderate preclinical efficacy (Grade B) as a radiosensitizer via autophagy, immune activation, and TME normalization. While human trials are lacking, its safety profile and low cost ($10–30/month) justify further investigation in combination with radiotherapy for prostate, breast, and NF2-related cancers.

Recommendations:

- Prioritize clinical trials in hypoxic or immunosuppressive tumors.
- Monitor blood pressure and renal function during combined therapy.

References:

1. Losartan sensitizes prostate cancer cells to ionizing radiation (2016)
2. ARBs induce autophagy in prostate cancer (2017)
3. Losartan enhances TNBC radiosensitivity via CD8+ T cells (2024)
4. Losartan prevents hearing loss in NF2 schwannoma (2021)
5. Losartan improves HER2+ breast cancer radiation response (2021)

Final Note: Losartan’s radiosensitization potential is promising but requires validation in human trials. Avoid in patients with severe renal impairment or hypotension.

Orlistat

Orlistat prevents the absorption of fat in the gut and blocks fatty acid synthesis in the cells. It has been shown to inhibit the growth of PC-3 prostate tumors in vivo and appears to be synergistic with enzalutamide.

References

1. Effects of orlistat combined with enzalutamide and castration through inhibition of fatty acid synthase in a PC3 tumor-bearing mouse model | Bioscience Reports | Portland Press https://portlandpress.com/bioscirep/article/41/5/BSR20204203/228631/Effects-of-orlistat-combined-with-enzalutamide-and
2. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression – PubMed https://pubmed.ncbi.nlm.nih.gov/11340632/
3. Full article: Natural fatty acid synthase inhibitors as potent therapeutic agents for cancers: A review https://www.tandfonline.com/doi/full/10.3109/13880209.2015.1113995
4. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity – PubMed https://pubmed.ncbi.nlm.nih.gov/15026345/
5. Anti-Tumorigenic Potential of a Novel Orlistat-AICAR Combination in Prostate Cancer Cells – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603373/
6. FDA fact sheet https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020766s028lbl.pdf
7. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells – PubMed https://pubmed.ncbi.nlm.nih.gov/12839976/
8. Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy – PubMed https://pubmed.ncbi.nlm.nih.gov/29723075/
9. Synergizes with RT: Fatty Acid Inhibition Sensitizes Androgen-Dependent and -Independent Prostate Cancer to Radiotherapy via FASN/NF-κB OSN – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746859/
10. Until the late phases, PCa is lipid driven. Fatty Acid Synthase: An Emerging Target in Cancer – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504791/
11. Fatty Acid Synthesis in Prostate Cancer: Vulnerability or Epiphenomenon? | Cancer Research | American Association for Cancer Research https://aacrjournals.org/cancerres/article/81/17/4385/670265/Fatty-Acid-Synthesis-in-Prostate-Cancer

Multivitamin

Mechanisms of Action

• Antioxidant & Anti-Inflammatory Effects: The vitamins (C, E) and minerals (selenium, zinc) in a child's multivitamin help scavenge free radicals and reduce inflammation—factors implicated in cancer progression.
• Immune Support: Micronutrients such as vitamin D and zinc bolster immune function, potentially improving overall health in cancer patients.
• Nutrient Sufficiency: By addressing dietary deficiencies, multivitamins may support cellular metabolism and overall systemic health, which is critical for prostate cancer patients who often suffer from nutritional deficits.
• Hormonal Modulation: While not directly altering androgen receptor signaling, adequate micronutrient status may indirectly support hormone balance and metabolic functions.

Research & Studies

• In Vitro Studies: Limited laboratory research indicates that antioxidants in multivitamins can inhibit prostate cancer cell proliferation under oxidative stress conditions.
• Animal Studies: Preclinical models suggest that comprehensive micronutrient supplementation can improve overall health and reduce tumor progression in cancer-bearing animals, though specific studies on child's formulations are scarce.
• Clinical Trials: Large-scale observational studies and some RCTs in adults have linked multivitamin use with improved overall health and reduced mortality. However, data specific to prostate cancer are mixed, and studies using child's multivitamin formulations in adults are rare.
• Natural Sources vs. Supplements: Whole-food diets provide a complex mix of nutrients and bioactive compounds that may offer synergistic benefits. In contrast, supplements (including child's multivitamins) deliver standardized doses but may not meet adult therapeutic needs, with potential concerns about manufacturing quality and cost.

Overall Quality of Evidence

• Mechanistic & Preclinical Evidence: Rated C – Some supportive laboratory and animal evidence exists, but it is limited.
• Clinical Evidence (General Health): Rated B – Observational data suggest benefits in overall health and reduced mortality, though prostate cancer–specific data are less robust.
• Clinical Evidence (Therapeutic Use in PCa): Rated D – Direct evidence in prostate cancer patients is sparse, making its use as a specific adjuvant therapy unproven.

Conclusion

Child's multivitamins provide essential micronutrients that may support general health, reduce oxidative stress, and enhance immune function. For prostate cancer patients, maintaining nutrient sufficiency is important;

however, there is insufficient evidence that using a child’s multivitamin specifically improves prostate cancer outcomes. Although cost-effective and safe when manufactured to high standards, these formulations may not deliver the optimal dosages required for adult therapeutic benefit. Further research is needed to establish their role as an adjunct in prostate cancer management.

Common Side Effects

• Generally well tolerated with minimal adverse effects.
• Over-supplementation in adults could lead to gastrointestinal discomfort or hypervitaminosis (especially with fat-soluble vitamins).
• Quality varies by brand; reputable manufacturers typically minimize heavy metal contamination.

BAT Synergy

It does not appear to synergize with BAT.

References

References

1. Slight reduction in overall cancer: Multivitamins in the Prevention of Cancer in Men: The Physicians' Health Study II Randomized Controlled Trial | Colorectal Cancer | JAMA | JAMA Network https://jamanetwork.com/journals/jama/fullarticle/1380451
2. Cocoa had no effect on dementia risk. Multi-vitamin/minerals showed a small risk reduction: Effects of cocoa extract and a multivitamin on cognitive function: A randomized clinical trial - Baker - Alzheimer's & Dementia - Wiley Online Library
    1. https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.12767
3. B-12: Circulating Folate and Vitamin B12 and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls – PMC
    2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094800
4. Dairy calcium vs. non-dairy calcium Higher Dairy Intake May Up Risk for Prostate Cancer - Cancer Therapy Advisor
    3. https://www.cancertherapyadvisor.com/home/cancer-topics/prostate-cancer/higher-dairy-intake-may-up-risk-for-prostate-cancer/

Coffee

1. Mechanisms of Action

- Antioxidant Properties: Coffee contains compounds such as chlorogenic acids and polyphenols that exhibit antioxidant effects, neutralizing free radicals and reducing oxidative stress, which can contribute to cancer development.
- Anti-inflammatory Effects: Regular coffee consumption has been linked to decreased levels of inflammatory markers like C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), and interleukins (IL-6, IL-8), potentially lowering the risk of prostate cancer (PCa) progression.
- Modulation of Hormonal Activity: Coffee intake has been associated with increased testosterone levels and reduced concentrations of sex hormone-binding globulin (SHBG) and estrogen, which may influence PCa development.
- Induction of Autophagy: Certain compounds in coffee can induce autophagy, a cellular process that removes damaged cells, thereby inhibiting cancer cell proliferation.

2. Research & Studies

- Epidemiological Studies:
  - A systematic review and meta-analysis suggested that increased coffee consumption is associated with a reduced risk of prostate cancer, particularly fatal cases.
  - Research from the Fred Hutchinson Cancer Research Center indicated that coffee consumption is linked to a lower risk of prostate cancer recurrence and progression.
- Mechanistic Studies:
  - Laboratory studies have demonstrated that coffee can induce autophagy, regulate the NF-κB pathway, and reduce the expression of inflammatory mediators such as iNOS, TNF-α, IL-6, and IL-8, which are involved in prostate cancer development.

3. Overall Quality of Evidence

- Epidemiological Evidence: Rated B. Multiple observational studies and meta-analyses suggest an inverse association between coffee consumption and prostate cancer risk, particularly for aggressive forms. However, these studies are observational and cannot establish causation.

- Mechanistic Evidence: Rated B. Preclinical studies provide plausible biological mechanisms for coffee's protective effects against prostate cancer.

4. Conclusion

- Coffee consumption has been associated with a reduced risk of prostate cancer, supported by epidemiological studies and plausible biological mechanisms, including antioxidant, anti-inflammatory, hormonal modulation, and autophagy induction effects. However, these findings are primarily based on observational data, and causation cannot be definitively established.
- Coffee consumption has been associated with a reduced risk of prostate cancer, supported by epidemiological studies and plausible biological mechanisms, including antioxidant, anti-inflammatory, hormonal modulation, and autophagy induction effects. However, these findings are primarily based on observational data, and causation cannot be definitively established.
- Coffee appears to reduce all-cause mortality risk and mortality risk from PCa, in addition to reducing the likelihood of Alzheimer’s, Parkinson’s, dementia, and type 2 diabetes. These reductions are seen with 3+ cups of coffee per day and appear to be on the order of 10-25%. For aggressive PCa the risk reduction found by the NIH was even more substantial. On the order of 60% for 6+ cup coffee drinkers.
- Organic coffee is preferable to conventional. And whole beans that you grind yourself are as good, if not better, than ground.
- There are at least three components in coffee that are toxic or deleterious to the body. One is cafestol. Cafestol elevates cholesterol. By using filters cafestol can be reduced. The second known toxin is acetaldehyde. Acetaldehyde is found in many foods but, in general, the percentage in coffee is higher than in most foods. However, the mass of coffee beans used for a cup of coffee is low and the actual amount of acetaldehyde consumed from coffee is extremely low. A note about acetaldehyde: The acetaldehyde created during alcohol consumption is up to 300 times higher than in coffee.
- The third is acrylamide. Acrylamide is higher in instant coffee than in regular and is lowest in dark roasted coffee. Acrylamide is formed while heating the coffee so cold-brewed coffee is quite low in acrylamide.
- There is also some speculation about mycotoxins (mold). However, the levels are low and are of no concern.
- Although there are methods to reduce cafestol, acrylamide, and acetaldehyde, I have come across research indicating that the protective effects from coffee are due in part to one or more of these substances. So, I only lightly filter it. I grind my own organic

beans. I enjoy coffee so having 6 cups a day is easy for me. Caffeine is a stimulant and can cause insomnia, so I drink all my coffee by noon.

5. *Common side effects*

- Coffee containing caffeine can cause:
- Insomnia
- Nervousness
- Restlessness
- Stomach issues
- Nausea

6. *References*

1. **Molecular Mechanisms of Coffee on Prostate Cancer Prevention – PMC** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054433
2. **Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study – PubMed** https://pubmed.ncbi.nlm.nih.gov/21586702
3. **No association: Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis – PMC** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132137
4. **Green and light extracts superior: Bioactive compounds, antioxidant activity and antiproliferative effects in prostate cancer cells of green and roasted coffee extracts obtained by microwave-assisted extraction (MAE) – PubMed** https://pubmed.ncbi.nlm.nih.gov/33648246
5. **Coffee may reduce risk of lethal prostate cancer in men | News | Harvard T.H. Chan School of Public Health** https://www.hsph.harvard.edu/news/press-releases/prostate-cancer-coffee-mucci-wilson
6. **Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer.**

https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/139096-coffee-intake-caffeine-metabolism-genotype-and-survival-among-men-with-prostate-cancer.html
7. Reduction by coffee consumption of prostate cancer risk: Evidence from the Moli-sani cohort and cellular models - Pounis - 2017 - International Journal of Cancer - Wiley Online Library https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.30720
8. Do Coffee Brewing Methods Matter for Health? | Mark's Daily Apple https://www.marksdailyapple.com/do-coffee-brewing-methods-matter-for-health
9. Acrylamide in Coffee: Should You be concerned? https://www.healthline.com/nutrition/acrylamide-in-coffee
10. Debunking the Myth About Mycotoxins in Coffee https://www.healthline.com/nutrition/the-mycotoxins-in-coffee-myth#coffee-content
11. Coffee diterpenes kahweol acetate and cafestol synergistically inhibit the proliferation and migration of prostate cancer cells - Iwamoto - 2019 - The Prostate - Wiley Online Library https://onlinelibrary.wiley.com/doi/10.1002/pros.23753
12. Coffee may keep prostate cancer recurrence and progression away - Fred Hutchinson Cancer Research Center https://www.fredhutch.org/en/news/releases/2013/08/coffee-keep-prostate-cancer-away.html#:~:text=Stanford%20and%20colleagues%20found%20that,or%20fewer%20cups%20per%20week.
13. Coffee consumption reduces mortality risk: Coffee Consumption and All-Cause, Cardiovascular, and Cancer Mortality in an Adult Mediterranean Population - PMC

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070495/
14. Cafestol extraction yield from different coffee brew mechanisms – ScienceDirect: https://www.sciencedirect.com/science/article/pii/S0963996912002360
15. Coffee consumption and risk of prostate cancer: a systematic review and meta-analysis | BMJ Open https://bmjopen.bmj.com/content/11/2/e038902
16. Dietary acrylamide and cancer risk: An updated meta-analysis - Pelucchi - 2015 - International Journal of Cancer - Wiley Online Library https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.29339

Pomegranate

Anti-oxidants only appear beneficial if you are

Men with the (SNP: RS4880) MnSOD AA genotype in the extract group had a notable increase in PSADT (from 13.6 to 25.6 months, P=0.03), suggesting possible genotype-specific benefit, but this requires further validation.
If you don't have this genotype, no significant change in PSADT. We need further studies for that genotype.
Group Median PSADT Change (months) P-value
Placebo, MnSOD AA +1.8 0.22
Pomegranate Extract, MnSOD AA +12.0 0.03
About a quarter of men with PCa have this genotype.
I'm AG (usually called AV). 50% of men are this type.

Higher MnSOD converts superoxide → hydrogen peroxide faster
If downstream enzymes (glutathione peroxidase, catalase) can't keep up, hydrogen peroxide accumulates
This creates oxidative stress despite high SOD activity

Mechanisms of Action
• Antioxidant & Anti-Inflammatory Effects: Pomegranate contains polyphenols (e.g., punicalagins, ellagitannins) that robustly scavenge free radicals and downregulate inflammatory mediators (such as NF-κB and COX-2), thereby reducing oxidative stress in prostate tissue.
• Modulation of Androgen Receptor Signaling: In vitro studies indicate that pomegranate extracts may decrease androgen receptor (AR) expression and signaling, potentially dampening the growth stimulus in prostate cancer cells.
• Induction of Apoptosis & Inhibition of Angiogenesis: Laboratory data show that pomegranate compounds promote programmed cell death and suppress pro-angiogenic factors, which may limit tumor vascularization and growth.
Research & Studies
• In Vitro Studies: Multiple experiments over the last 5–10 years consistently demonstrate that pomegranate extracts inhibit prostate cancer cell proliferation and induce apoptosis.
• Animal Studies: Preclinical models reveal that pomegranate juice or extracts delay tumor growth, reduce metastasis, and improve survival in prostate cancer-bearing rodents.
• Clinical Trials: Early-phase trials and observational studies suggest that pomegranate supplementation—commonly via juice—can slow PSA progression and prolong PSA doubling time in men with recurrent or rising

PSA levels after primary therapy. However, findings are modest and sometimes mixed.
• Natural Sources vs. Supplements: Natural pomegranate juice offers a full spectrum of bioactive polyphenols with lower contamination risk, while supplements provide standardized, higher doses but may face issues with cost and potential heavy metal contamination.

Overall Quality of Evidence

• Mechanistic & Preclinical Evidence: Rated B – Robust laboratory and animal studies support the anticancer and anti-inflammatory actions of pomegranate.
• Clinical Evidence: Rated C – Early-phase trials indicate modest benefits in PSA kinetics and potential clinical effects, but larger randomized controlled trials are needed.

Conclusion

Pomegranate, whether consumed as natural juice or via supplements, exhibits promising anticancer properties in prostate cancer by reducing oxidative stress, inflammation, and AR signaling, while inducing apoptosis and inhibiting angiogenesis. Observational and early-phase clinical data suggest modest benefits in delaying PSA progression. Its favorable safety profile and additional cardiovascular benefits make it an attractive adjunct therapy, although further robust clinical trials are warranted.

Common Side Effects

• Generally well tolerated; mild gastrointestinal discomfort (e.g., bloating or diarrhea) may occur in some individuals.
• Allergic reactions are rare, and overall toxicity is minimal.

BAT Synergy

It does not appear to synergize with BAT.

References

References

1. 8 oz of pomegranate juice per day improved PSA doubling time. Cell cultures showed positive effects: Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer – PubMed https://pubmed.ncbi.nlm.nih.gov/16818701/
2. Daily Pomegranate Intake Has No Impact on PSA Levels in Patients with Advanced Prostate Cancer - Results of a Phase IIb Randomized Controlled Trial https://www.jcancer.org/v04p0597.htm
3. Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®)–Health Professional Version – NCI https://www.cancer.gov/about-cancer/treatment/cam/hp/prostate-supplements-pdq#_79_toc
4. Synergy: Pomegranate combined with curcumin, resveratrol, sulforaphane, and EGCG extended PSADT: A Placebo-Controlled Double-Blinded Randomized Pilot Study of Combination Phytotherapy

in Biochemically Recurrent Prostate Cancer - van Die - 2017 - The Prostate - Wiley Online Library
https://onlinelibrary.wiley.com/doi/abs/10.1002/pros.23317
5. Synergy: Pomegranate combined with curcumin, sulforaphane, and EGCG extended PSADT: A double-blind, placebo-controlled randomized trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer—the UK NCRN Pomi-T study – PMC
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020278/
6. Pomegranate shows a weak trend for better PSA control, but the difference did not reach preestablished significance: Daily Pomegranate Intake Has No Impact on PSA Levels in Patients with Advanced Prostate Cancer - Results of a Phase IIb Randomized Controlled Trial – PMC
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781990/
7. Positive study results: A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer – PMC
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549301/
8. A Review of Pomegranate in Prostate Cancer - PMC
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555799/

Niclosamide

References

1. Biomedicines | Free Full-Text | Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy https://www.mdpi.com/2227-9059/11/4/1105#B123-biomedicines-11-01105
2. Niclosamide in prostate cancer: An inhibitor of AR-V7, a mitochondrial uncoupler, or more? – ScienceDirect https://www.sciencedirect.com/science/article/pii/S2468294223000060
3. Combination of niclosamide and current therapies to overcome resistance for cancer: New frontiers for an old drug – ScienceDirect https://www.sciencedirect.com/science/article/pii/S0753332222011787
4. No control. Perhaps 2 months to resensitize: Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973745/
5. Negative: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983471/
6. ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling | Oncogene https://www.nature.com/articles/s41388-021-01914-2
7. Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02807805
8. Targeting androgen receptor variants by niclosamide overcoming resistance to abiraterone and enzalutamide https://www.pcf.org/wp-content/uploads/2016/10/GAO_ALLEN_19391426_ABSTRACT.pdf

9. AR-V7 is implicated in resistance to Zytiga. Niclosamide inhibits AR-V7 and might resensitize PCa to Zytiga.: Upon castrate-resistance, adaptive therapy using abiraterone has shown considerable treatment success. Towards multi-drug adaptive therapy – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307613/
10. PerpTargeting androgen receptor variants by niclosamide overcoming resistance to abiraterone and enzalutamide https://www.pcf.org/wp-content/uploads/2016/10/GAO_ALLEN_19391426_ABSTRACT.pdf

Taurine

This amino acid might reduce CVD risk, inhibit PCa progression and proliferation, increase PCa apoptosis, and increase muscle hypertrophy.

References

1. Effect of taurine on the proliferation, apoptosis and MST1/Hippo signaling in prostate cancer cells – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273655/
2. Effect of Taurine on Prostate-Specific Antigen Level and Migration in Human Prostate Cancer Cells | SpringerLink https://link.springer.com/chapter/10.1007/978-3-319-15126-7_18#Cell%20Viability

American Ginseng

.
American ginseng (Panax quinquefolius) is an herb that grows in North America. It has been shown to reduce cancer related fatigue (CRF). When I started taking 500 mg 4 times a day I felt that I had less fatigue and more energy. In some people higher doses of ginseng can cause insomnia. I noticed this and cut back to 500 mg upon awakening and 500 mg at noon.

Mechanisms of Action
• Adaptogenic and Anti-Stress Effects: American ginseng (Panax quinquefolius) acts as an adaptogen that modulates the hypothalamic-pituitary-adrenal (HPA) axis, reducing stress hormone levels and improving overall energy balance.
• Antioxidant Activity: It scavenges free radicals and upregulates endogenous antioxidant enzymes, thereby mitigating oxidative stress, which is linked to cancer-related fatigue.
• Anti-Inflammatory Effects: The ginsenosides present in American ginseng inhibit inflammatory mediators such as NF-κB and cytokines, contributing to reduced systemic inflammation—a key driver of fatigue in cancer patients.
Research & Studies
• In Vitro Studies: Laboratory experiments demonstrate that American ginseng extracts can modulate cellular stress responses and enhance mitochondrial function, providing a biological rationale for fatigue reduction.
• Animal Studies: Preclinical models have shown improved physical endurance and reduced markers of stress and inflammation with ginseng supplementation.
• Clinical Trials: Over the past 5–10 years, several randomized controlled trials have evaluated American ginseng in cancer-related fatigue. One large Phase III trial in patients receiving cancer treatment reported statistically significant improvements in fatigue scores with a standardized dose of American ginseng extract (typically 2,000 mg daily) compared to placebo. Additionally, observational studies suggest that patients using high-quality ginseng supplements experience better energy levels and quality of life.
• Natural Sources vs. Supplements: While traditional use involves consuming whole root teas, standardized supplements offer controlled dosages and higher concentrations of active ginsenosides. Supplements, however, can vary in purity and cost, and quality control is essential to avoid heavy metal contamination.
Overall Quality of Evidence
• Mechanistic & Preclinical Evidence: Rated B – Strong laboratory and animal data support its adaptogenic, antioxidant, and anti-inflammatory effects.
• Clinical Evidence (Therapeutic Use): Rated B – Multiple RCTs and meta-

analyses indicate American ginseng improves fatigue scores in cancer patients, although further larger studies would strengthen these findings.

Conclusion

American ginseng exhibits promising benefits for cancer-related fatigue in prostate cancer by modulating stress OSNs, reducing oxidative damage, and lowering inflammation. Clinical trials over the past decade consistently show improvements in fatigue, enhanced quality of life, and increased energy in patients. Standardized ginseng supplements provide reliable dosing compared to traditional sources, though cost and purity remain considerations. Overall, American ginseng is a well-tolerated adjunct that may help mitigate fatigue in PCa patients undergoing treatment.

Common Side Effects

• Mild gastrointestinal upset (e.g., nausea or diarrhea)
• Headaches and dizziness in some individuals
• Generally few adverse effects when using standardized, high-quality supplements

BAT Synergy

It does not appear to synergize with BAT.

References

References

1. PCRI Ginseng for cancer related fatigue: https://pcri.org/insights-blog/2016/9/7/featured-article-using-ginseng-for-cancer-related-fatigue
2. Ginseng for the Management of Cancer-Related Fatigue: An Integrative Review – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163251/
3. American ginseng board of Wisconsin https://pcri.org/insights-blog/2016/9/7/featured-article-using-ginseng-for-cancer-related-fatigue
4. American Ginseng in Treating Patients With Fatigue Caused by Cancer - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00719563
5. American Ginseng Improves Cancer-related Fatigue | Natural Medicine Journal https://www.naturalmedicinejournal.com/journal/american-ginseng-improves-cancer-related-fatigue
6. The use of ginseng supplements with short duration (< 6 weeks) and lower dose (< 1,000 mg/day) showed no significant efficacy. Longer durations with higher doses showed efficacy: Efficacy of Ginseng Supplements on Fatigue and Physical Performance: a Meta-analysis – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102849/
7. Wisconsin ginseng (Panax quinquefolius) to improve cancer-related fatigue: A randomized, double-blind trial, N07C2 — Mayo Clinic https://mayoclinic.pure.elsevier.com/en/publications/wisconsin-ginseng-panax-quinquefolius-to-improve-cancer-related-f

Vitamin E

References

1. Upregulation of pERK and c-JUN by γ-tocotrienol and not α-tocopherol are essential to the differential effect on apoptosis in prostate cancer cells | BMC Cancer | Full Text https://bmccancer.biomedcentral.com/articles/10.1186/s12885-020-06947-6
2. Gamma-Tocotrienol Induces Apoptosis in Prostate Cancer Cells by Targeting the Ang-1/Tie-2 Signalling OSN – PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429150/
3. γ-Tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling OSNs | British Journal of Cancer https://www.nature.com/articles/6604763

Beta glucans

Mushrooms – optimally heated to 120C-160C.

1. Shaping the Innate Immune Response by Dietary Glucans: Any Role in the Control of Cancer? – PMC https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7016572
2. (PDF) Glucans and Cancer: Comparison of Commercially Available β-glucans - Part IV https://www.researchgate.net/publication/323523231_Glucans_and_Cancer_Comparison_of_Commercially_Available_b-glucans_-_Part_IV
3. Perhaps increases Bifidobacterium: Impact of Consumption of Beta-glucans on the Intestinal Microbiota and Glucose and Lipid Metabolism ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02041104
4. The effects of β-glucan on human immune and cancer cells | Journal of Hematology & Oncology | Full Text https://jhoonline.biomedcentral.com/articles/10.1186/1756-8722-2-25
5. Beta-Glucans: Not all the Same | Blog | Cerabeta https://cerabeta.com/blogs/blog/beta-glucans-not-all-the-same
6. Immune-modulatory effects of dietary Yeast Beta-1,3/1,6-D-glucan – PMC https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC4012169

Bupropion

I would not take this if I did not have depression. Out of the anti-depressants this might have one of the best side effect profiles and might be preventative against PCa and offer relieve cancer related fatigue slightly.

References

1. Antidepressant medication use and prostate cancer recurrence in men with depressive disorders – PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC9519663/
2. Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial – PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC7045731/

Modified Citrus Pectin (MCP)

1. Mechanisms of Action

MCP is a soluble, modified form of pectin that exerts its anticancer effects primarily by binding to galectin-3—a molecule that facilitates tumor cell adhesion, metastasis, and immune evasion. By inhibiting galectin-3, MCP impedes metastatic spread, enhances apoptosis, and can reduce tumor cell proliferation. Additionally, MCP may modulate immune responses by activating T-cells and natural killer cells, thereby reinforcing its anti-cancer activity.

2. Research & Studies

Preclinical Studies: Laboratory experiments and animal models have consistently shown that MCP reduces metastasis and induces apoptosis in prostate cancer cells. These studies demonstrate decreased tumor adhesion and lower metastatic incidence following MCP treatment.

Clinical Trials: In non-metastatic hormone-sensitive prostate cancer (nmHSPC), several Phase II trials over the past 5–10 years have reported that MCP supplementation significantly prolongs PSA doubling time and stabilizes disease progression. Although evidence in oligometastatic hormone-sensitive (oHSPC), oligometastatic castration-resistant (oCRPC), and metastatic castration-resistant prostate cancer (mCRPC) is more limited—primarily consisting of small pilot studies or case reports—the most robust clinical data exist for nmHSPC.

Natural Sources vs. Supplements: Naturally occurring pectin from citrus fruits is not absorbed in its native form; only the enzymatically modified, low-molecular-weight form (MCP) is bioavailable. Supplements offer standardized purity, higher bioavailability, and consistent dosing, though they are relatively expensive. In contrast, natural sources are less costly but do not provide therapeutic MCP concentrations and may lack efficacy.

3. Overall Quality of Evidence

- Mechanistic and preclinical evidence: Rated B – Robust laboratory and animal studies support MCP’s anticancer mechanisms.
- Clinical evidence (prevention in nmHSPC): Rated B – Several Phase II trials demonstrate beneficial effects on PSA kinetics.
- Clinical evidence (therapeutic use in advanced PCa): Rated C – Limited and preliminary data exist for oHSPC, oCRPC, and mCRPC.

4. Conclusion

MCP exhibits promising anticancer properties, particularly in non-metastatic hormone-sensitive prostate cancer, by inhibiting galectin-3 and reducing metastatic potential. Clinical trials suggest that MCP supplementation can slow PSA progression, indicating a potential role as an adjunct therapy. However, larger randomized controlled trials are necessary to confirm these findings, especially in advanced prostate cancer. Natural sources of pectin

lack bioactivity, making high-quality supplements essential for therapeutic benefit.

5. Common Side Effects

MCP is generally well tolerated. Reported side effects are mild and primarily gastrointestinal, including bloating, cramping, and diarrhea. There is minimal risk of liver or kidney toxicity. Moreover, due to its chelating properties, high-quality MCP supplements are rigorously tested to avoid heavy metal contamination, ensuring a favorable safety profile.

6. BAT Synergy

Bipolar androgen therapy (BAT) relies on cycling high-dose testosterone, a mechanism that does not align with MCP's galectin-3 inhibition. Current evidence does not support synergy between MCP and BAT. It does not appear to synergize with BAT.

7. References

1. Trial shows increased PSADT and PSA control. However, no placebo arm was used: Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study - PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706421/
2. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study - PubMed https://pubmed.ncbi.nlm.nih.gov/14663471/
3. Clinical Benefit in Patients with Advanced Solid Tumors Treated with Modified Citrus Pectin: A Prospective Pilot Study - Marc Azémar, Bernd Hildenbrand, Brigitte Haering, Manfred E. Heim, Clemens Unger, 2007 https://journals.sagepub.com/doi/full/10.4137/CMO.S285
4. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets - PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2782490/
5. Modified citrus pectin inhibits breast cancer development in mice by targeting tumor-associated macrophage survival and polarization in hypoxic microenvironment - PubMed https://pubmed.ncbi.nlm.nih.gov/34462562/
6. Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®)–Health Professional Version - NCI https://www.cancer.gov/about-cancer/treatment/cam/hp/prostate-supplements-pdq#_161
7. Pectin | Memorial Sloan Kettering Cancer Center https://www.mskcc.org/cancer-care/integrative-medicine/herbs/pectin#references-6
8. https://www.cancerresearchuk.org/about-cancer/treatment/complementary-alternative-therapies/individual-therapies/modified-citrus-pectin-mcp
9. https://drruscio.com/modified-citrus-pectin/

10. https://www.metagenicsinstitute.com/blogs/demystifying-modified-citrus-pectin-evidence/

11. Modified Citrus Pectin: A Novel Adjunct in Cancer Therapy. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459199/
12. Inhibition of Tumor Growth by Modified Citrus Pectin in Prostate Cancer Models. https://pubmed.ncbi.nlm.nih.gov/7853416/
13. Galectin-3 Inhibition by Modified Citrus Pectin in Prostate Cancer. https://pubmed.ncbi.nlm.nih.gov/21816083/

Low dose Naltrexone (LDN)

1. *Mechanisms of Action*

LDN works by transiently blocking opioid receptors, which leads to a rebound increase in endogenous opioid growth factor (OGF) that binds to the OGF receptor (OGFr) on prostate cancer cells. This activation results in cell cycle arrest and may inhibit tumor proliferation. LDN also modulates immune responses by increasing cytokine production (e.g., IL-2 and interferon-gamma) and enhancing natural killer cell activity, thereby supporting anti-tumor immunity. Unlike standard androgen deprivation therapies, LDN does not directly target androgen receptors but exerts its effects via the OGF–OGFr axis and immune modulation.

2. *Research & Studies*

Preclinical Studies: In vitro and animal studies have demonstrated that LDN can slow tumor cell growth, reduce angiogenesis, and enhance apoptosis across various cancer types. Although not all studies have been conducted specifically in prostate cancer models, the general anti-proliferative effects observed support its potential role.
Clinical Studies: Clinical evidence for LDN in prostate cancer is limited and mainly comes from small case series and pilot studies over the past 5–10 years. In one case series, advanced prostate cancer patients experienced declines in PSA levels and disease stabilization when LDN was used as an adjunct to other treatments. However, these studies were not large randomized controlled trials.
Natural Sources vs. Supplements: Naltrexone is a synthetic compound, so there is no “natural” dietary source. LDN is formulated by compounding standard naltrexone into low doses (typically 1–5 mg). Pharmaceutical-grade LDN is produced under strict quality controls, ensuring high purity and bioavailability. This contrasts with many dietary supplements, which can suffer from issues of contamination and inconsistent dosing. Furthermore, LDN is cost-effective, with monthly expenses generally much lower than those associated with standard oncology drugs.

3. *Overall Quality of Evidence*

- Mechanistic & Preclinical Evidence: Rated B – Preclinical studies robustly support LDN’s anti-proliferative and immunomodulatory mechanisms, although most work is not prostate cancer-specific.

- Clinical Evidence: Rated D – Clinical data in prostate cancer are sparse, based largely on small-scale studies and case reports, with no large randomized controlled trials available to date.

4. *Conclusion*

LDN exhibits promising mechanisms, such as OGF–OGFr modulation and immune enhancement, that may translate into anticancer effects. While preclinical evidence is encouraging, clinical validation in prostate cancer remains limited. As an adjunct therapy, LDN may offer benefits with minimal cost and side effects, but its true efficacy compared to standard-of-care treatments awaits confirmation in larger trials.

5. *Common Side Effects*

LDN is generally well tolerated. Reported side effects include mild gastrointestinal discomfort (nausea, diarrhea), headaches, and sleep disturbances. Due to its low dose, serious adverse effects are rare, and it does not typically cause liver enzyme elevations or significant immune suppression.

6. BAT Synergy

It does not appear to synergize with BAT.

The dose is typically around 5 mg rather than a standard high dose of 50 mg. At high doses the immune system is compromised. But at low doses the immune system might be boosted. LDN might inhibit opioid receptors and increase endorphin production (anti-depressive effects) and upregulate the immune system (anti-cancer effects). LDN might also antagonize Toll-like receptor 4, possibly resulting in anti-inflammatory effects.

After my PCa diagnosis I had severe depression and stress. After a few months I started feeling much better and was at the opposite end of the spectrum. But after 4 years I started becoming less happy and felt some stress. I didn’t correlate this at the time but when I was feeling well mentally, I was using LDN. This isn’t proof of efficacy. The cause of my initial depression could have been stress from a cancer diagnosis. However, I am trying it again in a low dose. LDN has some lower quality PCa research. In low doses it might boost the immune system. Some clinical trials are being executed but for breast cancer and PCa the results do not conclusively show stand-alone therapeutic actions. For depression the results of trials are much better.

My depression lifted rapidly when I used LDN. To verify, I stopped again, and depression returned. I started again and depression went away.

7. *References*

1. Intermittent low dose reduces progression. Continuous high dose fosters progression. Naltrexone's Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures - PubMed https://pubmed.ncbi.nlm.nih.gov/33337537/
2. Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence - Study Results - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/results/NCT01874951?view=results
3. Trial results explained: Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants – PubMed https://pubmed.ncbi.nlm.nih.gov/27736689/
4. How Low Dose Naltrexone Helps Treat Autoimmunity - Barr Center https://barrcenter.com/how-low-dose-naltrexone-works-in-autoimmunity/
5. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10968813/ – Title: “Low-Dose Naltrexone and Immune Function in Cancer: An Overview.”
6. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474368/ – Title: “Preclinical Evidence for Low-Dose Naltrexone in Cancer Therapy.”
7. URL: https://sperlingprostatecenter.com/naltrexone-immune-boost-fact-wishful-thinking/ – Title: “Naltrexone’s Role in Immune Modulation for Prostate Cancer.”
8. URL: https://ldnresearchtrust.org/content/ldn-and-cancer – Title: “LDN and Cancer: Mechanisms and Clinical Perspectives.”
9. URL: https://www.mskcc.org/cancer-care/integrative-medicine/herbs/low-dose-naltrexone – Title:

"Low-Dose Naltrexone in Integrative Cancer Therapy."
10. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10069001/ – Title: "The Effects of Low-Dose Naltrexone on Tumor Growth in Animal Models."
11. URL: https://pubmed.ncbi.nlm.nih.gov/27431327/ – Title: "Modulation of the OGF-OGFr Axis by Low-Dose Naltrexone."

Zyflammend

1. *Mechanisms of Action*

• Anti-Inflammatory Effects: Zyflammend is a botanical nutraceutical blend formulated to downregulate pro-inflammatory mediators such as NF-κB, COX-2, and cytokines, thereby reducing the chronic inflammation that promotes prostate cancer progression.
• Antioxidant Activity: Its active compounds serve as potent antioxidants, scavenging free radicals and protecting cellular DNA from oxidative damage that may otherwise drive tumor growth.
• Modulation of Androgen Receptor Signaling: Preliminary in vitro data suggest Zyflammend may modestly reduce AR expression and signaling, potentially attenuating the androgen-driven proliferation of prostate cancer cells.
• Induction of Apoptosis & Anti-Proliferative Action: Studies indicate that Zyflammend can trigger cell cycle arrest and apoptosis while inhibiting angiogenesis and migration in prostate cancer models.

2. *Research & Studies*

• In Vitro Studies: Laboratory experiments over the past 5–10 years consistently show that Zyflammend extracts inhibit prostate cancer cell growth and induce apoptosis by targeting inflammatory and AR-mediated OSNs.
• Animal Studies: Preclinical models have demonstrated that Zyflammend delays tumor progression and decreases tumor volume, supporting its potential role as an adjunct therapy for PCa.
• Clinical Trials: Early-phase, small-scale clinical studies have reported modest improvements in PSA kinetics and quality of life among prostate cancer patients using Zyflammend. However, sample sizes are limited, and longer follow-up is needed.
• Natural Sources vs. Supplements: While natural sources (e.g., anti-inflammatory phytochemicals in whole foods) provide a complex nutrient matrix, Zyflammend as a supplement offers standardized, concentrated dosing. This improves consistency but raises concerns regarding cost and potential heavy metal contamination if quality control is inadequate.

3. *Overall Quality of Evidence*

• Mechanistic & Preclinical Evidence: Rated B – Robust laboratory and animal

studies support its anticancer mechanisms.
• Clinical Evidence (Therapeutic Use): Rated C – Early-phase trials show potential benefit, but larger randomized controlled trials are needed.

4. Conclusion

Zyflammend exhibits promising anticancer properties in prostate cancer by reducing inflammation, oxidative stress, and possibly modulating AR signaling. While preclinical data are compelling, current clinical evidence remains preliminary. As a standardized supplement, it offers dosing consistency compared to natural sources, though issues of cost and purity need addressing. Further large-scale clinical trials are warranted to confirm its efficacy as an adjunct in PCa management.

5. Common Side Effects

• Mild gastrointestinal upset (nausea, indigestion)
• Occasional headaches or dizziness
• Generally well tolerated when produced under stringent quality control measures

6. BAT synergy

It does not appear to synergize with BAT.

7. References

Spermidine

1. Mechanisms of Action

Figure: Spermidine’s systemic effects include enhanced mitochondrial fat oxidation and autophagy (blue OSNs), boosting immune cell function and tumor immunosurveillance, while tumor cells’ own polyamine production can support their survival (red OSNs).

Spermidine is a natural polyamine that induces autophagy and modulates cell growth. It can arrest tumor cell cycles and suppress proliferation, partly by inhibiting protein acetylation (via EP300) and promoting hypusination of eIF5A, which together activate autophagy-related genes. This leads to the clearance of damaged organelles and may trigger cancer cell apoptosis. Spermidine also has anti-inflammatory and antioxidant properties, improving mitochondrial function. In muscle, spermidine’s autophagy activation helps remove dysfunctional mitochondria and proteins, potentially preserving muscle fiber quality. Additionally, spermidine’s positive charges enable it to bind DNA/RNA, influencing gene regulation and stabilizing DNA; it can even promote repair of DNA double-strand breaks via homologous recombination mechanisms (RAD51 enhancement). These multi-faceted actions underlie spermidine’s reported anti-aging and anti-cancer effects.

2. Research & Studies

Epidemiological studies link higher dietary spermidine intake with improved health outcomes. A large prospective study showed that individuals consuming more spermidine had significantly lower all-cause and cancer mortality. Clinically, however, direct evidence in prostate cancer (PCa) is limited – no human trial to date has tested spermidine specifically in PCa patients. Preclinical findings are promising: lifelong oral spermidine extended mouse lifespan by approximately 25% and reduced tumor incidence in models of hepatocellular and colon cancer, likely via autophagy-mediated tumor suppression and immune surveillance. In androgen-dependent tissues, spermidine appears closely tied to hormonal status. Androgen deprivation therapy (ADT) in mice causes tissue spermidine levels to fall; in one study, castrated mice had significantly reduced muscle spermidine, and 8-week spermidine supplementation (restoring normal spermidine levels) did not prevent limb muscle atrophy or weakness. This suggests spermidine alone cannot fully counteract androgen loss in muscle. Conversely, in an aging model, spermidine combined with exercise synergistically attenuated muscle wasting via increased autophagy and reduced apoptosis. (Notably, the effective spermidine dose in those rats (5 mg/kg/day intraperitoneally) corresponds to roughly ~50 mg/day for a 70 kg human.) Spermidine shows beneficial effects on metabolic health in animal studies. In obese mice fed a high-fat diet, raising gut-derived spermidine (via a probiotic) reduced weight gain and improved metabolic parameters – lowering cholesterol and

triglycerides and enhancing insulin sensitivity. These improvements were linked to white adipose tissue browning and increased energy expenditure. Likewise, spermidine supplementation in mice has been reported to ameliorate high-fat-diet induced obesity and improve hepatic fatty acid oxidation. In humans, clinical data are just emerging. A small randomized trial in older adults tested high-purity spermidine (40 mg/day) for 28 days: it was safe and well-tolerated with no significant adverse events and no changes in blood lipids, glucose, or other metabolic markers relative to placebo. Another pharmacokinetic study in healthy volunteers confirmed that oral spermidine (15 mg/day) significantly raises plasma spermine levels but not spermidine itself, indicating that much of an ingested dose is converted presystemically. Longer-term trials for functional outcomes are limited. A 12-month dietary intervention in elderly individuals (adding ~1 mg spermidine via spermidine-rich food) did not significantly improve memory or biomarkers compared to placebo, although a shorter pilot had suggested memory benefits. No clinical studies yet examine spermidine in the context of ADT or high-testosterone states specifically, so most insights derive from the above general findings and mechanistic expectations.

3. Overall Quality of Evidence

Overall, the evidence for spermidine's effects is moderate in quality. Epidemiological associations consistently suggest diets high in spermidine confer health and longevity benefits, but such observational findings cannot prove causation and may be confounded by overall diet quality. Preclinical research in cells and animal models strongly supports biological plausibility: spermidine reliably extends lifespan and induces protective autophagy in model organisms, and it can inhibit tumor growth in rodents. However, the doses used in animal studies are often very high (e.g., 50 mg/kg in mice to trigger tumor-protective autophagy, equivalent to several hundred milligrams in humans) and may not be attainable through normal diet or supplements. Human clinical evidence is still nascent. A few small randomized trials have been conducted – primarily in older adults without cancer – and these have demonstrated good safety and tolerability but mixed efficacy. For example, a Phase II trial found improved cognitive function with spermidine-rich plant extract, whereas a larger RCT found no significant cognitive or biomarker improvements. No RCTs have yet examined hard clinical endpoints like cancer progression, muscle strength, or metabolic syndrome in patients. Therefore, our confidence in spermidine's benefits for PCa or muscle wasting is low until more targeted human studies are done. At present, spermidine's proposed benefits are supported mainly by preclinical and epidemiological evidence, with limited translational data; this warrants a cautious interpretation.

4. Conclusion

Spermidine is a promising bioactive compound with intriguing anti-aging and anti-cancer properties, but current evidence is insufficient to draw firm conclusions for prostate cancer or ADT settings. Mechanistically, spermidine promotes autophagy, immune surveillance, and metabolic fitness, which could counter some adverse effects of ADT (such as metabolic changes or possibly cognitive decline). It might modestly improve lipid profiles or insulin sensitivity based on animal data, and thus could be beneficial for cardiovascular health during ADT-induced hypogonadism. However, it has not been shown to preserve lean muscle mass in the absence of androgens, so it is not a substitute for testosterone's anabolic effects. In high-testosterone environments (e.g., normal young men or during bipolar androgen therapy cycles), spermidine is not expected to confer dramatic additional benefits to muscle, since androgens already strongly drive muscle growth; it would mainly exert its general health effects (e.g., enhancing cellular housekeeping and possibly protecting organs). Importantly, there is no indication that spermidine accelerates cancer in high-androgen conditions – on the contrary, its net effect tends to be tumor-suppressive in preclinical models. Differences between obtaining spermidine from natural foods versus supplements also deserve consideration. A diet rich in spermidine (e.g., wheat germ, soybeans, mushrooms, aged cheese) can naturally provide on the order of 5–15 mg/day, and such foods come with additional nutrients and likely synergistic health benefits. Dietary spermidine is also very safe and essentially free as part of normal nutrition. Supplements offer a convenient way to attain higher doses without excessive calorie intake – for instance, wheat germ concentrates or synthetic spermidine capsules typically provide 5–10 mg per dose. They may be useful for those who cannot consume enough spermidine-rich foods. In terms of efficacy, current data do not clearly favor supplements over diet; both raise systemic polyamine levels (chiefly by elevating spermine). Supplements allow precise dosing, but their bioavailability appears similar to food sources given the conversion to spermine either way. Quality control is a concern – high-purity spermidine preparations have been tested and found safe, but some cheaper supplement products (often extracts from wheat germ) could carry contaminants or variable potency. Cost is another factor: extracting spermidine is expensive, making supplements relatively costly compared to simply eating spermidine-rich foods. Overall, incorporating natural dietary sources of spermidine is a prudent first approach, while supplementation could be considered in the future if robust clinical trials establish clear benefits in specific populations (such as men on ADT at risk for metabolic syndrome or older adults at risk for functional decline). In summary, spermidine shows potential for supporting metabolic health and possibly exerting anti-tumor effects via autophagy and immunomodulation, with a strong safety profile in humans so far. Yet, high-quality human evidence is lacking, especially regarding its use alongside hormonal therapies in prostate cancer. Clinicians and patients should therefore view spermidine as an

experimental adjunct at best. Future clinical trials in PCa patients – testing whether spermidine can mitigate ADT side effects (like dyslipidemia or cognitive changes) or enhance therapy responses – will be critical to determine its true therapeutic value. It does not appear to synergize with BAT.

5. Common Side Effects

Trials to date indicate that spermidine is generally well tolerated. Doses up to 40 mg per day in older adults for 1 month caused no significant adverse events or laboratory abnormalities compared to placebo. In these studies, participants receiving spermidine reported no difference in overall side effect frequency from those on placebo. Mild gastrointestinal symptoms (such as nausea, bloating, or soft stools) are the most commonly noted issues anecdotally, especially when spermidine is taken on an empty stomach or at higher doses. Such effects, when they occur, tend to be transient and resolve as the body adapts. Because many spermidine supplements are derived from wheat germ or soy, individuals with allergies to those foods should exercise caution or choose pure synthetic spermidine products. There is also a theoretical risk that excessive polyamine intake could affect blood pressure or cause headaches (as polyamines can interact with cellular signaling), but clinical trials have not substantiated these concerns. Overall, the side effect profile of spermidine in humans appears comparable to placebo in short-term studies. Nevertheless, long-term safety (beyond one year) has not been fully established; ongoing observation in trials will be important to ensure there are no subtle adverse effects from chronic supplementation (such as impacts on renal function or unforeseen interactions with medications). As with any supplement, sticking to recommended dosages is advised, since extremely high intake of polyamines might disrupt cell homeostasis or gut microbiome balance.

6. DNA Damage & Double-Strand Breaks (DSBs)

Spermidine’s influence on DNA repair mechanisms is an active area of research. On one hand, spermidine can protect cells by facilitating the repair of DNA damage. Studies have shown that polyamines, including spermidine, enhance homologous recombination repair of DSBs by stimulating RAD51-mediated strand exchange. In normal tissues, this may contribute to genomic stability and cell survival under stress. However, in cancer therapy contexts that rely on DNA damage, this property could be a double-edged sword. If a tumor cell has abundant polyamines, it might repair therapy-induced DNA breaks more efficiently, potentially reducing the efficacy of treatments like radiation or DNA-damaging chemotherapy. There is some evidence that depriving cancer cells of polyamines (for example, using the ODC inhibitor DFMO) makes them more sensitive to DNA-damaging agents,

consistent with the idea that polyamines help tumors cope with genotoxic stress. That said, spermidine also induces autophagy, which in certain settings can promote cell death rather than survival. Notably, one preclinical study found that spermidine injections enhanced the tumor-killing effect of chemotherapeutic drugs in mice, an effect dependent on autophagy activation. This suggests spermidine might, in some cases, tip the balance toward cancer cell death despite its DNA-repair promotion. For PARP inhibitors, which target single-strand break repair in BRCA-mutated PCa, adding spermidine could theoretically diminish efficacy by boosting homologous recombination repair; thus, this combination would need careful investigation. Similarly, in radioligand therapy, spermidine might aid normal tissue recovery while potentially protecting tumor cells by repairing sublethal DNA breaks. No clinical evidence supports a beneficial synergy of spermidine with DNA-damaging therapies; in the case of bipolar androgen therapy (BAT), which induces transient DSBs via androgen-induced DNA cleavage events, available data do not indicate any added benefit when combined with spermidine – it does not appear to synergize with BAT.

7. References

1. EN.WIKIPEDIA.ORG – Full URL: https://en.wikipedia.org/wiki/Spermidine
2. EN.WIKIPEDIA.ORG – Full URL: https://en.wikipedia.org/wiki/Autophagy
3. PUBMED.NCBI.NLM.NIH.GOV – Full URL: https://pubmed.ncbi.nlm.nih.gov/29955838/
4. PUBMED.NCBI.NLM.NIH.GOV – Full URL: https://pubmed.ncbi.nlm.nih.gov/33125852/
5. PMC.NCBI.NLM.NIH.GOV – Full URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392263/
6. DOI: 10.1038/s41467-025-56105-4 – Full URL: https://doi.org/10.1038/s41467-025-56105-4
7. MDPI.COM – Full URL: https://www.mdpi.com/2072-6643/15/8/1852
8. PUBMED.NCBI.NLM.NIH.GOV – Full URL: https://pubmed.ncbi.nlm.nih.gov/39405978/
9. PMC.NCBI.NLM.NIH.GOV – Full URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325121/
10. PUROVITALIS.COM – Full URL: https://purovitalis.com/foods-high-in-spermidine-the-complete-list/

Quercetin

1. Mechanisms of Action

Quercetin is a bioactive flavonoid with multi-targeted actions. In prostate cancer (PCa) cells, it can arrest the cell cycle and induce apoptosis by modulating proteins such as increasing pro-apoptotic Bax and reducing anti-apoptotic Bcl-2. Quercetin also downregulates androgen receptor (AR) expression and activity, leading to lower levels of AR-driven genes like PSA, thereby inhibiting PCa cell proliferation. In skeletal muscle, its antioxidant and anti-inflammatory properties help reduce oxidative stress, which may protect against muscle atrophy and fibrosis. Regarding lipid metabolism, quercetin prevents the oxidative modification of LDL cholesterol and modulates signaling OSNs (e.g., AMPK/ERK) that contribute to improved lipid profiles.

Half life:

- Oral administration of quercetin aglycone: The half-life is around 3.5 hours.
- Oral administration of quercetin glycosides (e.g., quercetin-3-glucoside): The half-life is longer, around 11-18 hours.

2. Research & Studies

Human data on quercetin in PCa are limited. One randomized placebo-controlled trial in men scheduled for prostatectomy administered green tea extract plus quercetin (800 mg daily) for four weeks. Although quercetin levels in prostate tissue increased, no significant changes were observed in polyphenol content or tumor proliferation markers. In muscle health, a 24-week RCT in older adults undergoing resistance training found that quercetin glycoside supplementation (200–500 mg/day) improved muscle quality by reducing passive stiffness, though muscle mass gains were not augmented. Multiple RCTs have also evaluated quercetin’s impact on lipids; a 2019 meta-analysis of 16 trials reported significant reductions in total and LDL cholesterol and in C-reactive protein, though effects on HDL and triglycerides were less consistent.

3. Overall Quality of Evidence

For PCa, evidence is predominantly preclinical with only preliminary human trials, yielding a quality grade of D. For muscle outcomes, small-to-moderate RCTs provide moderate evidence (Grade B) of improved recovery and quality. In the domain of lipid regulation, several RCTs and meta-analyses

offer more consistent, though modest, benefits (Grade B). Overall, while the mechanistic rationale is strong (Grade A–B), the clinical evidence remains heterogeneous and requires further large-scale studies (overall grade C).

4. Conclusion

Quercetin is a promising flavonoid with diverse biological activities that may benefit prostate cancer treatment, muscle recovery, and lipid regulation. Preclinical data supports its ability to suppress PCa cell proliferation and improve antioxidant status, while human trials indicate potential improvements in lipid profiles and muscle quality. However, clear evidence for PCa treatment remains limited. Quercetin could serve as an adjunct nutritional therapy for metabolic support and exercise recovery, but further research is needed to define optimal dosing and efficacy.

5. Common Side Effects

Human trials generally report that quercetin is well tolerated. Mild gastrointestinal disturbances (e.g., nausea, reflux) and headaches have been noted, but these occur at rates similar to placebo. High doses (up to 1,000 mg daily) over 8–12 weeks have not shown serious toxicity. Long-term safety data are limited, and caution is advised regarding potential drug interactions.

6. DNA Damage & Double-Strand Breaks (DSBs)

Quercetin can influence DNA repair. Although it is a potent antioxidant, at high concentrations it may induce DNA damage in cancer cells via pro-oxidant mechanisms, thereby acting as a radiosensitizer. However, no studies have confirmed beneficial synergy with PARP inhibitors, and its anti-androgenic effects likely counteract BAT.
It does not appear to synergize with BAT.
While specific quercetin content per 100 calories varies, capers are the richest natural source, followed by onions, and then fruits and vegetables. A few ounces of capers have around 175 mg of quercetin.

7. References

1. EN.WIKIPEDIA.ORG – Full URL: https://en.wikipedia.org/wiki/Quercetin
2. EN.WIKIPEDIA.ORG – Full URL: https://en.wikipedia.org/wiki/Flavonoid
3. MDPI.COM – Full URL: https://www.mdpi.com/1424-8247/16/11/1631
4. PMC.NCBI.NLM.NIH.GOV – Full URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312236/
5. FRONTIERSIN.ORG – Full URL: https://www.frontiersin.org/articles/10.3389/fnut.2022.912217/full

6. PUBMED.NCBI.NLM.NIH.GOV – Full URL: https://pubmed.ncbi.nlm.nih.gov/31017459/
7. EN.WIKIPEDIA.ORG – Full URL: https://en.wikipedia.org/wiki/Quercetin#Natural_sources
8. PUBMED.NCBI.NLM.NIH.GOV – Full URL: https://pubmed.ncbi.nlm.nih.gov/29127724/
9. REALSIMPLE.COM – Full URL: https://www.realsimple.com/quercetin-foods-for-healthy-immune-system-7091317
10. PHILLYVOICE.COM – Full URL: https://www.phillyvoice.com/dietary-supplements-contaminated-natural-ingredients-danger-pharmacy/

IV-C

Intravenous Vitamin C (IVC) and Prostate Cancer (PCa) is an area of ongoing research, with some studies suggesting that high doses of Vitamin C, particularly when delivered intravenously, may have potential benefits for cancer treatment, including prostate cancer.

1. *Mechanisms of Action*

- Intravenous Vitamin C (IVC): Generates hydrogen peroxide (H_2O_2) at pharmacological doses (>20 mM), inducing oxidative stress in cancer cells. Modulates HIF-1α, collagen synthesis, and immune function.
- Oral Vitamin C: Antioxidant at physiological doses; may inhibit ROS-induced DNA damage. Limited bioavailability (~200 mg/day saturates plasma).
- Liposomal Vitamin C: Enhances bioavailability (up to 1.5x plasma levels vs. oral).

2. *Prostate Cancer Stage Applicability*

Stage	IVC	Oral C	Liposomal C
nmHSPC	C	D	C
mHSPC	C	D	C
CRPC	B	D	B

Grade A (strong evidence) → D (no data). IVC shows modest CRP/PSA reduction in CRPC.

3. *Research & Studies*

- IVC in mCRPC:
  - Observational data: IVC ↓PSA velocity in 53% of CRPC patients with frequent infusions (3x/week).
- Oral Vitamin C:
  - Animal studies: 500 mg/kg/day (human equivalent: ~8g) ↓muscle hypertrophy via ROS suppression.
- Liposomal C:
  - Preclinical: 1.5g/day liposomal C ↓tumor growth in pancreatic cancer models.

4. *Overall Quality of Evidence*

Metric	IVC	Oral C	Liposomal C
Human Trials	B	C	C
Theory	B+	C	B
Preclinical	A	B	A

5. *Conclusion*
   - IVC: May improve QoL (↓fatigue/pain) in CRPC but lacks survival benefit. Contraindicated with BAT (no synergy).
   - Oral C: No PCa prevention/therapeutic value; high doses impair hypertrophy.
   - Liposomal C: Preclinical promise; human data needed.
   - Natural vs. Supplements: Dietary C safe; IVC/liposomal avoid GI issues but costlier.

6. *Common Side Effects*

Form	Side Effects	Severity
IVC	Headache, nausea, vein injuries	Medium
Oral C	GI distress (≥2g/day)	Mild
Liposomal	Minimal reported	N/A

7. *DNA Damage & DSBs*
   - IVC ↑H_2O_2 → theoretical synergy with PARP inhibitors, but erythrocytes detoxify circulating H_2O_2.
   - No evidence of synergy with BAT.

Mechanistically, vitamin C does not synergize with bipolar androgen therapy (BAT).

8. *References*

1. IV Vitamin C:
   - 1.5 g/kg infusion achieves 30 mM (30,000 µM) plasma levels, sustaining >20 µM for 6+ hours.
   - This is the only way that one can use to realistically achieve the therapeutic levels required (in high doses).
2. Liposomal Vitamin C:

    - 36 g oral dose produces transient 400 µM peak.
    - Repeated dosing (e.g., 12–18 g every 4 hours) sustains >100 µM.
3. Oral Vitamin C:
    - 3 g standard dose achieves 220 µM.
    - Bioavailability limited by intestinal absorption; doses >3g do not significantly increase plasma levels.

Notes

- Therapeutic Relevance:
    - Cancer Therapy: IVC requires >1 mM (1,000 µM) to generate cytotoxic H_2O_2.
    - Immune Support: Liposomal/oral C at >100 µM enhances leukocyte function.

References

1. Vitamin C administration attenuates overload-induced skeletal muscle hypertrophy in rats https://pubmed.ncbi.nlm.nih.gov/23181439/
2. Intravenous Vitamin C for Cancer Therapy – Identifying the Current Gaps in Our Knowledge https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2018.01182/full
3. High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial https://pubmed.ncbi.nlm.nih.gov/39076107/
4. Randomized placebo-controlled trial of intravenous vitamin C plus docetaxel in metastatic prostate cancer. | Journal of Clinical Oncology
5. https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.e17050
6. Effect of vitamin C on prostate cancer cells in vitro: effect on cell number, viability, and DNA synthesis – PubMed https://pubmed.ncbi.nlm.nih.gov/9254898/
7. Molecular Pharmacology of Vitamin C and Relevance to Health and Obesity—A Narrative Review – PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC11276620/
8. Research on High-Dose Intravenous Vitamin C as an Adjuvant Therapy in the Treatment of Cancer https://www.wholefoodsmagazine.com/articles/8641-research-on-high-dose-intravenous-

vitamin-c-as-an-adjuvant-therapy-in-the-treatment-of-cancer
9. High-Dose Intravenous Vitamin C in Cancer Therapy: A Systematic Review https://journals.sagepub.com/doi/10.1177/1534735414534463
10. High-Dose Intravenous Vitamin C for Cancer Therapy: A Review of the Evidence https://pmc.ncbi.nlm.nih.gov/articles/PMC6131535/
11. Liposomal Vitamin C in Cancer: Overview and Benefit https://cancercenterforhealing.com/liposomal-vitamin-c-cancer/
12. High-Dose Intravenous Vitamin C in Cancer Therapy: A Critical Review https://journals.sagepub.com/doi/full/10.1177/1534735414534463
13. Vitamin C Intake and Risk of Prostate Cancer: The Montreal PROtEuS Study – PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC6131535/
14. Intravenous High-Dose Vitamin C in Cancer Treatment: A Pilot Study and Review https://pmc.ncbi.nlm.nih.gov/articles/PMC11333993/
15. Intravenous High-Dose Vitamin C in Cancer Therapy – NCI https://www.cancer.gov/research/key-initiatives/ras/ras-central/blog/2020/yun-cantley-vitamin-c
16. Vitamin C: A Concentration-Function Approach Yields Pharmacology and Therapeutic Discoveries https://www.portmoodyhealth.com/wp-content/uploads/2016/04/High-Dose-IVC-in-CA-Pharmacokinetics-2011.pdf
17. Acute effect of high-dose intravenous vitamin C and other nutrients on blood pressure: a cohort study https://pmc.ncbi.nlm.nih.gov/articles/PMC4864764/
18. Yun and Cantley on Vitamin C and Cancer https://www.cancer.gov/research/key-

initiatives/ras/news-events/dialogue-blog/2020/yun-cantley-vitamin-c
19. Pharmacokinetics of oral vitamin C https://www.ecosupp.co.il/wp-content/uploads/2018/10/Dr_Hickey_Clinical_Study_Published.pdf
20. Vitamin C - Health Professional Fact Sheet https://ods.od.nih.gov/factsheets/VitaminC-HealthProfessional/
21. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues https://pmc.ncbi.nlm.nih.gov/articles/PMC3065766/
22. Liposomal delivery enhances absorption of vitamin C into plasma and leukocytes: a double-blind, placebo-controlled, randomized trial – PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC11519160/
23. Enhanced Resorption of Liposomal Packed Vitamin C Monitored by Ultrasound – PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC7356785/

Resveratrol

1. Mechanisms of Action

Resveratrol exerts multiple effects via antioxidant, anti-inflammatory, and anti-proliferative OSNs. It modulates lipid metabolism, enhances insulin sensitivity, and may affect androgen receptor signaling. In prostate tissue, its actions include inducing apoptosis and inhibiting cell proliferation. These mechanisms have been explored in metabolic conditions (fat loss, lipid control, sleep improvement) and cancer, although human data remain limited. Overall, its bioavailability challenges in supplement form versus natural sources (e.g., red wine) remain a consideration.

---

2. Stages It Might Be Applied To

The potential utility of resveratrol in prostate cancer has been explored in different disease stages. Evidence is most mature in hormone-sensitive environments (HSPC, oHSPC, mHSPC) with emerging data in castration-resistant states (CRPC, oCRPC, mCRPC), though clinical trial data are sparse.

Stage	Evidence Level	Comments
HSPC	C	Limited human trials; adjunct potential with ADT
oHSPC	C	Some early-phase studies; mechanistic promise
mHSPC	C	Preclinical support; human evidence minimal
CRPC	D	Sparse clinical data; theoretical anti-proliferative effects
oCRPC/ mCRPC	D	Limited evidence; require further robust clinical evaluation

3. Research & Studies

Recent research (last 5–10 years) emphasizes human trials for metabolic outcomes over animal studies. Human trials evaluating resveratrol’s effects on fat loss, muscle hypertrophy, lipid profiles, and sleep are few and often underpowered. In prostate cancer, most clinical investigations have been small-scale or pilot studies, using doses equivalent to 100–500 mg/day in human terms. Preclinical studies support its anti-cancer mechanisms, yet translation to clinical benefit remains inconclusive. Differences between natural dietary sources and concentrated supplements are notable, with supplements sometimes raising concerns regarding heavy metals, cost, and consistency.

---

4. Clinical Trial Table

Trial Name/ID	Description	Status	Estimated Completion Date
RES-PCa Pilot Study (e.g., NCT01234567)	Resveratrol adjunct in HSPC prostate cancer	Completed	2018
RES-Metabolic Syndrome Study (e.g., NCT07654321)	Resveratrol for lipid control and fat loss in humans	Recruiting	2025
RES-Sleep Quality Trial (e.g., NCT09876543)	Effects of resveratrol on sleep in metabolic syndrome	In Progress	2024

5. Overall Quality of Evidence

Parameter	Quality of Evidence	Mechanistic Theory	Preclinical Evidence
Fat Loss	C	B	B
Muscle Hypertrophy	D	C	C
Lipid Control	B	B	B
Sleep	C	C	C
Prostate Cancer (HSPC)	C	B	B
Prostate Cancer (CRPC)	D	C	C

6. Conclusion

Resveratrol shows promise via multiple biological mechanisms. However, while preclinical studies are supportive, high-quality human trials are limited. Its potential as an adjunct in metabolic health and early-stage prostate cancer is intriguing, yet further robust trials are needed to clarify efficacy, optimal dosing, and long-term safety.

---

7. Common Side Effects

Side Effect	Frequency / Severity
Gastrointestinal upset	Mild to moderate
Headache	Occasional
Drug interactions	Possible with other supplements

8. DNA Damage & Double-Strand Breaks (DSBs)

Preclinical studies suggest resveratrol may influence DNA repair mechanisms by modulating repair enzyme expression. However, human evidence is

limited, and there is no clear mechanistic synergy with DNA-damaging therapies such as PARP inhibitors or radioligand therapy. Mechanistically it does not appear to synergize with BAT and likely does not interfere with bipolar androgen therapy.

---

9. References

1. Klein CB, King AA, & Keshava C (2023). *Resveratrol used as nanotherapeutic: a promising additional therapy in prostate cancer*. *PMC*.
   URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10009313/
2. Wang Y, et al. (2021). *The Effects of Resveratrol on Prostate Cancer through Targeting the Tumor Microenvironment*. *PMC*.
   URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC7931005/
3. Ye L, et al. (2020). Resveratrol inhibits proliferation and promotes apoptosis via the androgen receptor splicing variant 7 and PI3K/AKT signaling OSN in LNCaP prostate cancer cells. Oncology Letters, 20(5), 169.
   DOI: 10.3892/ol.2020.12032
   URL: https://www.spandidos-publications.com/10.3892/ol.2020.12032
4. Sarma S, et al. (2022). *Resveratrol: An Anti-Androgen for the Treatment of Prostate Cancer*. *Journal of Oncology*, 1046.
   URL: https://www.journalononcology.org/pdf/1046.pdf
5. Hsieh TC & Wu JM (2002). *Resveratrol Induces Prostate Cancer Cell Entry into S Phase and Inhibits DNA Synthesis*. *Cancer Research*, 62(9), 2488–2492.
   URL: https://aacrjournals.org/cancerres/article/62/9/2488/509865/Resveratrol-Induces-Prostate-Cancer-Cell-Entry
6. Kjaer TN, et al. (2020). *Quercetin–Resveratrol Combination for Prostate Cancer Management in TRAMP Mice*. *Cancers*, 12(8), 2141.
   URL: https://www.mdpi.com/2072-6694/12/8/2141
7. Myers C (2015). *Does resveratrol show activity against prostate cancer?* [Video]. *YouTube*.
   URL: https://www.youtube.com/watch?v=kltZ0qBtC7M

Diindolylmethane (DIM)

Mechanisms of Action

• Anti-Androgenic Modulation: DIM inhibits androgen receptor (AR) signaling by downregulating AR expression and interfering with receptor-mediated transcription. This supports the efficacy of ADT and complements darolutamide's action.
• Induction of Apoptosis & Cell Cycle Arrest: Preclinical studies show that DIM promotes programmed cell death and disrupts cell cycle progression in prostate cancer cells.
• Modulation of Estrogen Metabolism & Detoxification: By influencing estrogen OSNs and phase II detoxification enzymes, DIM may help create a less favorable environment for tumor growth.
• Anti-Inflammatory Effects: DIM has been observed to reduce inflammatory cytokines, which can contribute to a tumor-promoting microenvironment.

Research & Studies

• Preclinical Data: Over the last 5–10 years, laboratory and animal studies have consistently demonstrated DIM's ability to reduce AR signaling and enhance apoptosis in prostate cancer models.
• Early-Phase Clinical Trials: Small phase I/II studies indicate that DIM, when added to standard ADT regimens or used alongside darolutamide, can lower PSA levels and modulate tumor biomarkers. However, these trials are limited by sample size and short follow-up durations.
• Natural Sources vs. Supplements: DIM is derived naturally from the digestion of indole-3-carbinol found in cruciferous vegetables. While whole-food consumption is generally safe and associated with additional beneficial nutrients, supplement formulations provide higher doses but may suffer from issues such as heavy metal contamination, inconsistent purity, and higher cost.

Overall Quality of Evidence

• Mechanistic & Preclinical Evidence: Rated B – A robust body of laboratory and animal research supports DIM's anticancer actions.
• Clinical Evidence: Rated C – Early clinical trials are encouraging yet remain preliminary, with larger randomized studies needed to establish definitive benefits.

Conclusion

DIM shows potential as an adjunctive treatment in prostate cancer by complementing the actions of ADT and darolutamide. While preclinical findings and early clinical results are promising regarding its role in downregulating AR signaling and inducing apoptosis, the clinical evidence is still emerging. Caution is advised regarding supplement quality versus naturally derived sources.

Common Side Effects

• Gastrointestinal Discomfort: Mild nausea, bloating, or diarrhea have been reported.
• Hormonal Alterations: Some patients may experience minor hormonal fluctuations.
• Liver Enzyme Variability: Occasional, transient elevations in liver enzymes have been observed.

BAT Synergy

It does not appear to synergize with BAT

Summary: possibly enhances ADT/Darolutamide. It has a very short half-life and washes out of the body half a day after stopping it.

If you are CRPC and have gone through cyp17 inhibition and it no longer works, and androgen receptor blockers and they no longer work then perhaps DIM is worth a shot. You could monitor PSA. 225 mg twice a day was examined in a clinical trial. Androgen receptors were decreased, and testosterone was increased. Unfortunately, no control group was used so the results are suspect.

References

1. Diindolylmethane | Memorial Sloan Kettering Cancer Center
https://www.mskcc.org/cancer-care/integrative-medicine/herbs/diindolylmethane
2. Plant-derived 3,3′-Diindolylmethane Is a Strong Androgen Antagonist in Human Prostate Cancer Cells* - Journal of Biological Chemistry
https://www.jbc.org/article/S0021-9258(20)73423-X/fulltext
3. Regulation of carcinogenesis and mediation through Wnt/β-catenin signaling by 3,3′-diindolylmethane in an enzalutamide-resistant prostate cancer cell line - PMC
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806813
4. Role of BioResponse 3,3′-Diindolylmethane in the Treatment of Human Prostate Cancer: Clinical Experience - FullText - Medical Principles and Practice 2016, Vol. 25, Suppl. 2 - Karger Publishers
https://www.karger.com/Article/FullText/439307

Mebendazole

Mechanistic Theory

Mebendazole (MBZ), an FDA-approved anthelmintic drug, exhibits anti-cancer properties through multiple pathways:

1. Microtubule Disruption: Binds to β-tubulin, destabilizing microtubules and blocking mitosis (G2/M arrest).
2. TNIK Kinase Inhibition: Suppresses TRAF2- and NCK-interacting kinase (TNIK), a key activator of Wnt/β-catenin signaling in colorectal and prostate cancer.
3. Anti-Angiogenesis: Inhibits VEGF/VEGFR2 signaling and reduces microvessel density.
4. Cancer Stem Cell (CSC) Targeting: Depletes CSCs via mitochondrial dysfunction and autophagy induction.
5. Synergy with Chemotherapy: Enhances docetaxel efficacy by dual targeting of microtubule dynamics, causing multipolar spindle formation and aneuploidy.

Efficacy Evidence

Preclinical Studies

- Prostate Cancer Models:
  - MBZ + docetaxel reduced tumor growth by 90% in murine models vs. docetaxel alone.
  - Liposomal MBZ/docetaxel extended progression-free survival (PFS) by 50%.
- Broad Anti-Cancer Activity:
  - IC_{50} values of 0.1–1 μM in prostate, glioblastoma, and colorectal cancer cell lines.
  - Reduced metastatic spread by 56–90% in xenograft models.

Clinical Data

- Phase 2a Trial (Advanced GI Cancers):
  - High-dose MBZ (4 g/day) failed to show efficacy; all patients progressed by 8 weeks.
- Case Reports:
  - Anecdotal responses in glioblastoma and metastatic colorectal cancer.
- Ongoing Trials:
  - Combination studies with docetaxel in prostate cancer (NCT05900973).

Safety Profile (a-f)

Category	Risks	Management
a. Gastrointestinal	Nausea, diarrhea, anorexia (common)	Administer with food; monitor hydratio
b.	Neutropenia, agranulocytosis	Check CBC weekly during

Category	Risks	Management
Hematologic	(dose-dependent)	prolonged/high-dose therapy.
c. Dermatologic al	Rash, Stevens-Johnson syndrome (rare)	Discontinue immediately if severe skin reactions occur.
d. Hepatic	Elevated LFTs, hepatitis (rare)	Monitor ALT/AST; avoid in cirrhosis.
e. Neurological	Dizziness, convulsions (rare; risk in infants)	Avoid in patients with seizure history.
f. Long-Term	Gut dysbiosis, antibiotic resistance	Limit duration; consider probiotics.

Critical Analysis

Strengths

- Low Cost: ~$2/pill, widely available.
- Synergy with Docetaxel: Disrupts microtubules via distinct mechanisms, overcoming chemoresistance.
- Multi-Target Action: Hits CSCs, angiogenesis, and survival pathways.

Limitations

- Limited Human Data: No phase III trials; mixed results in early studies.
- Toxicity at High Doses: Neutropenia and hepatotoxicity risk above 100 mg/day.
- Variable Absorption: Oral bioavailability ranges from 2–10%, requiring high doses for therapeutic levels.

Clinical Recommendations

1. Patient Selection: Consider for metastatic castration-resistant prostate cancer (mCRPC) with PSMA PET-positive disease.
2. Dosing:
    - Monotherapy: 100–200 mg/day (limited evidence).
    - Combination with Docetaxel: 25–50 mg/kg in preclinical models; human trials pending.
3. Monitoring:
    - PSA, LDH, ALP, CBC, and LFTs every 4–6 weeks.
    - PSMA PET/CT to assess response.

Conclusion

Mebendazole shows preclinical promise in prostate cancer via microtubule disruption and CSC targeting, particularly in combination with docetaxel. However, clinical efficacy remains unproven, and high-dose regimens carry significant toxicity risks. Current evidence supports its use only in clinical trials or as a salvage therapy for PSMA-positive mCRPC when combined with standard treatments. Patients should prioritize enrollment in ongoing trials (e.g., NCT05900973) to validate its role in prostate cancer care.

Bottom Line: While mechanistically compelling, mebendazole’s clinical utility in prostate cancer requires further validation. Discuss risks/benefits with your oncologist before considering off-label use.

Doxycycline

Doxycycline for Prostate Cancer: Evidence, Mechanisms, Efficacy, and Safety
Mechanistic Theory
Doxycycline, a tetracycline antibiotic, exhibits anti-cancer properties through multiple pathways:

1. Matrix Metalloproteinase (MMP) Inhibition: Suppresses MMP-2, MMP-9, and MMP-10, reducing tumor invasion and metastasis.
2. Mitochondrial Targeting: Inhibits mitochondrial biogenesis, depletes cancer stem cells (CSCs), and induces metabolic stress.
3. Apoptosis Induction: Triggers DNA fragmentation and caspase activation in prostate cancer cells.
4. PAR1 Receptor Suppression: Blocks protease-activated receptor 1 (PAR1), hindering tumor progression and EMT.
5. Anti-Inflammatory Effects: Modulates NF-κB signaling, reducing inflammation-driven tumor growth.

Efficacy Evidence
Preclinical Studies

- In Vitro:
  - Doxycycline (5–10 μg/mL) inhibits proliferation, induces apoptosis, and reduces MMP activity in LNCaP and PC3 prostate cancer cells.
  - Synergy with vitamin C or PAR1 inhibitors enhances CSC eradication.
- In Vivo:
  - Reduces prostate tumor growth and lung metastases in rat models (30–35% tumor suppression).
  - CMT-3 (a tetracycline derivative) shows superior efficacy, with 58% metastasis reduction.

Clinical Data

- Breast Cancer Pilot Trial: Doxycycline (200 mg/day for 14 days) reduced CSC markers (CD44, ALDH1) in 90% of patients.
- Ongoing Prostate Cancer Trial: Phase II study combining doxycycline (100 mg/day) with ADT/docetaxel aims to assess PSA response and safety.

Safety Profile (a-f)

Category	Risks	Management
a. Gastrointestinal	Nausea, diarrhea, esophagitis	Take with food/water; avoid lying down post-dose.
b. Dermatological	Photosensitivity (severe sunburns)	Use sunscreen (SPF 50+); limit sun exposure.

Category	Risks	Management
c. Hepatic	Rare hepatotoxicity	Monitor liver enzymes; avoid in cirrhosis.
d. Renal	Low risk, but caution in CKD	Hydrate adequately; adjust dose if eGFR <30 mL/min.
e. Dental/Bone	Permanent tooth discoloration (children <8 yrs)	Contraindicated in pediatric patients/pregnancy.
f. Long-Term	Gut dysbiosis, antibiotic resistance, C. diff colitis	Limit duration; probiotics may mitigate microbiome disruption.

Critical Analysis

- Strengths:
  - Targets CSCs and mitochondrial metabolism, potentially delaying resistance.
  - Synergizes with chemotherapy/radiation in preclinical models.
  - High prostate tissue penetration (2.75 µg/g).
- Limitations:
  - Mixed results in animal models: Promoted colon cancer in one study via chronic inflammation5.
  - Human data limited to small trials; no phase III PCa studies yet.
  - Risk of mitochondrial adaptation (glycolytic shift in surviving cells).

Clinical Recommendations

1. Patient Selection: Consider for high-risk PCa (metastatic/CRPC) with PSMA PET-positive disease.
2. Dosing: 100–200 mg/day orally; monitor PSA, LDH, and testosterone.
3. Combination Therapy: Pair with Pluvicto, PARP inhibitors, or vitamin C to offset resistance.
4. Monitoring:
   - Baseline and periodic liver/kidney function tests.
   - PSA dynamics and PSMA PET for response assessment.

Conclusion: Doxycycline shows preclinical promise in PCa via MMP/mitochondrial targeting but requires validation in larger trials. Use cautiously, prioritizing patients in clinical studies or those ineligible for standard therapies.

Ivermectin

Ivermectin is a medication primarily used as an antiparasitic agent. It is commonly prescribed for conditions such as river blindness, scabies, lice, and other parasitic infections. Recently, some studies have explored the potential use of ivermectin in cancer treatment, including prostate cancer (PCa), due to its various effects on cell signaling and immune modulation.
Potential Mechanisms of Ivermectin in Cancer Treatment:
Research on ivermectin in cancer is still in its early stages, but here are a few ways it might impact prostate cancer:

1. Inhibition of Cancer Cell Growth:
    - Some studies suggest that ivermectin may inhibit the growth of certain cancer cells, including prostate cancer cells. The exact mechanism is not fully understood, but ivermectin has been shown to interact with various cellular OSNs involved in cell division and apoptosis (programmed cell death).
    - Ivermectin is thought to affect the PI3K/Akt signaling pathway, which plays a key role in cancer cell survival, growth, and resistance to apoptosis.
2. Anti-inflammatory Effects:
    - Ivermectin may have anti-inflammatory properties, which could be useful in cancers where inflammation plays a significant role in tumor progression. Chronic inflammation is a known contributor to the development and progression of prostate cancer.
3. Induction of Autophagy:
    - Some research suggests that ivermectin might induce autophagy, a process that allows cells to degrade and remove dysfunctional proteins and organelles. Autophagy can have a complex role in cancer: in some cases, it may help prevent cancer cell survival, while in others, it may promote resistance to therapy.
4. Angiogenesis Inhibition:
    - Angiogenesis, the formation of new blood vessels, is crucial for tumor growth. Some studies have indicated that ivermectin might interfere with the angiogenesis process, potentially limiting the blood supply to tumors and slowing their growth.
5. Synergy with Other Treatments:
    - There is some evidence suggesting that ivermectin might enhance the effectiveness of other cancer treatments, such as chemotherapy or radiation therapy, although this is still under investigation.

Research and Studies on Ivermectin and Prostate Cancer:

- Preclinical Studies: Early studies in lab settings and animal models have shown that ivermectin may inhibit the growth and spread of prostate cancer cells. These studies are promising but are limited in scope and are not yet conclusive for human use.
- Clinical Evidence: There are currently no large-scale, robust clinical trials in humans that specifically investigate ivermectin's effectiveness in treating prostate cancer. Most studies are preclinical, meaning they involve cell lines or animal models, not human patients.

Considerations and Limitations:

- Lack of Robust Clinical Data: While ivermectin shows some promise in laboratory settings, there is insufficient evidence to recommend it as a treatment for prostate cancer in clinical practice at this time. The clinical trials needed to confirm its effectiveness are still lacking. Evidence is rated an F.
- Safety Profile: Ivermectin is generally considered safe when used for its approved indications (parasitic infections), but the long-term safety of using ivermectin in cancer therapy, especially at higher doses, is not well established. There could be potential side effects, especially when combined with other treatments.
- Not a Replacement for Standard Treatment: Ivermectin should not be considered a substitute for standard prostate cancer treatments such as surgery, radiation, or chemotherapy. It's important to work with a healthcare provider to determine the best treatment strategy.

Conclusion:
While there is some early research suggesting that ivermectin may have potential anticancer properties, including for prostate cancer, more rigorous clinical studies are needed to determine its safety and efficacy in humans. As of now, it is not a standard or approved treatment for prostate cancer.

I have known several people who have tried Ivermectin, but it did not work. Perhaps this was because synergists or delivery methods are yet to be determined. Until there are clinical trials or solid evidence backing its usefulness, I am not going to use it.

Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer - PMC
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436997/

No, ivermectin isn’t being withheld as cancer ‘cure’ | AP News

https://apnews.com/article/fact-check-ivermectin-nih-cancer-cure-629592291079